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ABSTRACT 
In 1993, the World Health Organisation declared tuberculosis a global health emergency. Currently, efforts 
are underway to improve the way the disease is managed and to find more effective treatments that would 
combat the problem of long treatment periods, toxicity, drug-resistance and HIV-coinfection. In the 
process, natural product chemistry continues to play an important role in the search for new compounds to 
treat tuberculosis. Terrestrial plants have been investigated for antimycobacterial activity, while marine 
plants are yet to receive as much attention. In this project, three South African marine plants were drawn 
into the search for novel anti-tuberculosis compounds. One of the seaweeds is already part of the local 
seaweed industry, namely Gelidium pristoides, while Plocamium corallorhiza and Polysiphonia virgata 
have economic potential. These three red algae were extracted extensively and fractionated using 
preparative layer chromatography and preparative centrifugally accelerated radial thin-layer 
chromatography (Chromatotron). The crude extracts of the algae showed no inhibitory activity to growth of 
the causative agent of human tuberculosis, Mycobacterium tuberculosis. However, when the purified 
fractions were tested against M. tuberculosis in the BACTEC-460 radiometric method at a concentration of 
125 11 g/mL, fractions 322, 323 and 333 of P. virgata showed 100% inhibition, while two fractions of G. 
pristoides showed 91.7% and 79.2% inhibition, respectively. Two fractions of P. corallorhiza demonstrated 
41.2% and 73.5% inhibition. The bioactive fractions of P. virgata were further purified and resulted in the 
isolation of a known compound namely, 2-methoxyethyl-2-methacrylate (MEMA). When MEMA was tested 
by radiometric assay against M. tuberculosis, it showed anti-tuberculosis activity at a MIC-value of 100 
Ilg/mL and no cytotoxicity against Chinese hamster ovarian cells. However, in a re-investigation into the 
bioactive compounds of P. virgata it was established that MEMA was not the major bioactive compound. 
Long chain fatty acids were responsible for the antimycobacterial activity of the algal extract particularly 
oleic acid, linoleic acid, dodecanoic acid, and myristic acid. Oleic acid inhibited the growth of M. 
tuberculosis at and MIC-value of 25 11 g/rnL, while dodecanoic acid, myristic acid and linoleic acid all had 
MIC-values of 50 ~lg/mL. Stearic acid and palmitic acid was also isolated from the seaweed, but only 
moderate inhibition of M. tuberculosis was obseNed for at MIC-values of 50 11 g/mL. Oleic acid showed 
moderate inhibition at 50 11 g/mL against the multi-drug resistant isolate of M. tuberculosis, while myristic 
acid and dodecanoic acid showed significant inhibition against the same at 50 11 g/mL and moderate 
inhibition at 25Ilg/mL. Linoleic acid also inhibited the growth of the multi-drug resistant strain at 50 ~lg/mL. 
Oleic acid showed the most inhibition of the growth of M. smegma tis in direct bioautography with an MIC-
value of 0.8 Ilg/mL, while linoleic acid and dodecanoic acid had MIC-values of 1.56 Ilg/mL and 3.125 
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11 g/mL., respectively. Stearic acid, palmitic acid, and myristic acid did not inhibit the growth of M. 
smegma tis. 
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Chapter 1 
INTRODUCTION 
1.1 Tuberculosis 
Tuberculosis is defined as "an infectious disease caused by the bacillus Mycobacterium tuberculosis and 
is characterized by the formation of nodular lesions (tubercles) in the tissues" (Concise Medical 
Dictionary1). Tuberculosis can involve many organs (Gregory and Tolman, 2000). In cattle, it is caused by 
M. bovis. M. leprae is the mycobacterial pathogen responsible for leprosy. Mycobacteria are either 
tuberculous or nontuberculous (atypical) (Petri, 2001). In addition, tuberculous mycobacteria are regarded 
as slowly growing mycobacteria (8GM) and nontuberculous as rapidly growing mycobacteria (RGM), 
based on their growth rate on solid medium (Howard and Byrd, 2000). Those that form visible colonies in 
less than 7 days are 8GM while mycobacteria that do the same in more than seven days are RGM 
(Howard and Byrd, 2000). The major 8GM are M. tuberculosis, M. leprae and M. avium complex (Howard 
and Byrd, 2000). M. avium complex causes infections in patients with AID8 (Petri, 2001). RGM involved in 
human disease include M. abscessus and M. chelonae, which are associated with skin and soft tissue 
disease (Howard and Byrd, 2000) and M. fortuitum, which are normally saprophytes, but can cause 
chronic lung disease and infections in skin and soft tissues (Petri, 2001). M. kansasii causes a disease 
that is similar to tuberculosis, but milder (Petri, 2001). Of all the various types of tuberculosis, pulmonary 
tuberculosis (TB) or tuberculosis of the lungs is the most common and will be the focus of this 
investigation. Other forms of tuberculosis caused by M. tuberculosis include lymphatic tuberculosis, pleural 
tuberculosis, tuberculous meningitis, genitourinary tuberculosis, etc. (Frieden et a/., 2003). 
In pulmonary tuberculosis, M. tuberculosis settles in the lungs after inhalation and develops a primary 
tubercle from where it disseminates to the lymph nodes. Other mycobacteria that infect human lungs are 
the atypical or opportunistic mycobacteria that exploit a weakened immune system or prior lung damage. 
These include M. kansasii, M. xenopi, M. malmoense, M. avium. and M. in trace//ulare. Their infections are 
similar to pulmonary tuberculosis, but much more difficult to treat because of resistance to the primary 
tuberculosis drugs (Concise Medical Dictionary;». 
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1.2 Global perspective 
Pulmonary tuberculosis is one of the most deadly infections of our time and in 1993, the World Health 
Organisation (WHO) declared it a global emergency (Gandy and Zumla, 2002). Annually, the WHO 
compiles a global TB control report after obtaining data of TB case notifications and/or treatment outcomes 
from governments of up to 201 countries. According to the 2003 WHO Report, 72% of TB-cases were 
reported under directly observed therapy short-course (DOTS) programmes in 2001 and 77% in 2002 
(WHO Report, 2003). According to the 2004 WHO report on Global Tuberculosis Control, an estimated 8.8 
rnillion new cases of tuberculosis (TB) were reported in 2002, of which 3.9 million were confirrned by 
sputum smear microscopy or culture where resources were available (WHO Report, 2004). However, it is 
important to note that of the 2 billion individuals infected with M. tuberculosis only 10% developed active 
tuberculosis (Kaufmann, 2000). Approximately 3 million people die of tuberculosis each year while a third 
of the global population has dormant or latent tuberculosis infection (Gandy and Zumla, 2002). 
Furthermore, the global incidence rate of TB (per capita) has grown at approximately 1.1 % per year 
(Figure 1.1) and the number of tuberculosis cases at 2.4% per year. The case notifications were faster in 
African countries and in Eastern Europe - mainly in the former Soviet Union (WHO Report, 2004). Sub-
Saharan Africa countries are reported to have 290 infected individuals per 100 000 of the population, while 
the highly populated countries of Asia, such as India, China, Indonesia, Bangladesh and Pakistan have the 
largest number of tuberculosis cases, bearing more than half the global tuberculosis burden (Frieden et 
al., 2003). Most of the disease occurs in people aged 15 to 49 years (Frieden et al., 2003) and it is more 
common in the poor, and in people living in nursing homes, prisons, and homeless in inner city centers. 
Pulmonary tuberculosis is also often diagnosed in alcoholics, drug users, and patients recovering from 
gastrectomy, renal transplant, renal failure, or other weakening conditions (Gregory and Tolman, 2000). 
Another contributing factor to the increase in TB-notifications is the mass movements of people because of 
war or social disruptions resulting in crowding in inadequate housing and poor sanitation (Gandy and 
Zumla, 2002). Overall, the increase in tuberculosis incidence is the result of economic decline and 
deterioration in the management of tuberculosis and other health services (Frieden et al., 2003). 
Furthermore, the spread of the HIV/AIOS epidemic and multi-drug resistant tuberculosis increasingly 
makes it more difficult to treat TB-infected individuals (Corbett et al., 2003). With multi-drug resistant 
tuberculosis the treatment is individualized based on susceptibility testing (Kremer and Besra, 2002) and 
the second-line treatments required are more costly and in some cases more toxic (Fujiwara et aI., 2000). 
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Figure 1.1. Estimated TB incidence rates for 2002 (WHO Report, 
2004) 
1.3 Tuberculosis in South Africa 
.-
South Africa is among the 22 countries that bear 80% of the global tubercul sis case burden (Ravigloine, 
2002). Bradshaw et al. (2003) investigated the causes of mortality in South Africa in the year 2000 and 
estimated that tuberculosis was the third highest cause of death after HIV/AIDS and homicide. Another 
study published in the same year indicated that South Africa had the largest number of adults co-infected 
with HIV and tuberculosis worldwide, amounting to 2 million individuals (Corbett et aI., 2003). The 2004 
WHO estimates showed that the 44 759 187 population showed a TB case incidence of 558/100 000 of 
the population, with 60% of adults cases being co-infected with HIV (WHO Report, 2004). A plan for TB-
control was introduced in 2001 and is set to run to 2005; one of the first steps involves the appointment of 
TB-coordinators for all the provinces with the expectation that each province would function within a 
provincial orB-budget (WHO Report, 2003). It is hoped that greater political commitment to the eradication 
of TB would ensure more effective TB-control. 
1.4 Modern Medicine 
1.4.1 Traditional Medicine in TB-treatment 
Despite the tremendous advances in modern medicine, many people continue to rely on traditional 
remedies as their supply of medication (WHO, 2003). It is estimated that approximately 60% of the world 
population use traditional medicines to treat their illnesses (Harvey, 2000). In China, 30 - 50% of 
medicines are comprised of traditional herbal preparations, while in Europe, North America, and other 
industrialized countries 50% of the population used complementary or alternative medicine at least once. 
The global market for herbal medicines is estimated at about US$ 60 billion (WHO, 2003). These 
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traditional remedies are mainly of botanical origin. Historically, plants have played an important role in the 
medicines of the great civilisations of the ancient Chinese, Indians and North Africans (Phillipson, 2001). 
Today, some people in Britain make use of the Asian plant Centella asiatica and in the West a tonic is 
prepared from the bark of the Chinese herb Lycium chinense Miller (Evans, 1996a) to treat tuberculosis. 
Since the nineteenth century, scientists have isolated the active compounds of medicinal plants; for 
example, the isolation of quinine from Cinchona bark (Phillipson, 2001). Today, the scientific investigations 
of plants used in traditional medicines continue vigorously as is reflected in the many publications about 
medicinal plants; for example, Trease and Evans' Pharmacognosy (Evans, 1996a), various 
pharmacopoeias (Evans, 1996a), and the many reviews in journals, such as, Natural Product Reports, 
Phytotherapy Research and Phytochemistry. The battle against tuberculosis has not been excluded in the 
search for new bioactive compounds as is reflected by the number of reviews on antimycobacterial 
compounds published recently, such as, those by Newton et at. (2000), Cantrell et al. (2001), Copp (2003), 
and Okunade et at. (2004). 
Newton et al. (2002) investigated the antimycobacterial activity of 43 plant species known to be used in the 
treatment of tuberculosis and leprosy or various symptoms of these diseases. The plants originated from 
countries worldwide and were screened against Mycobacterium smegmafls and M. aurum. In another 
investigation, Lall and Meyer (1999) screened 20 South African plants used in traditional medicine to treat 
TB or its symptoms and found more than 50% of the plants selected to have significant antimycobacterial 
activity. Seidel and Taylor (2004) screened two Pelargonium species for antimycobacterial activity 
because the extracts of its roots were given to Charles Stevens by a South African healer and he was 
cured of tuberculosis. The results served to justify further investigation of the plant extracts against 
pathogenic mycobacteria. These are a few examples of the importance of traditional medicines in the 
search for new anti-tuberculosis drugs. 
1.4.2 Chemotherapy 
The year 1944 marked the beginning of chemotherapy of tuberculosis with the introduction of streptomycin 
(Fujiwara et al., 2000). Since then, many other anti-tuberculosis drugs have been introduced and are still in 
use. There has been much investigation into the efficacy and correct dose of these drugs to optimise their 
effectiveness and to combat drug resistance. The drugs currently used in the treatment of tuberculosis are 
divided into first- and second-line agents. The first-line a,gents are isoniazid, rifampicin, ethambutol, 
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streptomycin and pyrazinamide (Figure 1.2). Patients infected with drug-sensitive M. tuberculosis are 
treated successfully with the first-line therapy for a period of 6 months. During the first 2 months, first-line 
drugs are given followed by a 4 months long treatment of isoniazid and rifampicin only (Petri, 2001). 
Alternatively, a combination of rifampicin and isoniazid over a period of 9 months also proved effective. 
However, where there is resistance to isoniazid, therapy begins with the 4-drug combination with either 
streptomycin or ethambutol. Second-line drugs come into play if the patient has developed resistance to 
the first-line treatment or becomes drug intolerant (Fujiwara et al., 2000). They are less potent and more 
toxic than first-line treatment and include cycloserine, ethionamide, para-aminosalicylic acid, capreomycin, 
kanamycin/amikacin, and the fluoroquinolones ciprofloxacin, ofloxacin, levofloxacin, and sparfloxacin 
(Fujiwara et al., 2000). In the treatment of tuberculosis, anti-tuberculosis drugs are just half of the battle 
won. The rest of victory depends on adherence, which may be difficult as many drl~gs have to be taken 
over a long period and the cost of treatment can be unaffordable (Fujiwara et al., 2000). In 1999, the 
global impact of tuberculosis complicated by multi-drug resistance and HIV-infection encouraged the WHO 
to adopt a new strategy referred to as directly observed treatment short course (DOTS) (Fujiwara et al., 
2000). This strategy was not accepted by all countries, but the number of participating countries has 
increased gradually since. By 2002, 180 of the 210 countries worldwide had implemented the DOTS 
strategy (WHO Report, 2004). According to the same report, 69% of the world's population live in 
countries or parts of countries covered by DOTS. The success of DOTS relies on the commitment of 
governments around the world to work towards the eradication of tuberculosis. The strategy includes the 
diagnosis of tuberculosis by smear microscopy or culture growths where possible, a standardized course 
of chemotherapy that is taken under observation for at least 2 months, a supply of safe and high-quality 
drugs, and regular, effective reporting of treatment outcomes. Through the DOTS programmes, 3 million 
new TB cases have been notified, of which 1.4 million were smear-positive. WHO aims to achieve 70% 
case detection of TB cases worldwide by 2005. Currently, treatment success under DOTS for the years 
2000 and 2001 has been 82%. 
When patients cannot be observed directly, one of the keys to the success of tuberculosis chemotherapy 
lies in combination of antimycobacterial drugs, specifically fixed-dose combinations to prevent 
monotherapy that rapidly leads to development of drug resistance. Combinations of isoniazid and 
rifampicin (Rifamate) and isoniazid, rifampicin and pyrazinamide (Rifater) are used in the United States of 
America (Fujiwara et al., 2000), while combination tablets of isoniazid and thioacetazone or isoniazid and 
ethambutol are available elsewhere. 
5 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CH3 I~ 
OH I 
o 
OH 
NH 
r 
OH 
Isoniazid Rifampicin, Rifampin 
o 
.OH 
/ 
NI1 /NH""r -- "'CH 
I J 3 
" 
", OH 
Ethambutol Pyrazinamide 
Streptomycin 
Figure 1.2. First line anti-tuberculosis drugs: isoniazid, rifampicin, 
ethambutol, pyrazinamide, and streptomycin were reproduced 
from Petri (2001) and Chambers (2001). 
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1.4.2.1 Multi-drug resistant tuberculosis (MDR- TBJ 
A strain of M. tuberculosis is defined as being resistant if it shows resistance to isoniazid and rifampicin 
(Mukherjee et aI., 2004). Fujiwara et al. (2000) equate multi-drug resistance with poorly managed 
tuberculosis control programmes in which either patients do not adhere to treatment or health-care 
providers do not prescribe correctly. Before initiating treatment for tuberculosis caused by drug-resistant 
M. tuberculosis, it is important to establish to which drugs the strain is resistant and sensitive. Isoniazid-
resistant strains should be treated with a fixed dose combination of rifampicin, ethambutol, and 
pyrazinamide over a period of six months. Should the strain be resistant to more than one drug, the 
regimen becomes more complicated as it might not be possible to tell which drug would be more efficient. 
Where second-line drugs are resorted to, the side effects may make it impossible for the patient to 
continue treatment for the recommended period. Infections caused by strains resistant to both rifampicin 
and isoniazid are the most difficult to treat (Fujiwara et al., 2000). 
1.4.2.2 HIVIAIDS co-infection 
Worldwide, it is estimated that 11 % of new adult tuberculosis cases reported in 2000 were co-infected with 
HIV. This included 38% of new cases in SUb-Saharan Africa, 14% in developed countries, and 1 % in the 
Western Pacific (Frieden et aI., 2003). Of the 2 million people that died of tuberculosis in 2000, 
approximately 13% were co-infected with HIV (Frieden et aI., 2003). In Botswana, South Africa, Zambia 
and Zimbabwe approximately 60% of tuberculosis patients are reported also infected with HIV (Frieden et 
aI., 2003). Although pulmonary tuberculosis is the most common form of M. tuberculosis infection in HIV-
positive patients, 20% of cases with HIV/AIDS co-infection have extrapulmonary tuberculosis in HIV-
seronegative people and it is very common in those that are HIV-seropositive (Frieden et al., 2003). In the 
treatment of HIV-infection, protease inhibitors (Pis) and non-nucleoside reverse transcriptase inhibitors 
(Nt\IRTls) form an integral part of the multi-drug regimens in AIDS patients (Fujiwara et al., 2000). 
However, these medications have serious consequences for the treatment of tuberculosis. They interact 
with the rifamycins, the most important chemotherapeutic drug in the treatment of tuberculosis, namely 
rifampicin and rifabutin, but more so with rifampicin. Both Pis and rifamycins are metabolized by the 
hepatic cytochrome P450 system - rifamycins induce the cytochrome P450 system resulting in increased 
metabolism and decreased levels of Pis, while Pis inhibit the cytochrome P450 system resulting in toxic 
level of rifamycins (Fujiwara et al., 2000). Thus, NNRTls nevirapine and delavirdine should not be used 
with rifampicin, but nevi rapine and rifabutin can be safely used together. 
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1.4.3 Vaccines 
Currently, the Bacillus Calmette-Guerin (BCG) vaccine is the only vaccine routinely used against 
tuberculosis and BCG has been given to more people than any other vaccine (Kaufmann, 2000). Its side 
effects are minimal and it is believed to prevent miliary and meningeal tuberculosis in children, but it is not 
effective prevention against pulmonary tuberculosis (Kaufmann, 2000; Kremer and Besra, 2002). 
1.5 Demand for new anti-TS drugs 
Current tuberculosis drugs must be taken over a long period of time and in combinations to avoid the 
development of drug resistance (Kaufmann, 2000). The adverse reactions experienced by many patients 
lead to poor adherence and treatment failure (O'Brien, 2001). The drugs used to treat multi-drug resistant 
tuberculosis are even more expensive and toxic (O'Brien, 2001). Therefore, new TB-drug treatments are 
needed that ideally would shorten the treatment period, be effective against MDR-TB, eliminate latent TB 
infection (O'Brien, 2001), and be affordable to all. 
1.6 Initiatives in the search for new drugs: TB-drug development 
The Global Alliance for TB Drug Development (GATB), based in New York, Brussels and Cape Town 
together with their partners, stakeholders and allies worldwide are spearheading the development of new 
and improved drugs for the treatment of tuberculosis (b.ttfdLY!Y:J'!Y.JJ2.i:1Warlcf:?orq). Within its broad network 
the Alliance has compounds such as nitroimidazole analogs, carboxylates, quinolones, macrolides, Inh A 
inhibitors, isocitrate Lyase inhibitors and pleuromutilins in the discovery phase of its portfolio. Recently it 
teamed up with Bayer, a German pharmaceutical group to submit a patented Bayer antibiotic, 
moxlfloxacin, to global clinical trials in the treatment of tuberculosis ()J1tQ1L'6'lNvYJb[-@E!.H~i~,9lU). Another 
initiative involves the synthetic compound nitroimidazopyran, PA-824, which is also in Phase 1 clinical 
trials Ul1!pjLlNw.Y!.J.t)§JliaD~;(L~!Jg). A comprehensive approach to developing new drugs for the treatment of 
tuberculosis is ideal although the initial steps in the discovery process are taken in one of the many 
disciplines from which new drugs could be obtained, such as natural product chemistry and combinatorial 
chemistry. 
1.6.1 Natural product chemistry 
Natural products continue to playa vital role in drug discovery. On considering, that only 10% of the 
world's biodiversity has been investigated so far it is clear that humankind has only just begun to tap these 
remarkable resources (Harvey, 2000). Many organisms remain as new galaxies of natural products to be 
explored for example, microorganisms of which approximately 6000 bacterial species have been identified 
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(Harvey 2000). Recent drugs that were added to the medicinal armamentarium from natural products are 
the antimalarial drug artemisinin, isolated from the antimalarial herb Artemisia annua (Harvey, 2000; 
Phillipson, 2001), the anticancer drugs taxol, obtained from the bark of the Western Pacific Yew, Taxus 
brevifolia, (Phillipson, 2001) and camptothecin isolated from the tree Camptotheca acuminata (Wall et al., 
1966; Wani et al., 1971; Harvey, 2000; Oberlies and Kroll, 2004). 
Small-scale screening programmes are the most common form of natural product research that are being 
done at academic institutions, reflected in the many publications produced yearly in the search for new 
antimycobacterial compounds. It continues to be the main thrust in natural product chemistry and a focus 
for the training of students. Natural products screens test the extracts or isolated compounds in a single 
one bioassay against one organism or in various bioassays against many different organisms. When 
extracts were tested in more than one assay, unexpected bioactivities have been detected. In an 
investigation on seven plants species from The Republic of Congo, the plants were selected because they 
were found in a malaria endemic area and were used in the traditional medicine of the local people in the 
treatment of malaria. The extracts were tested for antimalarial activity, as well as, against M. tuberculosis, 
Trypanosoma cruzi, Bacillus megaterium, the fungus Microbotryum violaceum, etc (Tshibangu et al., 
2002). Five species showed considerable antiplasmodial activity and one species had noteworthy 
antimycobacterial and antitrypanosomal activity. Large-scale screening programmes have emerged in 
recent years, particularly after the 1992 Convention of Biodiversity (Harvey, 2000) with collaborations 
between research institutions, academia, the pharmaceutical industry, and indigenous communities. An 
example of such a programme is one where Peruvian medicinal plants were investigated as sources of 
new pharmaceuticals (Lewis et al., 1999). A collection of 492 plants was screened against M. tuberculosis 
and antimycobacterial active extracts were identified. In such large-scale programmes, many plant and 
animals species are investigated for a range of pharmacological activities. In the Peruvian study, 
indigenous peoples of the study area were actively involved and stood to gain financially should any drug 
be developed from the plants investigated. The networks established in this manner greatly advance the 
number of species that are screened and increase the number of bioassays for which an extract can be 
tested. 
1.6.2 Chemical modifications of known drugs, genomics and combinatorial chemistry 
Currently, efforts are underway to employ chemical modification to improve the properties of 
fluoroquinolones such as, norfloxacin and macrolides such as clarithromycin and rifamycin derivatives 
such as rifabutin and rifapentine (Tomioka, 2000). These modified compounds are showing great potential 
with characteristics such as good absorption, favourable pharmacokinetics, and host macrophage 
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penetration to mention a few, but further research is required before they can be regarded as suitable for 
clinical trials (Tornioka, 2000). 
With the sequencing of the genome of M. tuberculosis (Cole et al., 1998) it is hoped that new dn-1g targets 
will be easily established and new effective anti-tuberculosis drugs developed (Barry et al, 2000). 
Together with combinatorial chemistry, in which ideal and diverse drug structures might be optimised and 
compiled in a library from which a drug candidate could be selected, it has transformed drug discovery 
(Barry et al., 2000). 
1.7 Marine natural products 
Since the introduction of the self-contained underwater breathing apparatus (SCUBA) a few decades ago, 
marine organisms have increasingly become the objects of investigation of natural product chemists, 
intrigued by the diversity of their chemical composition. In the last decade, many investigations on marine 
organisms have been conducted as are reflected in the number of reviews available in the scientific arena. 
Faulkner has published yearly reviews on marine natural products, with many reports of isolated 
compounds and their biological activities (Faulkner, 2000). Fenical has been involved in many 
investigations in which marine animals and plants have been screened for novel compounds (Fenical, 
1974; Howard et al., 1977; Spyere et al., 2003) and bioactive agents (Lindquist et al., 1988; Lee et al., 
1997). He predicted that, "marine drug discovery has an exceedingly bright future" (Fenical, 1997). In 
2002, the review by Mayer and Hamann (2002) on marine pharmacology demonstrated the huge 
contribution marine organisms are making in the search for new therapeutic agents. 
The search for drugs from marine natural products has produced a significant number of drug candidates 
over the last few years (Proksch et al., 2002; Haefner, 2003). The venoms of marine cone snails have 
been found to contain conotoxins that inhibit various receptors. A particular conotoxin that has been 
synthesized and approved in the United States by the Food and Drug Administration is w-conotoxin MVIIA 
of which the synthetic form is called Ziconotide. It is a neuron-specific, N-type calcium-channel blocker 
(Haefner, 2003). Another w-conotoxin is in clinical development at AMRAD, one of four companies 
involved in conotoxin commercialisation (Haefner, 2003). The investigations of the nemertine worm 
Amphiporus lactifloreus have yielded a compound, 3-(2,4-dimethoxybenzylidene)-anabaseine, that is 
being investigated for efficacy in the treatment of Alzheimer's disease and scrlizophrenia (Haefner, 2003). 
Screens of bryozoans have resulted ill discovery of a potent anti-tumour compound, bryostatin (Haefner, 
2003). Since then, other bryostatins have also been isolated and bryozoans harvested commercially as 
there are difficulties in synthesising the highly potent anti-cancer agent (Haefner, 2003). 
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A closer look at the bioactivity of marine natural products resulted in the publication of many papers 
recording bioactivities, such as anti-angiogenic (Koyanagi et aI., 2003), anti-tumour (Hiroishi et al., 2001; 
Zhou et aI., 2004). anticoagulant (Chevolot et al., 1999), immunomodulating (Shan et aI., 1999). 
antioxidant (Ahn et a/., 2004; Zhang et a/., 2004), antiviral (Boyd et al., 1997; Carlucci et aI., 1999; 
Huheihel et aI., 2002; Ahn et al., 2002), anti-inflammatory (Okai and Higashi-Okai, 1997; Jiang et al., 1999) 
antimicrobial (Donia and Hamann, 2003; Haefner, 2003), hemaglutination (Kakita et al., 1999), and many 
more. The review by Donia and Hamann (2003) gave renewed appreciation for the diversity of marine 
organisms such as sponges, gorgonian, soft corals, bryozoans and other invertebrates, marine 
microorganisms and algae, and their isolates, as they highlighted bioactivities such as antitumour, 
antimycobacterial, antihelmintic, antifungal, and anti protozoal. Marine cyanobacteria are mentioned 
separately as these blue-green algae have great potential for future dn.jg discovery. Unique secondary 
metabolites with diverse pharmacological activities have been isolated from these marine organisms 
(Burja et al., 2001). From South Africa, Michael Davies-Coleman and some other researchers have 
investigated marine animals for novel compounds, e.g. the sea hare Aplysia dactylomela (Copley et al., 
2002), a nudibranch (McPhail et aJ., 2001) and gastropod (Brecknell et aI., 2000), to mention a few. 
Marine plants have not been excluded from marine natural product chemistry as they share the same 
environment with marine animals (Table 1.1). Certain algae have received much more attention than 
others either because they possess interesting novel compounds or they have economic value. Of the 
many marine algae investigated, the red alga Laurencia species has been the object of many screens 
resulting in numerous reports of their secondary metabolites (Brito et aJ., 2002; De Carvalho et aI., 2003; 
lIiopoulou et al., 2003) and bioactive compounds, such as halogenated metabolites with antibacterial 
activity (Vairappan et aI., 2001; Vairappan, 2003). Other reports of halogenated marine natural products 
have been published recently, e.g. antibacterial bromophenols from the red alga Rhodomela confervoides 
(Xu et aI., 2003). Antiviral activity of Korean seaweeds (Hudson et al., 1999, Ahn et al., 2002) has been 
clearly demonstrated in recent years (Huheihel et al., 2002). Of all the algae, contributing to marine natural 
product chemistry it appears that red algae have made the largest contribution and many of their 
bioactivities have been reported (Table 1.2). 
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Introd'iet/of! 
SEAWEEDS 
BROWN SEAWEEDS 
Ascophyllum nodosum 
Ascophyllum nodosum 
Bifurcaria bifurcata 
Bifurcaria bifurcata 
Carpophyllum angustifolium 
Cladosiphon okamuranus 
Cystophora retrof/exa 
Cystoseira tamanscifolia 
Dictyopteris undulata 
Dilophus okamurae 
Hijikia fusiformis 
Laminaria sinclarii 
Notheia anomala 
Sargassum spinuligerum 
Sargassum spinuligerum 
Spatoglossum schroederi 
Spatoglossum variabile 
Sporochnus pedunculatus 
Stoechospermum mar gina tum 
Stypopodium flabelliforme 
GREEN SEAWEEDS 
Caulerpa prolifera 
Chroomonas salina 
Codium decorticatum 
VIva lactuca 
Ulva pertusa 
RED SEAWEEDS 
Acantophora spicifera 
Agardhiella subulata 
Aisidium helminthocorton 
Ceramium tenuicome 
Champia novae-zealandiae 
Chondria armata 
Digenea simplex 
Digenea simplex 
Gelidium pristoides 
Gracilaria asiatica 
Gracilaria confervoides 
Gracilaria coronopifolia 
GracHaria coronopifolia 
Gracilaria edulis 
GracHaria longa 
GracHaria verrucosa 
Gracila riops/s lemaneiformis 
Grateloupia camosa 
Hypnea musciformis 
Laurencia sp, 
Laurencia claviform/s 
Laurencia majuscula 
Laurencia nipponica 
Laurencia periorata 
Laurencia rig/da 
Laurencia papillosa 
Laurencia saitoi 
Odonthalia corymbifera 
Odonthalia dentate 
Table 1.1 Seaweeds and the compounds isolated from them. 
ISOLATED COMPOUNDS 
Fucans 
Fucans (sulphated polysaccharides) 
Diterpenes 
Diterpenes 
T rihydroxyphlorethols 
Fucoidan 
Phlorotannins 
Meroditerpenoid 
Cyclozonarone (sesquiterpene-substituted benzoquinone) 
Dictyterpenoids A and B 
Fucoxanthin 
Divinyl ether latty acids 
Epoxy lipids 
Fucophlorethols 
Fuhalols, phlorethols 
Sulphated lucan 
Spatozoate, Varinasterol 
A Phenol 
Spatane diterpenoids 
Meroditerpenoids 
Acetylene sesquiterpenoid esters 
Betaine lipids 
Sterols, alcohols 
Lectin 
Long-chain aldehydes 
cholest-4-ene-3a, 6~-diol and cholest-4-ene-3-one, lauric acid 
Agardhilactone 
Kainic acid 
Hydroxylated and methoxylated brominated diphenyl ethers 
Polysaccharide 
Domoicacid 
Kainic acid 
Kainic acid 
Galactosyl glycerol 
Eicosanoids 
Galactosyl glycerol 
Malyngamides M and N 
Manauealides 
Sterols 
Cholesterol, Chlorophyll a, Lutein 
Chlorinated C12 fatty acids 
Floriside, Heterosides, Isethionic acid, amino acids 
Amino acid - Camosadine 
Iselhionic acid 
1 (S)-bromo-4-(R)-hydroxy-( -)-selin-7-ene 
Terpenes, Cls-acetogenins 
Acetogenins and terpenes 
Cls-bromoethers, Terpenes 
Sesquiterpenes 
Sesquiterpenes 
p-hydroxy-benzaldehyde, p-methoxy benzyl alcohol 
Brominated and non-brominated diterpenes 
Diarylmethane-type bromophenol 
Bromophenol 
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SEAWEEDS 
Pantoneura plocamioides 
Plocamium cartilagineum 
Plocamium cartilagineum 
Plocamium cartilagmeum 
Plocamium cartilagineum 
Plocamium coral/ohiza 
Plocamium costa tum 
Plocamium hamatum 
Plocamium leptophyl/um 
Plocamium sp. 
Polysiphonia lanosa 
Polysiphoma paniculata 
Polysiphonia urceolata 
Porphyra capensis 
Porph yra haitanensis 
Ptilota fJlicina 
Rhodomela confervoides 
Rhodomela contervoides 
Schizymenia dubyi 
Tichocarpus erimlus 
Vidalifl obtusaloba 
Vidalia sp. 
ISOLATED COMPOUNDS 
Terpenes 
Halogenated monoterpene 
Poly(~-hydroxybutyrate), Floridoside 
Terpenes 
Terpenes 
Polyhalogenaled monoterpenes 
Polysaccharide 
Terpenes 
Halogenated terpenes 
Terpene 
Galactan sulphate 
Dimelhylsulfoniopropionate 
Acrylic acid 
Polysaccharide 
Sulfated galactan 
Lectin 
Bromophenol 
Bromophenols 
Methoxy fatty acids 
Fatty acids 
Vida lois A and B 
Vidalenolone 
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Table 1.2 Red seaweeds and the bioactivities reported for Iheir extracts or isolates. 
SEAWEED BIOACTIVITY COMPOUND REFERENCES 
Amphiroa ephedraea Antimicrobial Vlachos et at, 1997 
Arthrocardia carinata Antimicrobial Vlachos et al. , 1997 
Asparagopsis taxilormis Antibacterial Horikawa et al., 1999 
Beckerel/a pinnatifida Antimicrobial Vlachos et al., 1997 
Botryocladia botryoides Antiviral Caccamese et al., 1980 
Cal/ithamnion pikeanum Antiviral Kim et al., 1997 
Cal/ophycus serratus Cytotoxic Bromophycolide A Kubanek et al., 2005 
Cal/ophylis sp. Antimicrobial Heriquez et ai, 1979 
Cal/ophyl/is japonica Antioxidant Kang et al., 2005 
Cal/ophyl/is megalocarpa Antibacterial Pratt eta1., 1951 
Campylaephora hypnaeoides Antiviral Ohigashi et al., 1992 
Carpoblepharis flaccida Anti-inflammatory 51i rk et a1., 1996 
Cheilosporum sagitta tum Antimicrobial Vlachos et al., 1997 
Chondria annata Hypotensive Solimabi el al., 1980 
Chondria atropurpurea Anthelminthic Chondriamides A, B, C Davyt et al., 1998 
Chondria alropurpurea Anthelminthic 3-indoleacrylic acid Davyt el al., 1998 
Chondria coerulescens Antimicrobial Caccamese et at, 1985 
Chondria dasyphyl/a Antimicrobial Homsey and Hide, 1974 
Chondrus crispus Antimicrobial Homsey and Hide, 1976 
Chondrus ocel/alus Antiviral Hudson el al., 1999 
Coral/ina elongata Anti-inflammatory Bustos el al., 1992 
Coral/ina pi/ulifera Antiviral Kim et al., 1997 
Corallina pilulifera Antiviral Hudson et al .. 1999 
Coraltina vancouveriensis Antiviral Kim et al., 1997 
Oelessenacean sp. Anlimicrobial Almazole 0 N'Diaye et al., 1996 
Delisea fimbriata Antimicrobial Fimbrolides Reichelt and Borowitzka, 1984 
Dellsea hypnoides Antimicrobial Reichelt and Borowitzka. 1984 
Digenea simplex Antiviral Sekine et aI., 1995 
Falkenbergia rufolanosa Antibacterial Ballesteros et al., 1992 
Gataxaura marginata Cytotoxic Desmosterols Konig et al., 1994 
Gafaxaura marginata Cytotoxic Oxygenated desmoslerols Sheu el al., 1997 
Galaxaura oblongata Anti-inflammatory Bustos et al., 1992 
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SEAWEED BIOACTIVITY COMPOUND REFERENCES 
Galaxaura oblongata Anti-inflammatory Paya et ai, 1990 
Gelidiella ace rosa Antifertility Solimabi et al., 1980 
Gelidium abbott/orum Antimicrobial Vlachos et aI., 1997 
Gelld/um amansii Cy1otoxic Numata et aI., 1991 
Gigartina acicularis Antimitotic Chenieux et al., 1980 
Gigartina intermedia Antiviral Nakamura et aI., 1994 
Gigartina ten ella Anti-tumour Nakamura et al., 1997 
Gigartina skottsbergii Antiviral Carrageenan Carlucci et al., 1999 
Gloiosiphonia verticillaris Antimicrobial Dimethyl gloiosiphone Sturino et aI., 1997 
Gracilaria corticata Antibacterial Sastry and Rao, 1994 
Graci/aria domingensis Antimicrobial De Campos-Takaki etal., 1988 
Gracilaria pacifica Antiviral Kim et al., 1997 
Gracilaria sjoestedtli Antimicrobial De Campos-Takaki et aI., 1988 
Gracilaria textorii Cy1otoxic Numata et al., 1991 
Grateloupia sp. Antimicrobial Herfquez et al., 1979 
Grateloupia turuturu Antiviral Kim et al., 1997 
Grateloupia turuturu Antiviral Hudson et aI., 1999 
Haliptylon sp. Antimicrobial Heriquez et al., 1979 
Halosaccion glandiforme Antibacterial Pratt et aI., 1951 
Hypnea musciformis Antimicrobial De Campos-Takaki et al., 1988 
Hypnea musciformis Antimicrobial Melo et aI., 1997 
Hypnea musciformis Diuretic Solimabi et al., 1980 
Hypnea musciformls Anti-inflammatory Paya et at., 1990 
Iridaea membranacea Antimicrobial Heriquez et aI., 1979 
Indophycus flaCCldum Antibacterial P(att et aI., 1951 
Laurencia brongniartii Antibacterial Horikawa et al., 1999 
Laurencia complanata Antimicrobial Vlachos et al., 1997 
Laurencia hybrida Antimicrobial Homsey and Hide, 1974 
Laurencia implicata Cy1otoxic Acetogenins Konig et al., 1994 
Laurencia intermedia Antiviral Ohigashi et al., 1992 
Laurencia majuscula Antibacterial Elatol, iso-obtusol Vairappan, 2003 
Laurencia obtuse Antibacterial Laurencienyne Caccamese et ai, 1981 
Laurencia obtuse Antibacterial Mahasneh et al., 1995 
Laurencia obtuse Antimicrobial Caccamese et al., 1980 
Laurencia obtuse Antiviral Caccamese et al., 1980 
Laurencia obtuse Anti-inflammatory Bustos et al., 1992 
Laurencia okamurae Antibacterial Horikawa et al., 1999 
Laurencia papillosa Antibacterial Mahasneh et al., 1995 
Laurencia papillosa Antimalarial Wright and Konig, 1996 
Laurencia pinnatifida Antimicrobial Hornsey and Hide, 1976 
Laurencia sp. Antibacterial Vairappan et aI., 2001 
Mazzaella capensis Antimicrobial Vlachos et al., 1997 
Mazzaella cornucopiae Antiviral Kim et aI., 1997 
Mazzaella cornucopiae Cytotoxic Kim et al., 1997 
Nothogenia fastigiata Antiviral Xylomannans Kolender et aI., 1997 
Nothogenia fastigiata Antiviral Witvrouw and De Clercq (1997) 
Nothogenia fastigiata Antiviral Damonte et aI., 1994 
Odonthalia corymbifera Antifouling Bromophenol Kurata et al., 1997 
Odontha/ia corymbifera Antibacterial Horikawa et a1., 1999 
Odonthalia floccosa Antiviral Kim et al., 1997 
Pachymeniopsis elliptica Antiviral Kim et aI., 1997 
Peyssonnelia rosa-marina Cytotoxic Ballesteros et al., 1992 
Peyssonnelia rosa-marina Antimitotic Ballesteros et al., 1992 
Plocamium cartilagineum Antifeedant Argandona et ai, 2002 
Plocamium costa tum Antifouling Konig et al., 1999a 
Plocamium hamatum Antibacterial Konig et al., 1999b 
Plocamium hamatum Anti-algal Konig et a1., 1999b 
Plocamium leptophyllum Antifouling Sakata ef al., 1991 
Plocamium rigidum Antimicrobial Vlachos ef ai., 1997 
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SEAWEED BIOACTIVITY COMPOUND REFERENCES 
Plocamium telfairiae Insecticidal Telfairine, Aplysiaterpenoid a Watanabe et al., 1990 
Polysiphonia furcel/ala Antimicrobial Caccamese el aI., 1985 
Po/ysiphonia hendryi Antiviral Kim et al., 1997 
Polysiphonia lanosa Antimicrobial Homsey and Hide, 1976 
Polysiphonia lanosa Cytotoxic Bromophenols Shoeib et al., 2004 
Polysiphonia urceolala Antimicrobial Acrylic acid Glombitza, 1970a; Glombitza, 1970b 
Polysiphonia virgata Antimicrobial Vlachos et al., 1997 
Porphyra hailanensis Antioxidant Sulphated galactan Zhang el aI., 2004 
Portieria hornemannii Antitumor Halomon, halogenated Fuller et al., 1994 
monoterpenes 
Portierra hornemannii Antimicrobial Vlachos el aI., 1997 
Pterocladia capil/acea Antimicrobial Khaleafa et al., 1975 
Ptilonia auslralasica Antimicrobial Pentabromopyrone Reichelt and Borowitzka (1984) 
Rhodomela confervoldes Antibacterial Bromophenols Xu et al., 2003 
Rhodomela leres Antibacterial Horikawa el al., 1999 
Sarcothalia stiriala Anti-inflammatory Stirk et al., 1996 
Schizymenia binderi Antiviral Sulphated galactan Matsuhiro el al., 2005 
Schizymenia pacifica Antiviral Witvrouw and De Clercq (1997) 
Scinaia iaponica Cytotoxic Numata el al., 1991 
Symphyocladia latiuscula Antiviral Hudson et al., 1999 
Symphyocladia latiuscula Antiviral 2,3,6-tribromo·4,5- Park el al., 2005 dihydroxybenzyl methyl ester 
Symphyocladia marchantioides Antiviral Hudson et al., 1999 
Symphyocladia spp Antiviral Kim et al., 1997 
rrematocarpus dichotomus Antimicrobial Heriquez et al., 1979 
Vidalia obtusaloba Anti-inflammato~ Wiemer el al., 1991 
An important aspect of marine algae worth mentioning is that a few species are part of a global industry. 
The algal aquaculture industry is estimated yearly at US $5-6 billion worldwide (Wikfors and Ohno, 2001). 
The natural products currently supporting this industry include the algal phycocolloids, such as agar, 
carrageenan and alginates, the pigments beta-carotene, astaxanthin and the fatty acid docosahexaenoic 
acid (DHA). The phycocolloids are of particular interest with their ability to modify the viscosity or texture of 
food products. Whole algae are added to food for their nutritional value or their extracts are used as 
nutritional supplements as with the cyanobacterium Spirulina (Wikfors and Ohno, 2001). The bioactivities 
of phycocolloids have also been investigated. Carrageenans isolated from the red seaweed Gigar1ina 
skottsbergii have shown potent inhibition of herpes simplex virus types 1 and 2 (Carlucci et aI., 1999). 
These algae and many more should be investigated extensively for bioactivities; if significant findings are 
made, they could have considerable commercial value. In addition, building on an established harvesting 
culture the availability of this resource is a great advantage compared to terrestrial plants where the 
agriculture has yet to be established. 
1.8 Marine antimycobacterial compounds 
In the search for antimycobacterial compounds from marine organisms such as sponges, gorgonia, and 
soft corals, compounds with significant anti mycobacterial activity have been found (Donia and Hamann, 
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2003). One example is the isolation of two novel alkaloids manadomanzamines A and B (Figure 1.3) from 
the Indonesian sponge, Acanthostrongylophora sp. (Peng et aI., 2003) which inhibited the growth of M. 
tuberculosis with MIC-values of 1.9 and 1.5 fl9/mL, respectively. In another investigation Rodriguez and 
Ramirez (2001) isolated antimycobacterial serrulatane diterpenes (Figure 1.3) which caused up to 97% 
inhibition of growth of M. tuberculosis. Suwanborirux et a! (2002) isolated ecteinascidins 770 and 786 
(Figure 1.3) from a Thai tunicate Ecteinascidia thurstoni each of which showed antimycobacterial activity 
against M. tuberculosis. In 2000, Konig et at. screened 39 marine derived natural products for 
anti mycobacterial activity against Mycobacterium tuberculosis and M. avium (Konig et aI., 2000). The 
compounds represented various structural classes, including terpenes, aliphatics, aromatics, alkaloids, 
and sterols. Fifteen compounds were from red algae, one from a brown alga, three from cyanobacteria, 
ten were derived from sponges, one from a soft coral, three from a gorgonian, three from lichens and three 
were semi-synthetic. The seven sponge-derived compounds were the most anti mycobacterial against M. 
tuberculosis, with MIC-values below 10 fl g/mL. The compounds isolated from the red algae Laurencia 
obtusa, L. flexilis, L. rigida and Plocamium carti/agineum possessed antimycobacterial activity ranging 
from MIC-values of 16 to 64 ~,g/mL. Two compounds isolated from blue-green algae also showed 
antimycobacterial activity. The lichen derived compounds had anti mycobacterial activity, as did the 
compound isolated from a soft coral. In 2003, Nicholas et al. screened approximately 1500 crude organic 
extracts for inhibition of natural Mycobacterium smegmatis mycothiol-S-conjugate amidase (MCA) and 
recombinant M. tuberculosis MCA. An impressive 1200 extracts were obtained from marine plants and 
invertebrates and another 300 came from terrestrial fungi (Nicholas et al., 2003). The initial screen 
presented only 20 active extracts, of which 10 were further purified, and of the active compounds isolated 
13 active; 10 came from marine sponges and the remaining three from fungi. These studies demonstrate 
the antimycobacterial capabilities of marine-derived compounds and give strong support to their inclusion 
in any drug development programme. 
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Figure 1.3. A few anti mycobacterial compounds isolated from marine organisms. 
1.9 Rationale for this investigation 
In a previous investigation done by Cameron et al. (2001), seventeen South African marine red seaweeds 
were screened for antimicrobial activity following the findings of marine chemists such as Caccamese et 
al. (1985) that red seaweeds are potential sources of antibiotics. The algae were tested against 
Staphylococcus aureus, Candida albicans, and Mycobacterium smegma tis using the agar overlay 
bioautography method. The purified fractions of eight algae revealed the presence of antimicrobial 
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compounds. Most of the antimicrobial activities of both the crude and the fractions of these algal extracts 
inhibited growth of S. aureus and M. smegma tis. The extracts and fractions of Plocamium corallorhiza and 
Polysiphonia virgata produced the largest inhibition zones. Gelidium pristoides was among the eight 
species that showed antimicrobial activity. This made the selection of algae for this present study easy as 
P. corallorhiza and P. virgata have economic potential in addition to their reported antimicrobial activity and 
G. pristoides already has commercial value. Should any significant antimycobacterial compounds be 
present in these algal extracts, the source material will not be difficult to collect and the results of this 
investigation would serve to strengthen the motivation for a local seaweed pharmaceutical industry. 
1.10 Aim and Objectives 
The aim of this investigation has been to establish whether the algal extracts of P. corallorhiza, G. 
pristoides, and P. virgata contain compounds that inhibit the growth of Mycobacterium tuberculosis. 
Therefore, the objectives of this project were the following: 
• To extract the secondary metabolites of the three red algae and to purify the crude extracts. 
• To test the extracts and fractions against a sensitive strain of M. tuberculosis using the BACTEC-
460 radiometric method. 
• To isolate and characterize the bioactive compounds. 
In the course of this project, the in house availability of an antimalarial assay made it easy to test the 
antimalarial activity of some of the algal extracts. The importance of evaluating plant extracts for 
antimalarial activity needs no motivation, as malaria is one of the leading causes of mortality in the world 
causing about 1 million deaths annually of which 90% are Atrican children (WHO Health Report, 2005). A 
few of the algal extracts were therefore tested in a parasite lactate dehydrogenase assay for Plasmodium 
falciparum sensitivity. 
The seaweeds are described in detail by elaborating on their uses and where they are found in South 
Africa, their phytochemistry as reported in scientific publications, and the biological activities obtained for 
them from NAPRALERT and jOLimal articles. The various methods used in this investigation are described 
and the results obtained in the various assays are reported. The isolation and characterization of the 
isolated compounds and the antimycobacterial activities of the isolates are described and the findings 
reported into context. The overall assumptions of this investigation are stated and the implications for the 
future are reported. 
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Chapter 2 
SOUTH AFRICAN SEAWEEDS: PLOCAMIUM CORA LL ORHIZA, GELIDIUM 
PRISTOIDES, AND POLYSIPHONIA VIRGATA 
2.1. South African seaweed industry 
South Africa is home to a diverse seaweed population which is divided into four; namely, Cyanophyta (with 
the single class Cyanophyceae - blue-green algae), Rhodophyta (with the single class Rhodophyceae -
red algae), Chromophyta (including Phaeophyceae - brown algae, and Xanthophyceae), and Chlorophyta 
(with the single class Chlorophyceae - green algae) (Silva et aI., 1996). It is estimated that there are 
altogether 800 species (Stegenga et a/., 1997). Red seaweeds constitute most of the 800 species and 
more red than brown and green seaweeds are considered potentially harvestable and/or economically 
important (Critchley et a/., 1998). This is, however, not reflected in the current status of South Africa's 
seaweed industry that uses two kelps (brown algae) and three species of Gelidium and 
GracilariaiGracilariopsis, all red algae (Anderson et al., 2003). The beach-cast kelps, Ecklonia maxima 
and Laminaria pal/ida are sun-dried, milled and exported for the extraction of alginate. Powdered kelp is 
exported to Japan for use in formulated fish-feed. Fresh kelp is used in commercial abalone farming as 
feed and harvested to produce a liquid plant-growth stimulant, which contains cytokinins (Anderson et al., 
2003). In the Cape Floristic Region alone an estimated 1800 ton of kelp is harvested annually (Turpie et 
a/., 2003). Other seaweeds used in abalone farming include the green alga Ulva and species of the red 
algae Gracilaria and Plocamium. Gracilaria's commercial value comes from the demand from countries, 
such as, Japan and Korea. Its beach-cast material is collected in Saldanha Bay, dried, sorted and finally 
exported. Gracilariopsis makes a similar contribution although it is collected on a much smaller scale in 8t. 
Helena Bay (Anderson et al., 2003). For both these seaweeds, attempts are underway to establish 
suspended cultivation. Lastly, but not least, various species of Gelidium, namely, Gelidium pristoides, G. 
abbottiorum, G. pteridifolium and G. capense are harvested in the Eastern Cape and exported mainly to 
Japan and Korea for agar extraction (Anderson et al., 2003). Other seaweeds with potential commercial 
value include Gigartina polycarpa, Sarcothalia stiriata, Mazzael/a capensis, Aeodes orbitosa, Hypnea 
spicifera, and Porphyra capensis. Despite all this commercial activity, there is no extraction industry in 
South Africa (Melo, 1998) - research into the pharmaceutical potential of these algae could support the 
establishment of such an industry, which might also benefit other countries in our region, such as 
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Mozambique, Angola and Namibia that have commercial seaweeds. The latter has an agar factory that 
ceased production in 1995 (Anderson et al., 2003). 
2.2 Biological activities of South African algae 
Considering the vast amounts of seaweeds available along the South African coast, there has been Irille 
investigation into their pharmaceutical potential. Vlachos et at. (1997) screened 56 seaweeds for their 
antimicrobial activity against 16 microorganisms, including, Bacillus subtliis EL 39, Staphylococcus aureus, 
Pseudomonas fluorescens, Salmonella enteritidis, Penicillium sp., and Candida albicans. The brown alga, 
Zona ria subar1iculata, showed the highest amount of inhibition against all the microorganisms tested. Stirk 
et at. (1996) tested the crude algal extracts of 35 seaweed species for inhibitory activity to prostaglandin 
synthesis and found species from the red, brown, and green seaweeds with potential novel anti-
inflammatory activity. Stirk and Van Staden (1997) screened 20 algal species for cytokinin-like activity and 
found it present in most of the extracts. 
2.3 Seaweeds screened in this investigation 
All three seaweeds researched in this thesis are red and belong to the class Rhodophyceae. They 
possess chlorophyll, phycobiliproteins (allophycocyanin, phycocyanin and phycoerythrin), and carotenoids. 
The algae can be red, violet, brown, black, or blue in colour with floridean as the storage product and the 
cell walls are composed of cellulose or xylans and galactans. The Rhodophyceae have the largest variety 
of toxic secondary metabolites and they include compounds such as halogenated acetates, acrylates, and 
ketones (South and Whittick, 1987). 
Of the genera screened in this research, Plocamium species have been studied the most for their natural 
products and biological activities (Table 2.1). Gelidium has received much attention for its agar content, 
the chemical component largely responsible for its commercial value (Renn, 1997; Evans, 1996a) and for 
its management as a Wild resource (Tronchin et al., 2003; Santos et at., 2003). Polysiphonia have been 
part of screens in which antimicrobial activities were tested (Caccamese et aI., 1985; Vlachos et al., 1997). 
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Table 2.1 Red algal species of the genus Gelidium, Plocamium and Polysiphonia, their isolated compounds and 
biological activities reported for their extracts or isolates. 
Species 
Gelidium amansii 
Galidium amansii 
Gelidium amansli 
Gelidium attenuatum 
Gelidium cartilagineum 
Gelidium divaricatum 
Gelidium elegans 
Galidium pristoides 
Gelidium pusillum 
Gelidium sesquipedale 
Plocamium angusla/um 
Plocamium cartilagineum 
Plocamium cartilagineum 
Plocamium cartilagineum 
Plocamium cartilagineum 
Plocamium cartilagineum 
Plocamium cartilagineum 
Pkxamium cartilagineum 
Plocamium cartilagineum 
Plocamium cartilagineum 
P/ocamium cartilagineum 
Plocamium cartilaginaum 
Plocamium cartilagineum 
Plocamium cartilagineum 
Plocamium cartilagineum 
Pkxamium cartilagineum 
Plocamium cartilaglneum 
Plocamium cartilagineum 
Plocamium cartilaglneum 
Plocamium cartilagineum 
Plocamium cartilaglneum 
Plocamium coccineum 
Plocamium coccineum 
Plocamium corrallorlJiza 
Plocamium cos/a tum 
Plocamium costa tum 
Plocamium costa/um 
Plocamium costa tum 
Plocamium hamatum 
Plocamium hamatum 
Plocamium hamatum 
Plocamium hamatum 
Plocamium lep/ophyllum 
Plocamium leptophyllum 
Plocamium oregonum 
Biological activitynsolated compounds 
Cytoloxic activity 
Antitumour activity 
CytOtOXIC activity 
Antimitotic activity 
Antiviral activity 
Antioxidant activity 
Antitumour activity 
Galactosyl glycerol 
Antitrypanosomal activity 
Antimitotic activity 
Bromophenols 
PoIyhalogenated cyclic monoterpenes 
Terpenes 
PoIy(~-hydroxybutyrate), Floridoside 
Terpenes 
Acyclic halogenated rnonoterpenes 
Linear monoterpene 
Plocamapyranoid 
4-bromo-5-chloro-2-(E)-chlorovinyl-l ,5-dimethyl-l ,2-epoxycyclohexane 
(1 S,2R,4 R,5S, 1 AEJ-2,4,5-trichloro-l-(2Achloroethynyl)-
1,5-dimethylcyclohexane 
Polyhalogenated monoterpenes 
Polyhalogenated monoterpenes 
Polyhalogenated homosesquiterpenic latty acids 
Polyhalogenated homosesquiterpenic fatty acids 
Telrahydroluran halogenated monoterpene( 1), acyclic polyhalogenated 
monoterpenes(2)(3) 
(4) Furoplocamioid 
(5) Plocamenol 
PoIyhalohydroxylated monoterpenes, ptocamenols A - C 
Polyhalogenated monoterpenes 
PoIy(~-hydroxybutyrate), Floridoside 
Terpenes 
Terpenes 
Halogenated monoterpens 
Antimitotic activity 
Antibacterial activity 
Polyhalogenated monolerpenes 
Antilouling 
Polysaccharide 
Polysaccharide 
Antifouling activity 
Halogenated monoterpene 
Terper:les 
Compound 11 - weakly antimicrobial, Compound 4 - anti-algal against alga Chiarella 
fusca, Compound 3 - antimycobacterial, Compound 4 - antialgal, cytotoxic, 
antimycobacterial, Compound 6 - antimycobacterial 
Cyclic monoterpene 
Terpenes 
Antifouling 
Terpenes 
Halogenated monoterpene 
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Reference 
Harada et al., 1997 
Ohigashi at al., 1992 
Numata e/ ai, 1991 
Chenieux et al., 1980 
Gerber et al., 1958 
Fujimoto et al., 1985 
Nakamura et al . 1997 
Nunn and Von 
HoIdt, 1955 
Gonzalez et al., 1990 
Chenieux at al., 1980 
Whitfield et al., 1999 
Stier1e and Sims (1979) 
Abreu and Galindro (1996) 
Abreu et aI., 1997 
Cueto e/ aI, 1998 
Faulkner, 1998 
Faulkner, 2000 
Faulkner, 2000 
Faulkner, 2000 
Faulkner, 2000 
Jongaramruong and Blackman ,2000 
Danas et aI., 2001 
Rezanka and Dembitsky, 2001 
Dembitsky and Srebnik, 2002 
Diaz-Marrero et aI, 2002a 
Diaz-Marrero et al., 2002b 
Faulkner, 2002 
Abreu et al., 1997 
Cueto etal., 1998 
Abreu and Galindro, 1996 
Argandoiia e/ al., 2002 
Chenieux etal., 1980 
Usmanghani e/ a/., t984 
Knott et al., 2005 
Konig e/ aI, 1999a 
Miller, 1999 
Miller e/ aI., 1996 
Konig et a/., 1999a 
Konig et a/., 1994 
KOnig et a/., 1999b 
Faulkner, 1999 
Konig et al., 1999b 
Sakata e/ a/., 1991 
Sakata et al., 1991 
Crewse/al., 1984 
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Species 
Plocamium rigidum 
Plocamium sp. 
Plocamium telfairiae 
Plocamium violaceum Farlow 
Plocamium violaceum 
Plocamium violaceum 
Plocamium violaceum 
Polysiphonia brodiaei 
Polysiphonia nigrescens 
Polysiphonia paniculafa 
Polysiphonia sphaerocarpa 
Polysiphonia urceolafa 
Polysiphonia denudate 
Polysiphonia fruticulosa 
Polysiphonia hendryi var Gardneri 
Polysiphonia lanosa 
Polysiphonia lanosa 
Polysiphonia lanosa 
Polysiphonia subtilissima 
Polysiphonia urceolafa 
Polysiphonia urceolata 
POlysiphonia urceolafa 
Biological activity/lsolated compounds 
Antimicrobial 
Terpene 
Cytotoxic activity 
Oleic acid, palmitic acid, cis-vaccenic acid, dihomo-y-linolenic 
acid, arachidonic acid, eicosapentaenoic acid 
Cyclic monoterpene 
Acyclic polyhalogenated monoterpenes 
Larvicidal activity 
Brominated phenols 
Bromochlorophenols 
Dimethylsulfoniopropionate 
Brominated anisoles and cresols 
Polyunsaturated fatty acids 
Antiviral activity 
Antimitotic activity 
Antiviral activity 
Galactan sulphate 
Antimitotic activity 
Antibacterial activity 
Antibacterial activity 
Antioxidant activity 
Carotenoids 
Acrylic acid 
2.3.1 Gelidium pristoides (Turner) Kuetzing 
2.3.1.1 Description, ecology, distribution and uses 
Figure 2.1. Gelidium pristoides 
Reference 
Vlachos et aI., 1997 
Whitney ef al., 1997 
Harada et aI., 1997 
Khotimchenko et al., 2002 
Crews and Kho, 1975 
Crews and Kho-Wiseman, 1977 
Crews et al., 1984 
Pedersen et aI., 1974 
Pedersen, 1978 
Nishiguchi and Goff, 1995 
Flodin and Whitfield, 2000 
Li et al., 2002 
Serkedjieva, 2000 
Chenieux et al., 1980 
Kim ef al., 1997 
Batey and Turvey, 1975 
Chenieux et al., 1980 
Lustigman et al., 1992 
Perez et aI., 1990 
Fujimoto ef al., 1985 
Bjorland and Aguilar-Martinez, 1976 
Glombitza, 1970a; Glombitza, 1970b 
This is a bushy dark olive brown to black plant with a tough texture and it grows to approximately 20 cm 
(Stegenga et al., 1997). It is endemic to South Africa and commonly found growing on rocks and the shells 
of the limpet Patella in the mid and lower intertidal zones from Sea Point eastward, across the southern 
Cape and finally the eastern Cape and Transkei where its biomass is the greatest and it is harvested 
commercially (Stegenga et al., 1997). The phycocolloids extracted from species of Gelidium, amongst 
other algae, are used to prepare bacteriological and tissue culture media (South and Whittick, 1987) since 
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they are not metabolised by microorganisms, such as bacteria and fungi (Stegenga et ai, 1997). In 
addition, they are used as a gelling agent for fruit and vegetable jellies (Nagaoko et al., 2000), added to 
bakery products, confectionery (Stegenga et al., 1997) and pharmaceuticals (Renn, 1997) where they are 
used as a disintegrant in tablets and in the preparation of slow-release capsules (Nagaoko et al., 2000). 
Whole plants species of Gelidium are eaten in the Orient and Pacific Islands (South and Whittick, 1987) 
while in the West they are found in health stores or as additives in health products (Nagaoka et al., 2000) 
together with other seaweeds. Various ecological studies of Gelidium species have been undertaken, 
including investigation into the effects of grazing on the shore distribution of algal communities 
(Boaventura el al., 2002; Tronchin et al, 2003), algal population dynamic and productivity (Duarte and 
Ferreira, 1997), and its commercial exploitation worldwide (Melo, 1998). 
2.3.1.2 Phytochemistry 
Gelidium species are known for their high agar content (Evans, 1996a) - polysaccharides composed of 
sulphated and pyruvated galactoses (South and Whittick, 1987). Fatty acids have been reported in an 
investigation of Gelidium amansii (Li el al., 2002). One of the reasons why this alga is included in the diet 
of people in the Orient and elsewhere is because it is rich in protein and vitamins such as C, A, B1, 812, E, 
riboflavin, niacin, panthothenic acid and folic acid (South and Whittick, 1987). 
2.3.1.3 Pharmacological studies 
A crude extract of Gelidium abbottiorum has been reported to contain antimicrobial compounds (Vlachos 
el al., 1997). Gelidium amansii has cytotoxic constituents (Numata et al., 1991) and its agar has been 
reported to be effective in treating obesity, constipation, irritable colon, diverticulitis and gastritis (Moro and 
Basile, 2000). Other bioactivities are referred to in Table 2.1. 
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2.3.2 Plocamium corallorhiza (Turner) Harvey 
2.3.2.1 Description, distribution and uses 
Figure 2.2. Plocamium corallorhiza 
These plants are robust and grow to 30 cm. It has a bright red thallus and at times appears to have a 
bluish iridescence under water. It is endemic to southern Africa, and is commonly found in the sublittoral 
zone in Yzerfontein eastward to Natal and in northern Namibia. It is reported to be lacking from most of the 
Western Cape coast (Stegenga et al., 1997) and it is used in feeding abalone (Anderson et al., 2003). 
2.3.2.2 Phytochemistry 
Many halogenated monoterpenes, cresols, anisoles, fatty acids, and polysaccharides have been isolated 
from various species of algae belonging to this genus (Table 2.1). 
2.3.2.3 Pharmacological studies 
When compared to the genus Gelidium and Polysiphonia, the genus of Plocamium has been screened in 
many investigations. Anti-algal, antimicrobial and antimycobacterial activity has been reported for the algal 
extracts of various species (Table 2.1). 
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2.3.3 Polysiphonia virgata (C. Agardh) Sprengel 
2.3.3.1 Description, distribution and uses 
Figure 2.3. Polysiphonia virgata 
This dark red to blackish plant grows to 30 cm or more. It often grows within the tissues of other plants, but 
is not necessarily parasitic, e.g. as an epiphyte on the kelp Ecklonia maxima (Stegenga et al., 1997). 
Palysiphonia virgata is endemic to southern Africa and is found from the coast of Namibia to Brandfontein 
near Cape Agulhas. 
2.3.3.2 Phytochemistry 
From Polysiphonia paniculata dimethylsulfoniopropionate has been isolated (Nishiguchi and Goff, 1995) 
and P. sphaerocarpa contains brominated anisoles and cresols (Faulkner, 2000). The volatile compound 
dimethyl sulfide is given off spontaneously by P. fastigiata and P. nigrescens when they are exposed to air 
(Moore, 1977) and could be smelt in the laboratory while processing P. virgata in this investigation. 
2.3.3.3 Pharmacological studies 
Polysiphonia furcel/ata (Caccamese et al., 1985), P. lanasa, P. elongata, P. nigra, P. nigrescens, P. 
urceolata (Hornsey and Hide, 1976) and P. virgata (Vlachos et al., 1997) have been reported to contain 
antimicrobial compounds and P. hendryihas antiviral compounds (Kim et aI., 1997). Other bioactivities are 
referred to in Table 2.1. 
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Chapter 3 
MATERIALS AND METHODS 
3.1 Sample collection 
Two seaweed species, namely Gelidium pristoides and Plocamium corallorhiza were collected on 28 
February 2002 at Glen Cairn, False Bay, Cape Town (Figure 3.1). On 24 April 2002, a sample of 
Polysiphonia virgata was collected at Sweet Water, a little south of Kommetjie, Cape Town. For the re-
investigation of P. virgata a second sample was collected at Sweet Water on 4 July 2005. All the algae 
were collected and verified by Mr Mark Rothman and Mr Chris Boothroyd from the Seaweed Research 
Unit of the Department of Environmental Affairs and Tourism: Marine and Coastal Management, which is 
based in the Botany Department at the University of Cape Town. Voucher specimens of the seaweeds [G. 
pristoides: Bolus Herbarium (BH) 99074; P. corallorhiza: BH 99075 and P. virgata: BH 99073] were 
deposited in the Bolus Herbarium at the Botany Department of the University of Cape Town (UCT). The 
herbarium specimen no. of the second P. virgata sample is: BH 126936. In addition, five liters of seawater 
samples were collected at Glen Cairn, Simonstown Harbour (2.5 L at the boathouse and 2.5 L at East 
Gate), and Sweet Water on 10 February 2006. 
3.1.1 Background of collection sites 
Glen Cairn is protected from heavy wave action in False Bay and is close to Simonstown harbour. It is 
home to a kelp community where Plocamium corallorhiza grows on the holdfast area from where divers 
removed it. Gelidium pristoides was found on the exposed rocks at lowtide. Environmental events that 
could influence the quality of the algae at a point in time are algal blooms and chemical waste from the 
harbour area or outfalls. In contrast, at Sweet Water the coastline is exposed to the waves of the Atlantic 
Ocean. The first sample of Polysiphonia virgata that was collected in February 2002 was found scattered 
about in the tidal pools at low tide probably as a result from a storm the previous night. At the second 
collection, the alga was cut from the kelp forest that is commercially grown at Sweet Water. Environmental 
events that could influence the quality of algae include upwelling in southern Benguela, which is in season 
from September to March. During this season the water temperatures of newly upwelled water is 14° to 
16°C (Verheye et al., 1992) as opposed to the normal 100 to 120C. Upwelling brings about an increase in 
mesozooplankton (Verheye et a/., 1992) and so grazing of the algae in the effected area. 
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Materials and Method:; 
3.2 Extraction 
3.2.1 Preparation 
Figure 3.1. Map of False Bay indicating the positions of Glen 
Cairn and Kommetjie. Source is unknown. The photos were taken 
by Ms. Carmen Lategan 
The seaweed samples were placed into plastic bags and kept cool all ice. In the laboratory, the algae 
were washed with distilled water to remove surface salts, sand, and epiphytes. The seaweeds were 
dabbed with paper towel to remove excess water and cut into small pieces. Samples were weighed and 
covered with volumes of dichloromethane (OCM)-methanol (MeOH) (2: 1) solution. With the second 
collection of P. virgata the cleaned seaweed was weighed (6718.40 g) and placed in an oven at 50'C. A 
small portion of the wet sample was reserved to determine whether methoxyethyl methacrylate was 
adsorbed onto the algal surface or present inside the thallus. This was done by dipping the alga into 200 
mL of ethanol, followed by 200 mL of dichloromethane (OCM) and finally it was left to soak in OCM 
overnight. The resultant solutions were evaluated using a LC-MS. 
3.2.2 Solvent extraction 
The seaweed samples were homogenized using a Kinematica homogenizer, stirred for 36 hours and 
filtered using a BOchner funnel with Whatman no. 541 filter paper. The seaweeds were extracted thrice 
with a solution of OCM-MeOH (2: 1). This solvent was selected because it was recommended for the 
extraction of algal secondary metabolites by Cronin et al. (1995) and proved excellent in a previous study 
done by Cameron et al. (2001). Cronin et at. (1995) extracted two brown algae under various conditions 
and with different solvents. They found that when the seaweeds were extracted with methanol alone 
artifacts formed during the extraction procedure. When dichloromethane (OCM) was added to the 
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methanol in a 2:1 ratio, artifacts were reduced and the concentration of lipophilic secondary metabolites 
increased because of the less polar DCM. Other factors that also influenced the amount of secondary 
metabolites obtained included biochemical activity, light, vacuum, the drying procedure and the duration of 
extraction. These were all kept to a minimum during this extraction procedure. Therefore, the samples 
were extracted with a 2:1 mixture of DCM:MeOH. The samples that could not be processed on a particular 
day were stored in darkness in the freezer at -20Cl C. The filtrates were evaporated under vacuum in a 
Buchi Rotavapor R-20S at not more than SO"'C. The dried extracts were also stored in a freezer at 
approximately -20"C. For the preparative Centrifugal Layer Chromatograph (Chromatotron) it was 
determined that the more polar compounds were difficult to remove from the silica plates and therefore the 
DCM-MeOH (2: 1) crude extract was partitioned between dichloromethane and water using a separating 
funnel. The dichloromethane portion was dried with anhydrous magnesium sulphate. These filtrates were 
concentrated under vacuum at SO°C, while the water portion was concentrated by freeze-drying. The 
second collected sample of P. virgata was dried (782.S0 g), milled using a blender, and soaked in cold 
methanol for 2 hours at 4°C. The methanol was filtered off and the algal material steeped in 2 L 
dichloromethane (DCM) overnight at 4°C. The cold DCIVI was filtered trom the plant material and replaced 
with more DCM (S x 2000 mL) at room temperature. The extracts were concentrated under vacuum using 
a Buchi Rotavapor R-20S at 50°C. 
3.3 Isolation and Purification 
3.3.1 Preparative Layer Chromatography (PLC) 
Analytical thin-layer chromatography and PLC were carried out on Merck' pre-coated glass-backed, silica 
gel 60 F254 plates (0.2S mm and 2 mm or 1 mm thickness, respectively). Dichloromethane sample 
solutions were applied manually in approximately 17 cm long bands using a S mL glass pipette to PLC 
plates of the following specification: 1 mm thick 20 x 20 cm glass-backed silica 60 F254. Chromatogram 
development was achieved by introducing the PLC-plates into chambers saturated with the mobile phase 
hexane-chloroform-methanol (7:2:1) which was determined from many different solvent combinations to 
give the best component separation. Five hundred milligram of the algal crude sample was applied to each 
PLC-plate and six plates were prepared per sample adding up to 3000 mg for each sample. After the 
solvent front was allowed to travel to about O.S cm from the edge of the plate and the solvents allowed to 
evaporate, six distinct bands were identified under ultraviolet light of wavelength 2S4 and 366 nm. These 
fraction bands were marked and the silica removed from the glass plates by scraping with a spatula. The 
band numbers allocated increased from the least polar (B 1) to the most polar (B6). For each sample, 
bands of Silica with similar numbers were combined and powdered using mortar and pestle. Desorption 
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was achieved by washing the silica extensively with OCM followed by MeOH under vacuum using a 
sintered glass Buchner funnel noA. The washings were combined and evaporated under vacuum at SO°C 
in a Buchi Rotavapor R-20S. 
3.3.2 Preparative centrifugally accelerated radial layer chromatography (Chromatotron) 
Figure 3.2. The Chromatotron model 8924. This picture was 
reproduced from the product manual. 
Centrifugal preparative layer chromatography was performed using a Chromatotron model 8924 from 
Harrison Research Inc., USA (Figure 3.2). The dichloromethane-methanol (2:1) extract of the fresh and 
wet a~ae were partitioned between water and dichloromethane in a separating funnel. The water-soluble 
portion was frozen and Iyophllised while the OCM portion was concentrated under vacuum at SO°C in a 
Buchi Rotavapor R-20S. 
Separated sample Sample sotutJon . 
SOtvefit 
Soroont layer 
Figure 3.3 Purification of crude extract obtained using the 
Chromatotron. This image was reproduced from the product 
manual. 
Only the OCM-portion was fractionated on the Chromatotron using silica gel 60 PF-2S4 coated plates (2 or 
1 mm thickness) and hexane-OCM-MeOH (7:2:1) as solvent (Figure 3.3). The polarity of the solvent 
system was gradually increased to remove the more polar fractions from the rotor until only MeOH was 
effective. The less polar fractions were further fractionated using hexane-OCM-MeOH (S:3:2) or OCM-
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MeOH (5:5), while the polar fractions resolved well with either toluene alone or hexane: DCM:MeOH 
(7:2:1). In some cases, better separation was achieved by starting with hexane and introducing more polar 
solvents enabling the bands to elute from the silica plate. The fractions were observed under ultraviolet 
light of 254 and 366 nm. 
3.3.3 Flash Chromatography 
Flash silica gel chromatography of the resultant sample material (7.074 g) was done with hexane and 
increasing proportions of ethyl acetate (EtOAc) as eluant and resulted in 44 main fractions (Appendix 1). 
Fraction 45 was obtained by washing the silica column with absolution ethanol until the eluant became 
colorless. The fractions were concentrated under vacuum using a Buchi Rotavapor R-205 at 50"C and 
dried completely under a stream of nitrogen. 
3.4 Preparation and Isolation of Fatty Acid Derivatives 
The sample was reacted with methanolic HCI, 1.5 N to obtain the methyl esters of the lipids present. This 
was done by refluxing 10.0 mg of sample C1730 and 6.4 mg of sample 1730/11 in 5 mL of methanolic HCI 
for 2 hours. The reaction mixture was evaporated to dryness under vacuum. The fatty acid methyl esters 
were purified by silica gel column chromatography using a Pasteur pipette and eluting with hexane/ether 
(8:2 v/v). The solvent was evaporated to dryness and the methyl esters dissolved in hexane and analyzed 
by gas chromatography-mass spectrometry (GC-MS). 
3.5 Solvent partitioning of seawater samples 
The water samples were kept at 4°C until the lipids were removed by partitioning between chloroform and 
water. The chloroform portion was dried with magnesium sulphate and reduced under vacuum using a 
Buchi Rotavapor R-205 at 50°C. It yielded 3.4 mg and 6.3 mg for the samples taken in Simonstown 
harbour at the East Gate and Boathouse, respectively. Sweet Water extract amounted to 8.6 mg and the 
seawater extract obtained Irom Glen Cairn to 2.4 mg. 
3.6 Bioassay procedures 
3.6.1 The agar-overlay bioautography method 
This method was used to determine the antimicrobial activities of sample solutions. The microorganism 
used for testing was supplied by the Medical Microbiology Department of the University of the Cape Town. 
Staphylococcus aureus ATCC-25923 was cultured on Nutrient agar (Oxoid iso-sensitest) and later a 
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suspension was prepared in Muller-Hinton medium. The developed and glass-backed analytical TLC-
plates as recommended by Gibbons and Gray (1998) were removed from the freezer and maintained at 
37"C in an incubator. The agar mixtures were allowed to cool until they could be held in the hand 
comfortably (c.37"C). The agar mixture and the microorganism were mixed thoroughly. The plates were 
removed from the incubator as soon as the agar mixtures were prepared. Forty milliliters of the agar 
mixtures was poured over the chromatograms on each 20 x 20 cm TLC-plate, ensuring the 
chromatograms were completely covered. After solidification of the agar layers, the TLC-plates were 
placed into plastic trays with a beaker of water to maintain a humid atmosphere to prevent the TLC-plates 
from drying. The trays were covered with plastic bags and incubated at 37°C for 24 hours. After the 
incubation period, the plates were sprayed with a 0.1 % aqueous solution of 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazoliurnbrornide (MTI-reagent). The mitochondrial enzymes of live organisms reduce the 
MTI-reagent, which is a pale yellow substance, to a dark blue formazan product (Begue and Kline, 1972). 
The sprayed plates were incubated for 1 hour at 37'"C, after which the inhibition zones were recorded. 
3.6.2 Direct Bioautography 
Five hundred micrograms of each fraction (see Appendix 1) was applied to an analytical thin-layer 
chromatography (TLC) 20 x 20 cm glass-backed plate with a fluorescent indicator and allowed to develop 
to the centre of the plate (about 9 cm) using hexane: chloroform: methanol (7:2: 1) as the mobile phase. 
This permitted 18 fractions to be evaluated per plate. After development, the solvents were allowed to 
evaporate completely. Antimycobacterial activity was assessed using Mycobacterium aurum and M. 
smegma tis. These mycobacteria were cultured in Middlebrook-7H9 broth. The developed TLC-plates were 
dabbed with the bacterial suspension using sterile cotton balls and incubated in a moist atmosphere at 
37°C. Plates with M. aurum were incubated for 3 days and M.smegmatis for 2 days. At the end of the 
incubation period, the plates were sprayed with a p-iodonitrotetrazolium violet solution (0.4 mg/mL) that 
converted areas with bacterial growth into a pink colour. The sprayed plates were incubated for 1 hour at 
37"C, after which the clear zones were recorded as inhibition zones. Rt-value = Inhibition zone distance 
from origin (midpoint) in (mm)/Solvent front distance from origin in (rnrn). Purified fractions (500 11 g) were 
applied to the plates, but not allowed to develop in a solvent system, thus only inhibition zones sizes were 
measured. Minimum inhibition concentration values (MIC-values) of samples were deterrnined by applying 
sample sizes ranging from 500 l1.g to 0.4 I1g to the tic-plate. Ciprofloxacin (12 ~lL of 1 mg/mL solution, i.e. 
12 11. g) was used as a drug control. 
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3.6.3 Parasite lactate dehydrogenase assay for Plasmodium falciparum sensitivity 
The in vitro antimalarial activity was determined by using a modified method of the parasite lactate 
dehydrogenase assay as described by Makler et al. (1993). It is a colorimetric enzymatic method, which 
capitalizes on the distinction between parasite lactate dehydrogenase (pLDH) activity and host LDH 
activity, by using the 3-acetyl pyridine adenine dinucleotide (APAD) analogue of nicotinamide adenine 
dinucleotide (NAD). Pyruvate is converted to lactate by pLDH using APAD as a coenzyme. In the 
presence of the reduced APADH, the yellow coloured nitro blue tetrazolium (t\IBT) is converted to purple 
formazan salt. The concentration causing 50% growth inrlibition of P. falciparum was measured by 
observing the colour conversion from yellow to blue caused by surviving parasites. 
3.6.3.1 Cultivation of parasites 
A culture adapted chloroquine-sensitive (COs) cloned (Papua l\Jew Guinea 010) strain of P. falciparum that 
was donated by Dr. A. Cowman, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 
was used in this assay. Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were 
maintail1ed using a modified method of Trager and Jel1sen (1976). The parasite cultures were maintail1ed 
in complete tissue culture medium containing 10.4 giL RPMI 1640 with glutamine, 4 giL glucose, 6 giL 
Hepes buffer, 0.088 giL hypoxamine, 5 giL Albumax and 1.2 mUL (0.05 giL) gentamicin. Type O-positive 
human red blood cells obtained from the Western Province Blood Transfusion Service at Groote Schuur 
Hospital in Cape Town were washed with wash medium [10.4 giL RPMI 1640 with glutamine, 4 giL 
glucose, 6 giL Hepes buffer, 0.088 giL hypoxamine, and 1.2 mUL gentamicin] and centrifuged. Sorbitol 
was used to synchronise the parasitized-infected red blood cells (PRBC) in the ring stage. The PRBC 
were grown in sterile tissue culture flasks (Greiner Bio-One), which were flushed with gas (3% 02, 4% 
C02, 93% N2) for 1 minute and placed in an incubator at 370C in 3% C02, 97% 1\J2. A medium change took 
place every 24 hours. The parasitaemia was observed microscopically by staining a smear of PRBC with 
20% Giemsa stainil1g solution al1d its requirement in this experiment was 1 % with a 1 % hematocrit. 
3.6.3.2 Sample preparation 
The sample solution was prepared with methanol: water (1 :9) at a concentration of 2 mg/mL. A solvent 
control was included ill each analysis to el1sure tl1at the antimalarial activity was because of the plant 
extract alone. 
3.6.3.3 Assay procedure 
The suspensions were dispensed in 96 well flat-bottomed microtitre plates in the following order: row 1 -
blank (100 III 1% hematocrit + 100 ~I complete medium), row 2 - positive control (100 ~ll 1% parasite 
suspension + complete medium), row 3 to 12 - plant samples (conc. 100 IlglmL serially diluted two-fold in 
complete medium up to 0.195 11 glmL + 100 III of 1 % parasite suspension in each well). Chloroquine 
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diphosphate was used as the drug control and was serially diluted two-fold from 100 ng/mL to 0.195 
ng/mL. Each well had a final volume of 200 111. The microtiter plates were covered with a lid and placed in 
a chamber that was flushed with gas (3% 02, 4% C02, and 93% N2) for approximately 5 minutes and 
placed in an incubator for 48 hours at 37°C. After incubation, the samples were resuspended and 15 111 of 
the suspensions were transferred to 100 11.1 of Malstat (solution of 400 111 Triton 100, 4 g of L -lactate, 1.32 
9 tris-buffer and 22 mg APAD in 200 mL of mH20). To this was added 15111 of [\IBT (solution consists of 
160 mg NBT and 8 mg phenazine ethosulphate in 100 mL of mH20). Malstat was used to disrupt the red 
blood cell membranes and so expose the parasites to I\JBT. Air bubbles were removed with a hair dryer 
and the plates placed in a dark cupboard to develop. Once a colour change from yellow to purple was 
obseNed the absorbance of each well was read by using a microplate reader at 620 nm. The readings 
were plotted using GraphPad Prism v.2.01 and a non-linear dose response CUNe fitting analysis 
performed to determine the IC50-values. 
3.6.4 MIT cytotoxicity determination 
The mammalian cell line, Chinese hamster ovarian (CHO) cells, was obtained from S. Schwager from the 
Department of Medical Biochemistry, University of Cape Town, South Africa. This method is a rapid 
colorimetric method for the determination of cellular growth and chemosensitivity (Mosmann, 1983) and 
uses methylthiazoyltetrazolium chloride (MTI) salt. The tetrazolium ring is cleaved in active mitochondria 
therefore only viable cells are able to reduce the yellow water-soluble coloured MTI to water-insoluble 
purple coloured formazan (Siewerts et al., 1995). 
3.6.4.1 Sample preparation 
Plant samples of a concentration of 2 mg/mL were prepared in MeOH: H20 (1 :9), a solvent concentration 
that is not harmful to the Chinese hamster ovarian (CHO) mammalian cell line. Emetine dihydrochloride 
was used as the control drug. 
3.6.4.2 Assay procedure 
The cells were cultured in complete medium (45% Dulbecco's modified Eagle's medium, DMEM, 45% 
nutrient mixture F-12 HAM - Sigma ,HAMS and 10% Foetal Calf Serum, FCS). DMEM was prepared by 
stirring 13.53 giL DMEM and 3.7 giL l'JaHC03 in H20 for 30 minutes, adjusting the pH to 7.1 and adding 
0.05 g of the antibiotic gentamicin. DMEM was filtered using a 0.45 11m filter and filter sterilized using a 
0.22 11 m filter. The HAMS medium was prepared by dissolving 10.7 giL of HAMS and 1.176 giL NaHC03 
in water, adjusting the pH to 7.1, filtering the mixture and filter sterilizing it using a 0.22 11 m filter. Both 
media were stored at 4oC. The foetal calf serum was heat inactivated by placing it in a 560C water bath for 
30 minutes after which it was stored at -20°C. Each sample was tested in triplicate. The initial 
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concentration of 100 11 g/rnl was dispensed into a 96 well microtiter plate and serially diluted in complete 
medium with 10-fold dilutions to give 4 concentrations with the lowest being 0.1 11 g/ml. The cells were 
sub-cultured to obtain a suitable cell suspension and a small aliquot was mixed with crystal violet (1:1) to 
stain to enable counting. A concentration of 105 cells per ml was required. Row H was used as a blank 
and contained only complete medium. Row G to A contained 100 111 of complete medium and 100111 of 
the cell suspension at concentration of 105 cells/ml. The final volume in each well was 200 111. The plate 
was covered with a lid and placed in an incubator at 37°C for 24 hours with (5% C02, 95% 1\J2). After 24 
hours the plant samples were added and the medium carefully aspirated from each well. Row G was used 
as a positive control and contained cells and medium only. The plant samples were added to Row F and A 
at different concentrations and the covered plate allowed to incubate at 37°C for 48 hours in 5% C02, 95% 
N2. After the incubation period, 25 111 of the sterile MIT (5 mg/ml in PBS) was added to each well and the 
plates incubated for 4 hours at 37°C. The plates were then centrifuged at 2050 rpm for 10 minutes and the 
supernatant carefully aspirated from the well. The formazan crystal that remained in the wells was 
dissolved in 100 111 of OMSO and the plate gently shaken on the microtitre plate shaker for 5 minutes. The 
wells in column 1 was used to zero the reading of the spectrophotometer and the absorbance of the 
crystals was measured at 540 nm on a microtitre plate reader (Cambridge Technologies). The cell viability 
was calculated in each well using the formula: 
% Cell Viability = AA540 test well (cells + dr~g) x 100 
AA540 cell control well (cells + no dr~g) 
3.6.5 The radiometric method 
The radiometric method used was described by S.H. Siddiqi in the Product and Procedure Manual of 1995 
of the Bactec 460 TB System. The main component of this method is the 7H12 Middlebrook TB medium 
that contains the 14C-labeled substrate (palmitic acid) as a source carbon. As the bacterium grows, it 
consumes the palmitic acid, which results in the release of 14C02 into the atmosphere of the sealed vial. 
The BACTEC-460 instrument (Johnston laboratories, Towson MO) records the amount of 14C02 and 
processes it as a growth index (GI) on a scale of 0 - 999 (lall and Meyer, 1999). 
A sensitive Mycobacterium tuberculosis H37Rv ATCC strain was used in this investigation and was 
supplied by the Microbiology laboratory of the l\Jational Health laboratory Services, which is based at 
Groote Schuur Hospital, where it is routinely used to determine the bacterium's susceptibility to the first-
line drugs rifampicin, isoniazid, and occasionally ethambutol. The bacterium was grown on lowenstein-
Jensen slants or in Bacto Middlebrook 7H9 liquid medium. A multi-drug resistant clinical isolate of M. 
tuberculosis that was resistant to rifampicin, isoniazid and ethambutol was also supplied by the same 
laboratory. 
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The sensitive M. tuberculosis H37Rv strain was inoculated into a BACTEC-vial containing 4 mL 7H 12 
Middlebrook TB medium. When the growth index of the bacterium vial reached values of 300 to 500, the 
broth culture was considered ready to be introduced into the test and control vials, which each contained 4 
mL 7H 12 Middlebrook TB medium. The test vials contained 0.1 mL of the broth culture and plant extract 
while the two positive control vials or drug controls contained 0.1 mL of the broth culture and 0.1 ~g/mL 
isoniazid and 2.0 ~g/mL rifampicin each. In addition, two negative controls were used, one with only 0.1 
mL of broth culture and another prepared by adding 0.1 mL of a 1:100 dilution of the broth culture. The 
dilution was prepared in a special diluting fluid. For the plant extracts or purified fractions, a 5 mg/mL 
solution in 12.5% methanol or ethanol in Bacto Middlebrook 7H9 broth was prepared The plant sample 
test vials received 1 00 ~L of each 5 mg/mL plant extract resulting in a 40-fold dilution. Each sample vial 
therefore contained 500 ~ g of extract or a 125 ~ g/mL sample solution. All the vials were incubated at 
37°C and the growth index (GI) determined daily at the same time over a period of 4 to 12 days until the 
GI of tile 1:100 control vial reached 30 or more. The sample vials with GI-values below or equal to that of 
the 1:100 control vials on the final day of the assay were considered active against M. tuberculosis at a 
concentration of 12 ~ g/mL. The percent inhibition was calculated as 1 - (growth index of test 
sample/growth index of control) x 100 = % as done by Konig et al. (2000). 
3.7 Instrumental analysis 
3.7.1 Nuclear Magnetic Spectroscopy 
1H and 13C NMR spectra were run on a Varian UNITY-Inova Spectrometer using CDCb or CD2Cb at 600 
MHz and 150 MHz, respectively. The spectra were further processed using MestrRe-C Beta version 3.7.1 
obtained from mestrec.com. 
3.7.2 Mass Spectrometry 
The GC-MS analyses were recorded at 70 eV using a Carlo Erba GC 6000 Vega Series equipped with a 
40 m X 0.3 mm special performance capillary column (Lexus, PS089-0H) silanol-terminated (95%)-
methyl-(5%)-phenylpolisiloxane copolymer stationary phase and He as the carrier gas. Analyses were 
performed IJsing the following conditions: initial temperature, 130 oC; rate of increase 3 oC /min; final 
temperature, 270 °C, hold 10 minutes. The LC-MS spectra obtained for the initial identification of 2-
methoxyethyl methacrylate were obtained in electron impact (EI) mode using a direct probe in an AMD 
604 (AMD Intectra GmbH) mass spectrometer. The rest of the LC-MS/MS analysis was performed on an 
Applied Biosystems Sciex API-4000 mass spectrometer (Applied Biosystems Sciex, Ontario, Canada) 
using atmospheric pressure cllemical ionization (APCI) for ion detection in an acidic chemical environment 
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(0.1 % formic acid: acetonitrile 50%). The samples were infused at a flowrate of 10 IJl/min. APCI was 
conducted in the positive mode with nitrogen as the nebulizer and an ion spray voltage of 5500. 
3.7.3 High-Performance Liquid Chromatography 
The initial chromatography in which 2-methoxyethyl methacrylate was isolated was done uSing a 
Shimadzu Liquid Chromatograph LC-10AS with an auto-injector, communications bus module, and 
Shimadzu diodearray detector SPD-1\t11 OA. Semi-preparative reverse phase HPLC was performed using a 
semi-preparative Higgins Analytical HAISIL 100 C18 column, 250 x 10 mm PIN HS-2510-M185, injection 
volume of 100 I-l L with a flow rate of 3 mUmin over a run time of 40 minutes and solvent gradient of 20% -
100% acetonitnle in water. Fractions were collected every 2 minutes using a fraction collector. This was 
repeated many times until sufficient sample material was available for each fraction for the bioassays. 
Analytical HPLC was performed using an octadecyl silica column (Supelco Discovery® C18 column, 15 
cm x 4.6 mm, 5 I-l m). Separations were accomplished at room temperature with a solvent gradient of 20% 
- 100% acetonitrile in water in 30-minute long runs with a flow rate of 1 ml/min. In the second attempt to 
isolate the antimycobacterial compound(s) from Polysiphonia virgata, preparative separation was achieved 
using a Spectra-Physics IsoChrom LC HPLC equipped with a rheodyne injector, a Waters R401 
Differential Refactometer, a Rikadenki chart recorder and a Whatman Partisil 10 column. The mobile 
phase used in this purification was hexane (85%) in ethyl acetate at a flow rate of 4 mUmin. Before 
injecting the sample into the column the extract was washed through a small silica column prepared by 
putting slurry of silica 60 in 80% hexane in ethyl acetate into a plugged Pasteur pipette. The portion that 
eluted from the column was further purified using the Spectra-Physics IsoChrom LC HPLC. 
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Chapter 4 
ANTI-TUBERCULOSIS ACTIVITY OF GELIDIUM PRISTOIDES, PLOCAMIUM 
CORALLORHIZA, AND POLYSIPHONIA VIRGATA AND THE ANTI·PLASMODIAL 
ACTIVITY OF A FEW OF THE ALGAL EXTRACTS 
4.1. Introduction 
The algae that were investigated here have not been screened for anti-tuberculosis activity previously. In 
an antimicrobial screen of seventeen red algae collected in the Cape Peninsula, which was done at the 
University of the Western Cape by Cameron et al. (2001), it was shown that the crude extracts of 
Plocamium corallorhiza and Gelidium pristoides inhibited the growth of Mycobacterium smegma tis, a 
rapidly growing non-pathogenic mycobacterium (Howard and Byrd, 2000). In addition, the crude extract of 
P. coral/orhiza also inhibited the growth of the Iungus Candida albicans, while the crude extracts of G. 
pristoides and P. virgata inhibited the growth of the bacterium Staphylococcus aureus. At fractionation, the 
fractions of G. pristoides and P. virgata inhibited the growth of S. aureus, while the fractions of P. 
coral/orhiza inhibited the growth of both S. aureus and M. smegma tis. Consequently, these findings served 
as strong justification for the selection of these species for this investigation. G. pristoides and P. 
corallorhiza were selected for their inhibitory activity against M. smegmatis and P. virgata was selected for 
its inhibition of S. aureus and its potential antimycobacterial activity. 
Initially, the crude dichloromethane extracts of each alga showed no anti-tuberculosis activity, but when 
further punfied using the Chromatotron, the anti-tuberculosis activity became evident in some of the 
fractions of each alga. However, as the purification continued, incorporating preparative layer 
chromatography, many of the individual compounds that constituted the purified fractions were reduced to 
1 mg amounts or less, making complete structure elucidation with accessible instrumentation impossible. 
This chapter reports on the anti-tuberculosis activities of the purified fractions observed as the extracts 
were purified using the Chromatotron and preparative layer chromatography. Anti-tuberculosis activity was 
established as previously mentioned by selecting the samples with final growth index values of below or 
equal to the growth index of the 1 :100 control. In addition, samples with GI-values above that of the 1 :100 
controls that appeared low relative to the maximum GI-values obtained per assay were also selected for 
further purification, bearing in mind that the active compound(s) could be in low concentration and 
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Anli-tubercuiosl:> aCiI"lly cd filrer red aluae 
therefore give high growth indexes. The antiplasmodial activity of the initial crude extracts and purified 
fractions was also determined, as well as the cytoxicity of selected extracts. 
4.2. Results 
To confirm the findings of the project done by Cameron et al. (2001), the agar-overlay bioautography 
method was used to determine the inhibitory activity of the crude dichloromethane (OCM): methanol 
(MeOH) (2: 1) algal extracts (for yields see Table 4.1) against S. aureus (Table 4.2). 
Table 4.1. A record of the seaweed samples collected and the yields of obtained. 
Seaweed Sample no. Wet mass (g) Extract dry mass (g) % yield 
Gelidium pristoides 101.1 1000.42 27.89 2.8 
Plocamium corallorhiza 102.1 1015.72 18.17 1.8 
Polysiphonia virgata 103.1 495.32 8.08 1.6 
Table 4.2 Rf-values obtained for the crude extracts in the agar-overlay bioautography method against 
Staphylococcus aureus. 
SAMPLE NO. ZONE SAMPLE ZONE (MM) FRONT (MM) ZONE SIZE (MM) RF-VALUE 
Gelidium pristoides (101.1) 1 49 165 10 0.30 
45 163.5 10 0.28 
44 165 10 0.27 
2 31 165 1 0.19 
28 163.5 2 0.17 
26 165 2 0.16 
Plocamium corallorhiza (102.1) 125 166 12 0.75 
124 166 10 0.75 
125 166 5 0.75 
2 46 166 8 0.28 
44 166 8 0.27 
50 166 9 0.30 
3 25 166 2 0.15 
20 166 1 0.12 
25 166 3 0.15 
4 17 166 2 0.10 
15 166 2 0.09 
17 166 2 0.10 
Polysiphonia virgata (103.1) 45 158 4 0.28 
top most zone 44 158 4 0.28 
40 1,58 4 0.25 
2 0 158 32 0.00 
At origin 0 158 35 0.00 
0 158 33 0.00 
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Anti-tuberculOSIs actl Ity of three red algae 
The plates had inhibition zones for G. pristoides (Figure 4.1) and P. virgata with the same Rf-values as 
well as new inhibition zones. The extract of P. corallorhiza showed zones of inhibition that were not 
present in the crude extracts of the abovementioned project. 
Figure 4.1. The inhibitions zones obtained against 
Staphylococcus aureus for the crude extracts of Gelidium 
pristoides and Plocamium corallorhiza in the overlay 
bioautography method. 
Before the extracts were introduced into the BACTEC-460 system, attempts were made to test the 
extracts against Mycobacterium aurum, a bench top safe fast-growing mycobacterium, but problems 
occurred with culturing the organism. The DCM: MeOH (2: 1) extracts and some of the fractions obtained 
using preparative layer chromatography were tested in a parasite lactate dehydrogenase assay against 
the sensitive D10 strain of Plasmodium falciparum (Figure 4.2 and 4.3). 
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Figure 4.2. Dose-response curves obtained in the Parasite lactate dehydrogenase assay for Plasmodium 
falciparum sensitivity. Den 1 to Den 20 refers to fraction number 1 to fraction number 20 of the extract of 
Plocamium corallorhiza obtained using semi-preparative HPLC. 
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Figure 4.3. Dose-response curves obtained in the Parasite lactate dehydrogenase assay for Plasmodium 
falciparum sensitivity. 2B-samples refers to fractions of sample 102 (Plocamium coral/orhiza) and Den-
samples to the samples that were retested. 
In this screen, the crude extract of P. corallorhiza inhibited the grow1h of P. falciparum with an MIG-value 
of 12.5 l1g1mL (Table 4.3). Of the purified fractions, four fractions had antiplasmodial activity with MIG-
values below 10 11 g/mL. Although the crude extract of G. pristoides had a MIG-value of more than 100 
I1g/mL, three of its fractions inhibited the grow1h of P. falciparum with MIG-values below 20 I1g/mL. The P. 
virgata crude extract had a MIG-value of 70 l1g1mL and was not further investigated. Of the crude extracts 
that were tested in the parasite lactate dehydrogenase assay for Plasmodium falciparum sensitivity, that of 
P. corallorhiza and P. virgata showed the most potential with IG5a-values of 12.5 11 glmL and 70.0 11 glmL, 
respectively. The crude extract of G. pristoides had an IG5a-value of more than 100 I1g/mL while the 
purified fractions had significant IG5a-values of 12.0 to 37.5119/mL demonstrating the importance of 
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Table 4.3. IC50-values of the OCM:MeOH (2:1) crude extracts and their preparative layer chromatography purified 
fractions in the parasite lactate dehydrogenase assay against Dl0 strain of Plasmodium lalciparum. 
SAMPLE NO. 
1011 
81 
82 
83 
84 
85 
B6 
102.1 
81 
83 
84 
86 
103.1 
fC .... values in ~g/mL 
>100 
37.5 
17.0 
12.0 
19.0 
22.5 
>100 
12.5 
8.9 
8.0 
4.7,2.4 
6.4 
70.0 
8 in the sample no. refers to band: 81 being the least polar band and 86 the most polar 
band on the thin-layer chromatography plate. 
fractionation when working with plant extracts. The fractions of P. corallorhiza were even more inhibitory to 
the growth of P. lalciparum with ICso-values of 2.4 to 8.9 ~g/mL. For this reason, P. corallorhiza was 
selected for further purification on the HPLC and the 20 fractions so obtained were tested for 
anti plasmodial activity. Fraction 14 and 18 gave the best ICso-values of 4.2 and 5.2 ~ glmL, respectively 
(Table 4.4). 
Table 4.4 ICsa-values of the HPLC purified OCM:MeOH (2:1) extract that were tested in the parasite lactate 
dehydrogenase assay against 010 strain of Plasmodium fafciparum. 
Fractions of Sample 102.1 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
IC .... values in ~g/mL 
95 
100 
100 
66 
34 
24 
24 
23 
22 
20 
24 
24 
20 
9 
18 
12 
Notreliable 
Not reliable 
Not reliable 
50 
42 
Repeals -IC .... values (~g/mL) 
Not tested 
Not tested 
Not tested 
Nottesled 
30 
Not tested 
50 
50 
Not tested 
16 
Not tested 
Not tested 
12 
4.2 
9.0 
9.6 
19.0 
5.2 
8.0 
40.0 
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Other fractions also showed potential with ICso-values below 10 I1gJmL. These results were consistent with 
the results obtained using preparative layer chromatography. The data of this assessment is reported in 
Appendix 2. When the same fractions were tested in the Bactec-460 method, two fractions, namely, 18 
and 19 significantly inhibited the growth of M. tuberculosis (Table 4.5). These were further purified, but 
insuHicient sample masses made structure analysis of the isolated compounds unobtainable. At this stage, 
the Chromatotron was introduced as an alternative method for purification. 
Table 4.5 Growth-indexes of the 20 fractions of crude collected on the HPLC over. The assay ran over the period 24 
October 2002 to 4 November 2002. 
Sample no. 24/10 25/10 26110 27/10 28/10 29/10 30110 31/10 01/11 02111 03/11 04111 
1: 1 00 control 2 0 0 0 1 2 7 10 15 23 30 
INH 10 7 4 4 3 2 3 2 2 2 4 3 
RIF 6 3 0 0 0 0 0 0 0 0 0 
Negative control 12 22 45 86 145 229 307 335 363 446 565 521 
1 13 23 46 82 131 210 296 317 354 444 570 560 
2 9 21 54 118 216 355 473 458 500 635 689 527 
3 13 21 44 73 123 180 246 276 294 402 481 535 
4 15 31 52 90 138 191 261 296 331 446 431 559 
5 13 24 46 80 130 204 287 365 376 501 604 517 
6 9 16 34 61 98 150 177 208 261 383 487 437 
7 10 17 35 64 102 158 218 246 276 330 494 528 
8 12 21 36 61 92 162 233 290 348 424 481 490 
9 9 16 29 51 87 142 207 260 307 409 522 486 
10 12 17 29 46 63 91 120 152 187 231 331 348 
11 9 18 35 59 97 152 209 240 289 376 433 432 
12 12 21 41 75 132 212 297 322 355 462 545 497 
13 11 22 40 71 111 174 245 259 315 423 495 469 
14 7 8 13 21 33 53 76 114 157 212 275 302 
15 11 18 32 59 78 121 171 180 241 314 343 393 
16 12 20 31 47 72 109 142 185 221 267 310 343 
17 9 11 14 16 23 38 50 76 119 172 243 290 
18 7 5 6 8 10 10 13 15 17 18 17 12 
19 5 5 7 7 7 10 12 11 13 15 15 18 
20 11 19 32 5S 79 116 166 187 212 260 305 333 
Sample numbers 1 to 20 refers to the purified fractions of Plocamium corallorhiza collected from the semi-
preparative HPLC column. INH = isoniazid; RIF = rifampicin. Negative control = bacterium vial without a plant 
extract or control. The rows marked in red indicate the significantly anti mycobacterial fractions. 
When the crude extracts were fractionated using the Chromatotron, the first fractions were tested in the 
BACTEC-460 system against M. tuberculosis, but no inhibition of the mycobacterium was observed (Table 
4.6). However, on further fractionation of the dichloromethane portion, all three algae had purified fractions 
with anti-tuberculosis activity (Table 4.7, 4.8, and 4.10). The water-soluble portion of all three crude 
extracts showed no inhibition of M. tuberculosis (sample 101, 102, and 103 in Table 4.12) and was not 
cytotoxic against the Chinese hamster ovarian cells in the MTI cytotoxicity determination with ICso-values 
of above 100 I1gJmL (Figure 4.4). 
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Table 4.6 Growth-indexes 01 the first fractions obtained after purification of the crude extracts using the 
Chromatotron. 
Spec 08108103 09I08I03 10l08I03 11108103 12I08I03 13108103 14/08103 
1 :100 controt 4 4 6 12 18 29 45 
Negative control 104 200 305 395 474 598 709 
MeOH 111 231 357 494 654 810 867 
12 53 90 149 227 308 393 483 
13 57 125 207 331 471 651 798 
14 54 127 231 372 484 656 828 
15 55 140 282 423 452 354 298 
16 42 130 298 473 619 725 855 
21 77 182 309 453 564 712 885 
22 96 203 321 462 695 878 999 
23 91 198 285 414 584 778 939 
24 99 220 351 451 730 894 999 
25 121 261 397 534 747 913 898 
26 111 238 374 498 841 798 869 
31 96 220 351 512 640 803 880 
32 111 230 341 477 599 768 869 
33 130 276 422 578 738 759 919 
34 126 271 398 584 114 798 803 
35 84 194 315 434 614 810 869 
38 104 218 326 434 604 779 875 
39 84 196 350 502 706 884 964 
112 80 187 312 470 653 884 860 
114 69 149 248 350 529 726 852 
115 102 222 353 503 653 833 941 
116 124 272 432 559 778 957 999 
117 70 136 203 267 319 408 427 
Sample numbers sta~ing with 1, 2 and 3 refers to the fractions of Gelidium pris/oides, Plocamium 
coraflorhiza and Polysiphonia virga/a, respeclivety.tNH = isoniazid; RIF = rifampicin. Negalive control = 
bacterium vial without a plant extract or controt. MeOH = methanol control. 
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Table 4.7 Growth-indexes of the purified fractions of the algae investigated over the period 6 September to 17 
September 2003. 
Sample no. 06/09 07/09 08109 09/09 10/09 11/09 12109 13/09 14109 15/09 16/09 17109 
1: 1 00 control 01 0 0 0 1 0 0 5 7 14 19 34 
INH 5 4 0 1 0 1 1 1 0 1 0 1 
RIF 2 0 0 0 0 0 0 0 0 0 0 0 
ETHAM 9 9 8 5 4 3 4 2 2 2 2 3 
Negative 10 14 32 52 91 167 252 369 462 542 575 578 Control 
1111 8 13 29 50 95 172 265 436 433 477 449 351 
1112 4 7 17 35 72 126 212 313 375 448 516 480 
112 5 10 23 43 80 161 295 411 489 655 672 628 
114 10 12 19 25 31 54 70 110 141 155 213 296 
115 8 12 24 38 69 80 92 104 123 198 189 228 
116 7 10 21 38 no 119 165 262 363 376 506 686 
result 
117 15 32 68 108 169 263 370 577 743 950 940 784 
1131 17 34 68 102 137 210 264 390 505 472 441 430 
1132 12 26 58 84 138 228 304 441 516 547 564 571 
1133 5 12 30 50 79 146 213 356 484 604 649 585 
1134 11 22 48 84 142 237 345 536 637 687 604 543 
1135 15 29 66 107 175 298 409 547 566 499 366 347 
11321 8 13 28 39 61 97 135 203 284 358 453 504 
11322 8 12 26 44 70 116 178 no 391 525 543 472 
result 
11323 6 10 18 24 30 43 58 289 105 155 210 237 
11324 14 28 52 84 134 243 342 526 607 653 588 485 
11325 10 15 25 39 52 110 149 250 363 523 656 739 
11326 10 25 53 88 152 256 342 507 598 680 662 550 
11327 17 33 57 89 136 209 268 402 517 622 581 582 
141(1) 9 17 35 62 195 172 249 363 437 487 524 449 
142(1) 4 6 15 33 64 131 208 348 506 678 747 796 
143(1) 8 12 31 62 124 237 397 no 999 999 935 590 
result 
144(1 ) 8 19 44 77 125 207 340 456 557 660 637 543 
145(1) 9 18 43 74 137 247 373 543 645 630 661 608 
141(2) 9 17 33 52 79 117 189 236 306 380 430 478 
142(2) 4 5 12 30 70 149 244 421 635 743 888 866 
143(2) 4 9 27 67 142 283 463 786 955 981 873 655 
144(2) 7 14 30 58 99 167 260 326 406 484 502 552 
145(2) 5 7 18 41 77 159 251 408 525 599 684 610 
151 6 7 23 41 80 152 236 386 572 604 662 639 
152 7 11 26 48 90 167 241 364 480 597 691 668 
153 3 3 12 27 47 95 162 280 412 487 562 623 
154 4 7 21 45 90 180 281 410 497 482 664 595 
221 2 3 0 3 1 4 7 5 9 1 15 20 
222 4 3 3 3 3 4 3 5 5 5 6 9 
Sample numbers starting with 1 and 2 refers to the fractions of Gelidium pristoides and Plocamium 
corallorhiza respectively. I~IH = isoniazid; RIF = rifampicin; ETHAM = ethambutol; Negative control = 
bacterium vial without a plant extract or control. The rows marked in blue indicated relative moderate activity, 
while those in red indicate significant anti mycobacterial activity. 
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Table 4.8 Growth-indexes of the purified fractions investigated over the period 11 September to 22 September 2003. 
Sample no. 11/09 12/09 13/09 14/09 15/09 16/09 17/09 18/09 19/09 20/09 21/09 22/09 
1:100 0 0 0 3 186 999 999 Contaminated 
control 
INH 12 3 3 0 2 3 Not Not Not read Not 
read read read 
RIF 8 Not 0 0 0 0 0 0 !\Jot Not Not read !\Jot 
read read read read 
Negative 10 5 31 75 142 241 323 391 420 430 403 469 
control 
223 7 0 8 19 35 64 133 225 327 431 577 644 
161 3 0 0 2 6 14 23 52 93 153 252 366 
162 9 4 31 91 172 306 491 675 740 756 890 582 
163 8 3 25 60 132 247 474 590 611 570 600 476 
164 7 4 28 77 171 350 669 909 939 780 680 543 
165 7 3 20 60 137 269 487 651 687 684 716 584 
166 7 3 23 68 139 281 527 738 690 738 657 495 
167 6 2 17 51 114 250 517 771 870 884 645 445 
16 7 3 24 67 132 261 481 no 523 472 469 454 
reading 
311 10 2 5 12 23 54 117 888 386 571 666 680 
312 9 1 5 8 10 10 13 16 15 17 19 22 
313 7 1 1 3 3 6 8 18 20 43 86 167 
314 7 1 1 3 2 3 5 13 23 52 116 242 
315 8 2 2 5 4 7 13 27 57 120 221 358 
316 9 2 9 17 24 38 70 120 183 324 270 407 
317 8 4 30 71 160 273 447 577 530 481 410 408 
381 8 2 11 33 70 135 250 411 454 481 484 442 
382 10 4 22 53 112 196 309 378 461 519 524 575 
383 10 3 19 47 104 188 293 444 470 559 574 497 
384 6 2 10 29 73 162 338 537 497 570 607 557 
385 8 3 30 80 164 295 479 676 632 665 639 573 
36 6 0 10 30 70 156 285 474 538 690 773 780 
37 8 4 25 69 137 256 358 469 582 737 656 586 
Sample numbers starting with 1, 2 and 3 refers to the fractions of Ge/idium pristoides, P/ocamium 
corallorhiza and Po/ysiphonia virgata, respectively. INH = isoniazid; RIF = rifampicin; Negative control = 
bacterium vial without a plant extract or control. The rows marked in blue indicated relative moderate activity, 
while those in red indicate significant antimycobacterial activity. 
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Table 4.9 Anti-tuberculosis activities of the pure compounds, methoxyethyl methacrylate and hydroxyethyl 
methacrylate investigated over the period 27 April to 3 May 2004 .. 
Sample no. 01/10 02110 03/10 04/10 05/10 06/10 07/10 08110 
1:100 control 2 0 0 5 14 28 50 
INH 33 32 29 26 23 22 18 
RIF 15 9 6 5 3 2 1 
Negative control 82 293 446 593 720 826 708 
Solv EtOH 64 313 520 519 940 909 798 
Solv MeOH 81 387 611 877 988 965 751 
211 26 64 93 151 217 294 328 
212 16 30 44 58 77 111 123 
231 41 154 245 372 422 513 559 
232 35 80 102 127 145 175 203 
233 34 121 207 353 491 624 665 
234 28 143 285 488 668 750 691 
235 38 210 424 739 999 999 955 
261 40 122 194 291 360 421 456 
262 36 184 301 458 548 646 693 
263 40 204 350 577 862 999 999 
264 39 232 417 681 916 999 998 
265 55 247 392 585 688 803 746 
266 46 251 422 599 733 863 894 
267 39 222 365 554 756 920 944 
Sample numbers 2 refers to the fractions of Plocamium corallorhiza. INH = isoniazid; RIF = rifampicin; 
Negative control = bacterium vial without a plant extract or control. (-) indicates that no reading was taken. 
The rows marked in blue indicated relative moderate activity. Solv EtOH = ethanol control; Solv MeOH = 
methanol control. 
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Figure 4.4. The percentage cell survival recorded for the water 
portions of Sample 101 (G.pristoides), 102 (P. coral/orhiza) and 
103 (P. virgata). 
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4.2.1 Anti-tuberculosis activity of purified fractions of Gelidium pristoides 
The purified fractions numbered 122 and 123 inhibited the growth of M. tuberculosis by 91.7 and 79.2%, 
respectively, at a concentration of 12.5119/rnL (Table 4.10 and Table 4.15). Other fractions that were also 
selected included fractions numbered 161 (Table 4.8) and 124 (Table 4.10). Both showed inhibition 
relative to the completely non-active fractions. 
Table 4.10 Growth-indexes of the purified fractions investigated over the period 7 November to 23 November 2003. 
Sample no. 07/11 08111 09/11 10/11 11/11 12111 13111 14111 15111 16111 17111 18111 19111 20/11 21/11 22111 23111 
1:100 control 1 0 0 0 0 0 1 1 3 3 5 0 1 2 9 21 48 
INH 13 10 6 3 2 1 2 1 1 2 4 4 7 9 13 19 29 
RIF 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
121 7 7 8 9 10 60 807 999 451 208 485 403 207 189 284 483 507 
122 4 3 2 3 1 2 1 1 2 2 2 2 3 3 3 I 4 
123 1 1 1 0 0 1 1 2 1 0 3 1 3 4 4 6 10 
124 3 3 3 3 4 7 13 20 28 18 24 19 27 39 55 86 144 
125 5 4 6 11 209 244 248 283 456 949 835 351 126 60 36 26 21 
131 6 11 17 26 46 70 131 215 322 418 728 655 598 530 427 338 285 
132 2 0 3 31 71 96 111 115 145 203 376 516 664 839 855 768 609 
133 7 10 31 38 76 139 273 465 604 718 973 806 656 537 415 261 183 
241 6 6 6 9 10 14 23 33 48 66 131 184 265 399 461 522 631 
242 6 6 9 15 27 43 77 132 191 268 496 531 506 542 584 545 506 
243 11 13 29 54 102 179 336 549 710 814 979 789 589 451 334 215 144 
244 10 15 32 57 102 176 335 535 691 755 795 583 425 339 258 181 139 
332 3 2 2 3 3 5 6 8 9 10 12 7 7 6 6 7 8 
333 3 3 2 0 2 2 2. 1 1 1 3 0 2 0 0 0 0 
334 13 23 44 72 120 172 284 407 447 493 580 562 533 523 456 343 277 
341 11 21 39 61 94 137 236 356 472 512 671 661 593 562 501 362 270 
344 5 9 12 17 23 32 41 50 69 80 122 128 155 182 220 259 304 
345 7 10 15 23 29 41 76 122 197 275 524 644 593 583 537 427 391 
346 20 30 52 76 118 183 303 483 611 627 689 539 428 349 287 212 170 
Sample numbers starting with 1, 2 and 3 refers to the fractions of Gelidium pristoides, Plocamium 
corallorhiza and Polysiphonia virgata, respectively. INH = isoniazid; RIF = rifampicin. The rows marked in 
blue indicated relative moderate activity, while those in red indicate significant anti mycobacterial activity. 
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Table 4.11 G rowlh-indexes of the purified fractions investigated over the period 12 November to 2003 November 
2003. 
Sample no. 12111 13/11 14/11 15/11 16/11 17111 18111 19/11 20/11 
1: 1 00 control 1 0 0 0 1 7 11 19 30 
Negative control 29 54 91 154 238 472 538 570 589 
EtOH 20 47 96 185 312 663 749 833 826 
134 11 26 62 135 252 415 555 677 713 
135 10 16 35 75 152 382 527 712 773 
321 5 2 3 3 3 6 5 6 9 
322 4 1 1 2 0 0 1 1 0 
323 5 2 1 1 0 1 0 1 0 
351 8 14 26 45 75 189 250 437 588 
352 14 30 49 76 113 241 316 501 627 
353 17 37 80 171 299 634 634 665 675 
354 13 29 56 109 164 323 325 418 486 
355 15 34 78 158 285 617 724 733 722 
356 16 38 85 175 299 565 581 622 611 
391 12 25 55 116 202 331 399 519 588 
392 12 31 73 143 226 471 615 712 696 
393 17 38 80 157 262 572 700 740 720 
394 16 38 84 173 301 587 575 573 564 
Sample numbers starting with 1 and 3 refers to the fractions of Gelidium pristoides and Polysiphonia virgata, 
respectively. Negative control = bacterium vial without a plant extract or control; EtOH = ethanol solvent 
control. The rows marked in red indicate significant antimycobacterial activity. 
4.2.2 Anti-tuberculosis activity of purified fractions of Plocamium corallorhiza 
This alga was purified using semi-preparative HPLC and the Chromatotron. Of the 20 fractions repeatedly 
collected from the semi-preparative HPLC column, only two fractions inhibited the growth of M 
tuberculosis in the BACTEC-460 method (Table 4.5). This was a time consuming procedure with small 
fraction quantities as a reward. Preparative layer chromatography has the same drawback for large 
quantities of crude material. nis served as a strong motivation for the purchase of the Chromatotron. 
Fractions 212 and 232 were o ly weakly active (Figure 4.9). Fractions 221 and 222 obtained from the 
Chromatotron inhibited the growth of M tuberculosis by 41.2 and 73.5%, respectively, at a concentration 
of 12.5 ~g1mL (Table 4.7 and Table 4.15). These fractions were combined as they were collected as 
successive bands from the Chromatotron and purified further. 
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Table 4.12 Growth-indexes of the purified fractions investigated over the period 2 December to 11 December 2003. 
Sample no 02/12 03/12 04/12 05112 06/12 07/12 08/12 09/12 10/12 11/12 
1: 1 00 control 2 1 3 2 3 6 9 14 24 37 
Negative 10 25 45 89 177 343 469 580 684 713 control 
MeOH 16 31 61 115 206 373 483 446 480 523 
EtOH 11 23 50 105 208 373 515 554 607 591 
101 5 12 23 58 132 280 421 520 644 665 
102 7 10 20 53 120 245 403 541 748 795 
103 5 6 11 24 58 135 249 429 535 705 
251 4 5 9 21 54 135 255 378 425 569 
252 5 10 14 21 43 93 153 240 304 409 
253 8 15 30 66 180 290 412 504 613 658 
254 13 26 49 94 170 339 473 582 637 724 
255 9 15 29 61 129 239 439 547 581 677 
256 11 21 35 71 142 291 415 518 608 666 
386 8 19 41 89 177 328 457 551 688 666 
1134 insuHicientto test 
1173 10 17 32 68 130 232 333 457 548 670 
Sample numbers starting with 1, 2 and 3 refers to the fractions of Gelidium pristoides, Plocamium 
corallorhiza and Polysiphonia virgata, respectively. Negative control = bacterium vial without a plant 
extract or control. MeOH = methanol control, EtOH = ethanol control. 
4.2.3 Anti-tuberculosis activity of the purified fractions of Polysiphonia virgata 
The purified fractions 312 (the red marked sample in Table 4.8), 321,322, 323 (samples marked in red in 
Table 4.11), 332 and 333 (red marked samples in Table 4.10) showed M. tuberculosis inhibition of 26.7%, 
70.0%,100.0%,100.0%,83.3% and 100.0%, respectively (Table 4.15). Of these fractions, 312 was further 
purified while samples 321, 322, 323, 332 and 333 were not further purified due to low sample masses. 
Other fractions selected for further purification included fractions no. 313, 314 and 315 with more sample 
material and weak anti-tuberculosis activity (Table 4.8). Each fraction was purified until either the sample 
size became too small or the chromatography, using thin-layer chromatography and HPLG, indicated that 
a pure compound was obtained. 
As the bioactive fractions were further purified, the sample masses in many cases became too small for 
further testing. To ensure a complete account of bioactivity, some of the purified fractions were combined 
and tested against M. tuberculosis (Tables 4.13 and 4.14). The active fraction 312 separated into many 
fractions with small sample masses. When those fractions were recombined fraction 31271 - 3128 
inhibited the growth of M. tuberculosis (marked in red in Table 4.14) with a MIG-value of 12.5 ~g/mL. 
Fraction 314 that showed moderate activity when compared with fraction 312, on further purification 
produced two active fractions, namely 3148A and 3147 that significantly inhibited the growth of M. 
tuberculosis at a MIG-value of 12.5 ~g/mL (Table 4.14). 
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Table 4.13 Growth-indexes of the purilied fractions investigated over the period 19 May to 26 May 2004. 
Sample no. 19/05 20105 21/05 22/05 23105 24/05 25105 26105 
1 : 1 00 control 1 0 0 2 5 13 24 55 
Negative control 36 81 146 266 428 5548 594 640 
INH 21 18 12 10 13 11 10 13 
RIF 10 4 3 1 0 0 0 0 
1611·1616 (12.5 j.I glmL) 10 19 46 115 235 384 452 569 
1611·1616 (6.25 j.lg/mL) 17 39 89 195 363 467 502 610 
1611-1616 (3.125 Jl glmL) 19 43 102 205 381 485 569 645 
1617·16110 (12.5 pg/mL) 20 45 98 188 339 324 430 507 
1617-16110 (6.25 pglmL) 20 47 98 211 330 410 405 439 
1617·16110 (3.125 pglmL) 19 46 98 201 316 383 448 502 
222221·4 (12.5 ~ g/mL) 19 37 76 165 282 369 423 535 
222221-4 (6.25 j.lg/mL) 22 49 94 202 308 384 470 553 
222221-4 (3.125 Jlg/mL) 18 43 86 182 271 365 426 526 
312331·4 (12.51Jg/mL) 16 36 72 157 239 338 390 490 
312331-4 (6.25 Jlg/mL) 16 37 83 173 291 387 463 530 
312331·4(3.125 pglmL) 18 42 89 206 340 465 566 651 
312335-12 (12.5 JlglmL) 19 46 107 169 148 194 277 314 
312335·12 (6.25 pglmL) 19 46 159 761 780 892 918 687 
312335-12 (3.125 ~ g/mL) 21 53 109 206 357 435 465 543 
3131·3137 (12.5 pglmL) 14 28 44 75 120 160 217 325 
3131-3137 (6.25IJg/mL) 17 39 76 146 256 265 429 584 
3131·3137 (3.125 pg/mL) 19 42 84 164 278 347 419 441 
3138A-12 (12.5 j.lg/mL) 20 49 103 222 266 315 663 941 
3138A·12 (6.25 j.lg/mL) 25 58 119 233 374 464 555 624 
3138A·12 (3.125 j.lglmL) 25 62 122 228 363 437 522 557 
31381·7 (12.51Jg/mL) 16 14 26 57 80 75 65 67 
31381·7 (6.25IJglmL) 23 57 118 269 429 533 607 643 
31381-7C(3.125 pglmL) 18 43 90 197 317 394 478 506 
Sample numbers starting with 1, 2 and 3 refers to the fractions of Gelidium pristoides, Plocamium 
corallorhiza and Polysiphonia virgata, respectively. INH = isoniazid; RIF = rifampicin; Negative control = 
bacterium vial without a plant extract or control. The rows marked in blue indicated relative moderate activity. 
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Table 4.14 Growth-indexes of purified fractions measured over the period 27 May 2004 to 6 June 2004. 
Sample no. 27/05 28/05 29/05 30/05 31/05 01/06 02106 03/06 04/06 05/06 06/06 
1: 1 00 control 0 0 0 0 1 4 6 11 19 37 72 
Negative control 48 105 170 256 456 446 545 603 680 550 556 
31271-3128 (12.5 IJ g/mL) 24 32 30 27 24 22 19 20 18 22 13 
31271-3128 (6.25 lJg/mL) 25 49 73 93 150 168 242 301 429 552 807 
31271-3128 (3.125 IJg/mL) 26 14 64 150 231 254 299 348 413 453 647 
3141-46 (12.51Jg/mL) 19 45 104 181 334 431 583 715 896 683 593 
3141-46 (6.25IJg/mL) 21 50 122 203 393 489 731 708 527 404 441 
3141-46 (3.1251Jg/mL) 20 53 104 176 333 392 525 535 597 547 553 
3148A (12.5IJg/mL) 27 40 40 40 41 30 33 33 28 28 32 
3148A (6.251Jg/mL) 36 80 129 174 269 339 415 421 508 562 574 
3148A (3.1251Jg/mL) 35 89 157 252 413 480 581 603 608 465 401 
3147 (12.51Jg/mL) 29 31 27 23 18 19 19 16 14 15 10 
3147 (6.25IJg/mL) 44 72 99 109 141 143 180 225 294 407 648 
3147 (3.1251Jg/mL) 34 82 137 204 328 397 540 568 660 568 547 
3151A-3154A (12.5IJg/mL) 28 70 145 232 394 519 650 658 722 724 694 
3151A-3154A (6.251Jg/mL) 29 76 186 296 497 631 758 757 734 627 440 
3151A-3154A (3.125IJg/mL) 48 104 188 279 431 478 628 611 667 598 506 
31389-31813 (12.51Jg/mL) 31 74 140 92 315 737 985 999 808 433 628 
31389-31813 (6.25IJg/mL) 26 65 139 207 360 476 637 603 651 576 506 
31389-31813 (3.1251Jg/mL) 32 73 159 228 395 473 610 602 642 559 484 
3121-9 (12.51Jg/mL) 30 65 123 165 245 263 310 415 523 619 740 
3121-9 (6.251Jg/mL) 21 53 96 153 245 291 369 507 613 639 659 
3121-9 (3.1251Jg/mL) 30 76 194 319 488 539 613 735 749 629 545 
2222231-34 (12.5 IJ g/mL) 13 28 43 53 76 94 123 175 250 345 522 
2222231-34 (6.25 IJ g/mL) 29 63 103 148 208 236 304 393 523 638 733 
2222231-34 (3.1251lg/mL) 37 90 153 237 354 434 531 614 648 550 462 
Sample numbers starting with 1, 2 and 3 refers to the fractions of Gelidium pristoides, Plocamium 
corallorhiza and Polysiphonia virgata, respectively. Negative control = bacterium vial without a plant extract or 
control. The rows marked in red indicate significant antimycobacterial activity. 
Table 4.15 The percentage growth inhibition of Mycobacterium tuberculosis of the samples found active in this 
investigation using the BACTEC-460 method. 
Sample number Growth index of sample Growth index of control % Inhibition 
31381-7 (12.5IJglmL) 67 55 -21.8 
122 4 48 91.7 
123 10 48 79.2 
221 20 34 41.2 
222 9 34 73.5 
312 22 Contaminated, est. at 30 26.7 
321 9 30 70.0 
322 0 30 100.0 
323 0 30 100.0 
332 8 48 83.3 
333 0 48 100.0 
31271-3128 (12.5IJglmL) 13 72 81.9 
3148A (12.5IJglmL) 32 72 55.5 
3147 (12.511g/mL) 10 72 86.1 
Sample numbers starting with 1, 2 and 3 refers to the fractions of Gelidium pristoides, Plocamium 
corallorhiza and Polysiphonia virgata, respectively. 
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4.3. Discussion 
Finding the same zones of inrlibition against S. aureus in the agar-overlay bioautography method as were 
reported earlier by Cameron et al. (2001) suggested that the species might be in more or less the same 
phytochemical state, which initially served as motivation for their inclusion in this investigation. An increase 
in the number of zones of inl-libition could indicate that the antimicrobial compounds of the algal extracts 
were present in much greater concentrations or greater number. This might be because these samples 
were taken in Glen Cairn, part of a bay namely, False Bay as opposed to Kommetjie (the collection site of 
the previous study) where the shore was exposed. This difference in the environment might have an 
impact on the composition of the secondary metabolites. For future investigations, it is also important to 
note the time of year that these seaweed samples were collected as seasonal variations could greatly 
influence the results as noted by Pratt et al. (1951) and Homsey and Hide (1976). 
Of the three algae screened against Plasmodium falciparum, the purified fractions of P. corallorhiza 
showed the greatest inrlibition with ICso-values of 2.4 ~g/mL to 8.9 ~g/mL. G. pristoides also showed 
potential as a source of antiplasmodial compounds, particularly after the fractionation of the 
dichloromethane extract. This underlines the importance of fractionation as often studies only screen the 
crude extracts and do not have fractionation as part of the stand rd screening procedure. Although many 
more extracts can be screened if the crude extract serves as the main indicator, many potential bioactive 
compounds could be overlooked. Antiplasmodial activity could potentially serve as an indicator for anti-
tuberculosis activity. In 2000, Konig et al. investigated the anti-tuberculosis activity of 39 marine derived 
natural products and used a concentration range reaching values beyond 128 ~g/mL (Konig et aI., 2000). 
Amongst other more active compounds the compounds isolated from the red algae Laurencia obtusa, L. 
flexilis, L. rigida and Plocamium cartilagineum possessed significant antimycobacterial activity ranging 
from MIC-values of 16 to 64 ~.g/mL. The sponge-derived compounds that were selected because of their 
antiplasmodial activity in a previous investigation were the most active antimycobacterial compounds. In 
addition, in recent years, antimalarial drugs have been tested against mycobacteria and anti-tuberculosis 
drugs investigated for the treatment of malaria. Bermudez et al. (1999) investigated the in vitro and in vivo 
activity of lIJ1efloquine against Mycobacterium avium complex (MAC) and found that in vitro it was active at 
MICs of 8 to 16 ~g/mL. In vitro it showed potential against MAC, particularly when combined with 
ethambutol, a first-line anti-tuberculosis drug. Isoniazid, another first-line anti-tuberculosis drug, was 
investigated for its ability to inhibit malarial transmission in the mosquito gut and found to affect the 
mosquito by an unknown mechanism (Arai et al., 2004). These two examples show complementary action 
between antimalarial and anti-tuberculosis drugs. This might suggest that in vitro antimalarial activity could 
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serve as an indicator of antimycobacterial activity. This gives increased value to the readings obtained for 
the crude and purified fractions that were screened for anti plasmodial activity in this investigation. 
Two rractions of the extract of P. corallorhiza moderately inhibited the growth of M. tuberculosis. These 
fractions were further purified, but the purified fractions that were tested did not show inhibition of M. 
tuberculosis. This might suggest that there is synergy between the compounds that make up the fraction 
and that it might be better to use the active fraction as opposed to a single isolate. These differences were 
noted previously in an investigation of the antimicrobial activity of Indian seaweeds, when the crude 
extracts were active only against gram-positive bacteria, while the fractions inhibited the growth of both 
gram-negative and gram-positive bacteria (Sastry and Rao, 1994). They suggested that interfering 
compounds could be masking the bioactive compounds. Therefore, it is safe to say that P. corallorhiza has 
anti-tuberculosis compounds as shown by the bioactive fractions and that further investigation is required 
into the aspect of synergy. 
Of the three seaweeds screened in this investigation, the dichloromethane extract of Polysiphonia virgata 
had the most active fractions with the greatest inhibition. With purification, the antimycobacterial activity 
reduced slightly (Table 4.15), but remained significant. Where the fractions followed each other in 
succession off the circular centrifugal thin-layer chromatography plate, as was the case with fractions 321, 
322 and 323, it could be that one compound could be spread out over these three bands. Tovar and 
Ballantine (2000) observed that when one antimicrobial zone on a thin-layer chromatography plate was 
further investigated on HPLC, many antimicrob al compounds were found. This suggests that the fractions 
of P. virgata hold many anti-tuberculosis compounds. One of the compounds was isolated and its 
elucidation is discussed in Chapter 5. 
Two fractions of G. pristoides significantly inhibited the growth of M. tuberculosis at 12.5 ~ g/mL indicating 
that this commercial seaweed has potential as a source of anti mycobacterial compounds. On further 
purification of the most polar fraction of the OCM extract, fraction no. 161, no inhibition was observed 
against M. tuberculosis. 
When the fractions were collected from the Chromatotron, the numbers were allocated as the bands 
moved off the circular silica plates with increasing polarity with band no. 1 being the least polar and the 
higher band numbers the more polar. From the results, it is evident that the active bands were found 
around the first and second bands, which were the less polar portion of the dichloromethane extract. 
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The antimycobacterial activity of the active fractions compared very well with that of the drug controls 
isoniazid and rifampicin, since the inhibition was assessed at only one concentration and the actual MIG-
values were not determined. In other investigations, inhibitory concentrations of up to 200 flg/mL were 
considered as significantly antimycobacterial (Okunade et al., 2004). In a review of antimycobacterial 
natural products, Gopp (2003) considered compounds having MIG-values of $ 64 flg/mL or ~ 75% growth 
inhibition at 12.5 fl g/mL or less concentration as significantly antimycobacterial. It is possible that some 
active fractions were not detected since only one low sample concentration was used. Antilllycobacterial 
compounds could possibly have been in too low concentrations to inhibit the growth of M. tuberculosis. 
The concentration of the sample plays a crucial role in this analysis, as one is limited in the organic solvent 
volume that can be introduced into the 12B-vials. In establishing which solvents and at what volumes they 
are permissible, acetonitrile, methanol and ethanol had no inhibitory effect on M. tuberculosis at a 
concentration of 12.5%. Therefore, of the 200 microliters normally submitted for testing, only 25 microliters 
could consist of the organic solvent. The rest, 175 microliters was either distilled water or growth medium. 
In this case, the growth medium 7H9 was used to ensure that if the sample was not completely soluble it 
would then form a suspension. With water, the less polar samples would not form a suspension, but rather 
an insoluble mass at the bottom of the eppendorf and poor solubility could possibly have resulted in false 
negatives. Another aspect of concentration is the question of how much of an extract or compound 
dissolves in the organic solvent selected. The correct sample mass weighed out for a high concentration to 
determine the minimum inhibition of a less polar sample with the small amount of solvent volume does not 
ensure that the entire expected sample makes it to the sample test vial. Thus, it appears that one could 
have more confidence in the assay results with smaller sample concentrations that work well for pure 
compounds, but could potentially give false negatives for crude extracts or purified fractions. Another point 
of concern is the testing of unstable compounds in an assay that could take 4 to 12 days to run to 
completion. One hopes that the values obtained had no relation with the break down products of the 
original marine plant derived compounds. Here other assays that use fast-growing mycobacteria have an 
advantage, although the results from those determinations could not give conclusive indications as to the 
anti-tuberculosis activity of the extracts against the sensitive or resistant strains of M. tuberculosis. 
The non-cytotoxic water portions of the algal dichloromethane extracts are worth further investigation, 
particularly for in-vivo experiments. As these extracts were not purified, a complete assessment of their in 
vitro anti-tuberculosis activity cannot be given and should be considered in future investigations. 
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The samples tested against M. tuberculosis in the BACTEC-460 method was not tested in triplicate and 
there is no minimum inhibition concentration (MIC-value) reported for most of them. The cost involved with 
this assay could not bear the demands for such a large sample amount. However, the samples were 
screened with reliable controls and contamination could immediately be detected. 
4.4. Conclusion 
Of the three algae investigated for anti-tuberculosis activity, Polysiphonia virgata showed the greatest anti-
tuberculosis activity. As an epiphyte on the commercial kelp Ecklonia maxima, it is a resource with 
economic potential. Instead of being separated as waste from E. maxima, which is exported and used in 
abalone farming (Anderson et al., 2003), it could be processed for pharmaceutical use. The results 
obtained in this screen clearly showed that these algal extracts have anti-tuberculosis compounds and that 
seaweeds should be included in drug development programs. In addition, the antiplasmodial activities 
together with the anti-staphylococcal activities, obtained are equally promising and encourage 
investigations into many more bioactivities that could lead to the development of new drugs for the 
treatment of so many neglected and untreatable diseases. 
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Chapter 5 
ISOLATION OF ANTI-TUBERCULOSIS COMPOUNDS FROM POLYSIPHONIA 
VIRGATA 
5.1. Introduction 
The fractions that inrlibited the growtl1 of Mycobacterium tuberculosis were purified repeatedly using the 
Chromatotron and preparative layer chromatography. Many new fractions were obtained after each 
purification step resulting in pure compounds of approximately 2 mg in mass. The compounds that 
appeared pure with analytical thin-layer chromatography were analysed using HPLC. Those that produced 
single peaks and that showed the potential of purity with a mass of approximately 1 to 2 mg (Table 5.3) 
were submitted for I\IMR analysis at the Chemistry Department of the University of Stellenbosch. The 
samples amounted to a total of eleven. From the NMR analysis, only four compounds presented spectra 
that supported their purity wrlile tile spectra of the other samples showed the presence of impurities. 
However, the spectra of all four pure compounds were identical suggesting them to be the same 
compound. These pure compounds were all isolated from the alga Po/ysiphonia virgata. The number one 
in the sample numbers indicate that they all initially came off the Chromatotron in the very first non-polar 
band. When tl1at band was further chromatograpl1ed on tile Chromatotron, it presented seven bands of 
which bands 313882, 3148A, 3155A, and 3156 were in four distinctly different bands and came from sub-
bands within those bands. Significantly, the sample masses of the pure compounds were a strong 
determinant for selection because besides structure determination the antimycobacterial activity had to be 
evaluated. As a result, the impure compounds were not purified further because of their small sample 
masses. When the ~IMR spectra were analysed, the structures that were extracted were that of 
methoxyethyl methacrylate for all four compounds. A closely related derivative, 2-hydroxyethyl-2-
methacrylate (HEMA) was available at tile Polymer Institute of Stellenbosch University. Its NMR 1 H-
spectrum was obtained to verify the characterization of MEMA and see whether its anti mycobacterial 
activity was comparable with that of MEMA. 
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5.2 Results 
5.2.1 Structure Elucidation 
° 
II 
H'lC /4, 
'3" /' ~ 
"f r 
I~ ~) 
H/ -'H ~6 
1a 1b I 
0, 
~CH 2 
1 3Figure 5.1. SLuvlJreS 
of 2-rnethoxyethyl-2-rnethacrylate (1) and 2-hydroxyethyl-
rnethacrylate (2). 
The Electron Impact Mass Spectrum (ElMS) of (1) gave a molecular ion at m/z 144, with prominent 
fragment ions at m/z 113 (base peak), 69 and 41. ElMS m/z (reI. int.) 144 [M+] (3),113 [M+-OCH3] (100), 
86 (11), 69 [C4HsO+] (83), 45 (8), 41 [C3H5+] (42). This is in agreement with the calculated molecular 
weight of 144.168 for the formula C7H1203. Two double quartets at 8 5.6 and 6.1, respectively long-range 
coupled in the COSY spectrum (Appendix 3) to a CH3-groUP, were assigned to the non-equivalent olefinic 
protons H-1 a and H-"I b. In turn, the CH3-groUP resonating as a double-doublet at 8 3.9 was identified from 
its long-range coupling to H-1a and H-1b. Two triplets at 8 3.7 and 8 4.2 were assigned to the two 
methylene groups at 5 and 6. Finally, a singlet at (5 3.6 was attributed to the methoxy methyl at position 
seven. The DEPT spectrum identified three methylene and two methyl groups. From the HSOC (Appendix 
3) spectrum, the resonances of all the protonated carbons could be assigned. In the HMBC spectrum, the 
position of the carbonyl group at four was identified from 3-bond couplings from 3 CH3 to C-4 and from H-
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1 a and H-1 b to C-4. Further correlations, which confirmed the structure, were from 2 H-5 to C-4 and 3 CH3 
to C-1 and C-2. Ful1 1H and 13C assignments are given in Table 5.1. 
Table 5.1. 'H NMR (3/ppm, multiplicity, J/Hz at 600 MHz and 13C NMR (8/ppm, multiplicity) at 150 MHz and 'H - 'H 
COSY and HMBC data in CD2Cb for compound 3155A. 
Position olH HSQC COSY'H-'H HMBC 
1a 6.1 dq (1.5, 1.2) 125.51 H-lb, 3 CH3 C-2, C-3, C-4 
1b 5.6 dq (1.5, 1.2) 125.5 t H-la, 3 CH3 C-3 
2 136.8 s 
3 1.9 dd (1.2, 0.9) 18.4 q la, 1b C-1, C-2, C-4 
4 167.4 s 
5 4.2t (4.8) 64.2t H-6 C-4, C-6 
6 3.7 t (4.8) 694 t H-5 C-5, C-7 
7 3.6 s 70.99 C-6 
The lHMR spectrum of 2-hydroxyethyl-2-methacrylate showed the expected protons at (56.1, 5.6, 4.3, 3.9 
and 1.9 that fits the assignments of the ethyl methacrylate portion of the molecule, but was without the CH3 
protons of the methoxy group at (53.6 (Table 5.2). 
Table 5.2 'H-NMR assignments for compound 2 (J in Hz in parentheses) 
H BCDCb 
la 6.1 dq (1.5,1.2) 
lb 5.6 dq (1.5, 1.2) 
3 1.9 dd (1.2, 0.9) 
5 4.3 t (4.8) 
6 3.9 t (4.8) 
Table 5.3 Purified samples submitted for NMR analysis. 
Sample no. Sa mass (mg) Experiments Purity Structure 
1611 1.00 'H Impure 
1617 2.00 'H Impure 
3138A 0.96 lH Impure 
3141 1.60 'H Impure 
3148A 0.98 'H Pure MEMA 
3155A 1.8 'H, '3C, DEPT, COSY, GHSOC, GHMOC Pure MEMA 
31156 1.04 'H, '3C Pure MEMA 
16110 2.18 'H Impure 
222224 1.05 'H Impure 
313882 2.02 'H, '3C Pure MEMA 
2223221 2.14 'H Im~ure 
Methoxyethyl Methacrylate 
2-Methoxyethyl-2-methacrylate (MEMA) is a known compound, also known as ethylene glycol methyl 
ether methacrylate. As a synthetic monomer, it plays a very important role as a copolymer for example 
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Isolalion of aniHubercu/oSI5 compounds from PolYSlphonia virgafa 
with styrene (Stejskal and Kratochvil, 1978; Elliot et al., 2003). It is commonly used to prepare polymeric 
materials in the pharmaceutical industry (Peppas et al., 2000). Its polymers have shown excellent blood 
compatibility (Tanaka et ai., 2002) which is an important consideration for blood contacting devices such 
as catheters, dialyzers and blood ccntainers (Zou et al., 2002). In addition, MEMA has been added to 
antifouling paint mix1ures as a copolymer to increase the control of the release rates of the biocide cuprous 
oxide (Yonehara et ai., 2001). To determine its anti-tuberculosis activity, it was purchasedlrom Sigma-
Aldrich Go. Related monomers are easy to get hold of, as was the case with 2-hydroxyethyl-2-
methacrylate (HEMA) which was obtained from the University of Stellenbosch. It plays an important role in 
the preparation of soft contact lense polymers (Nicolson and Vogt, 2001). 
5.2.2 Anti-tuberculosis activity of MEMA and HEMA 
MEMA inhibited the growth of M. tuberculosis by 66.7% at a MIG-value of 100 flg/mL (Table 5.4 and Table 
5.6) when it was tested in the Bactec-460 method. At 50 fl g/mL, it showed slight inhibition of the growth of 
M. tuberculosis (Table 5.4). HEMA showed greater inhibition of M. tuberculosis of 76.7% at a MIG-value of 
100 flg/mL (Table 5.6). It too showed slight inhibition of the growth of M. tuberculosis at a concentration of 
50 flg/mL (Table 5.4). When it was tested for cy1otoxicity against Ghinese hamster ovarian cells, it did not 
show significant cy1otoxicity with IGso-values above 100 flgimL (Figure 5.2). MEMA also showed moderate 
inhibition of the multi-drug resistant strain if M. tuberculosis (Table 5.5) 
Table 5.4 Anti-tuberculosis activities against Mycobacterium tuberculosis H37Rv of the pure compounds, 
methoxyethyl methacrylate and hydroxyethyl methacrylate investigated over the period 27 April to 3 May 2004. 
Sample 27/04 28104 29/04 30/04 01105 02105 03/05 
1 :100 controt 3 0 2 2 7 15 30 
Negative control 45 133 231 410 619 842 918 
INH 23 24 17 15 16 17 15 
RIF 16 17 11 10 8 5 5 
MEMA 100 ~g/mL 13 10 7 B 7 B 10 
MEMA SO ~ g/mL 16 t6 16 20 27 33 43 
MEMA 25 ~g/mL 23 41 59 85 132 210 356 
MEMA 12.S jlg/mL 26 69 124 213 347 533 750 
MEMA 6.25 jlg/mL 27 85 166 297 461 658 841 
MEMA 3.125 jlg/mL 26 83 170 305 482 631 741 
MEMA 1.5625 ~g/mL 27 92 177 324 540 631 747 
HEMA lDOJ!g/ml 13 9 7 6 7 7 7 
HEMA 50 llg/mL 21 29 33 34 41 49 57 
HEMA 251lglmL 22 42 95 177 330 557 872 
HEMA 12.5 Il g/mL 21 51 112 220 419 678 908 
HEMA 6.25 jlglmL 21 61 133 249 460 701 849 
HEMA 3.1251lg/mL 27 87 190 334 529 739 844 
HEMA 1.56251!~mL 22 74 159 276 478 671 750 
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Table 5.5. Anti-tuberculosis activity of MEMA against a multi-drug resistant clinical strain of Mycobacterium 
tuberculosis. 
Sampte (Cone. in IIg1mL) 23-Mar-{)6 24-Mar-{)6 25-Mar-{)6 26-Mar-{)6 27-Mar-{)6 
Negative controt 162 346 570 852 999 
1 :100 2 1 4 10 49 
Rilamplcin 85 136 164 193 234 
Solvent oontrol 114 174 240 325 443 
MEMA (125) 53 69 83 115 143 
MEMA(62) 88 149 257 442 705 
MEMA(31) 87 163 315 520 784 
MEMA (15) 112 210 390 633 879 
MEMA (7.8) 119 241 393 632 909 
Table 5.6 The percentage growth inhibhion 01 Mycobacterium tuberculosIs by MEMA and HEMA in the BACTEC-
460 method. 
Sampfeno. Growth index of 88 Growth index of control % Inhibition 
MEMA 100 ~gJmL 10 30 66.7 
MEMA 50 IIg1mL 43 30 -43.3 
HEMA 100~g/mL 7 30 76.7 
HEMA 50 II glmL 57 30 -90 
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Figure 5.2. The percentage cell survival recorded lor the MEMA 
and HEMA against CHO-cells in the cytotoxicity determination. 
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5.3 Discussion 
The results clearly show the isolation of 5.84 mg 01 MEMA lrom P. virgata (0.072% of crude extract and 
0.00118% of the whole alga). The methoxy group places the compound under the isolations of 
methoxylated compounds from marine organisms that are common as shown by the many publications on 
such natural products. For example, malyngamides were reportedly isolated from a marine cyanophyte 
Lyngbya majuscula (Cardellinall el al., 1978; Mynderse and Moore, 1978; Loui and Moore, 1979; Todd 
and Gerwick, 1995; Wu et al., 1997; Mesguiche el aI., 1999) and methoxylated fatty acids from the red 
seaweed Schizymenia dubyi (Barnathan et al., 1998). The rnethoxylated fatty acids included 9-
methoxypentadecanoic, 9-methoxyheptadecanoic, 13-methoxyheneicosanoic and 15·methoxytricosanoic 
acids. 7 (S)-methoxytetradec-4(E)-enoic acids showed activity against Staphylococcus aureus and Bacillus 
subtilus. Many a-methoxylated fatty acids were identified in the phospholipids of marine sponges 
(Carbalieira, 2002) (Figure 5.3). 
:~ 
H CI 
14 
Figure 5.3. Two malyngamids and three methoxylated fatly acids, 
namely, (-)-7 -methoxydodec-4(E)-enoic acid, 7( 5)-
methoxytetradec-4(E)-enoic acid and 7-methoxy-9-
methylhexadeca4(E),8(E)-dienoic acid were isolated from 
Lyngbya majuscula (Carballeira, 2002). 
However, this was the first report of the isolation of the commercially available MEMA from an alga and 
specifically from P virgata. Concerning commercially available compounds, a red alga of the genus 
Asparagopsis produced small quantities of carbon tetrachloride, bromoform and halogenated acetones of 
which mono bromoacetone is a major component of tear gas (Josephson, 1997). The isolation 01 methyl 
ethers from red algae is also common, particularly from other species 01 Polysiphonia, for example, 
Polysiphonia lanosa where the methyl, ethyl and n-propyl ethers oj lanosol where reported to have 
cytotoxic activity against human colon adenocarcinoma (Shoeib et aI., 2004). 
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Earlier in the description of MEMA, reference was made to its current uses of which its role as monomer in 
antifouling paints suggests the possibility it being an environmental pollutant. Algae are known to 
accumulate environmental pollutants and are often used as pollution indicators along with mussels (Moy 
and Walday, 1996). In their investigation, Moy and Walday (1996) looked at bioaccumulation of the 
radiolabelled hydrophobic toxicants, namely, polychlorinated biphenyl (14C-PCBT7) and a polycyclic 
aromatic hydrocarbon, benzo[a]pyrene (14C-BaP) and found both mussels and algae rapidly absorbed the 
contaminants. They noted that with the algae, the pollutant concentration was determined on the whole 
plant and a distinction between absorption into the plant and adsorption on to the surface of the seaweed 
was not made. Similarly, in this investigation no provision was made for compounds that might be 
adsorbed to the mucus surface of the seaweed. Moy and Walday (1996) also noted that the algal 
polysaccharides that make up the outer cell walls "act as a sponge which adsorbs cations and lipophilic 
compounds from the environment". Therefore, the isolation of MEMA from P. virgata will have to be further 
investigated, particularly clarifying whether it was an authentic plant compound or adsorbed onto the 
surface of the alga or absorbed into the alga as an environmental pollutant. 
Another observation made by Moy and Walday (1996) was the variation in the time it took for the 
seaweeds and mussels to release the contaminant and that possibly a pool of contaminants could be 
stored over a period. The concentration of BaP reduced over a period of one and two months once the 
pollutant was removed. This was mainly due to metabolic degradation. The concentration of PCB however 
did not show this reduction and the pollutant was retained in the organisms for much longer. In this 
investigation, 5.84 mg (Table 5.3) from 8.08 g (Table 4.1) of extracted material (0.07%) was present at the 
time of collection and this could have accumulated over time or have been the result of a single event. 
In scientific literature, much is said about the harmful environmental impact of organic tin-based antifouling 
paints on marine organisms (Huggett et al., 1992; Michel and Averty, 1999) not targeted by antifouling 
agents applied to underwater marine structures (Yamamoto et al., 1997;Yebra et al., 2004). After 
attempting different solutions, tributyltin self-polishing copolymer paints (TBT-SPC) in which MEMA is a 
key monomer are currently the most successful tool in dealing with biofouling on ships and other 
underwater structures. However, tributyltin continues to be harmful to the environment and new tin-free 
biocides are under investigation, such as copper-based self-polishing copolymer technology. In the 
process, little has been done to account for the monomers, of which methacrylates are the most important, 
leaching from the copolymer paints during seawater exposure. Since these algae were collected in Sweet 
Water, south of Hout Bay harbour there were not many possible sources for MEMA as an ingredient in 
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antifouling paints of underwater structures. Hout Bay harbour is a small harbour with vessels ranging from 
fishing boats to yachts. 
In the process of searching for new environmental safe antifouling compounds, natural compounds are 
considered a good option. Sessile marine organisms have their own armamentarium of compounds to 
prevent them from being fouled by other marine species. In recent years, a few antifouling compounds 
have been isolated from marine organisms for example; a diterpene-alkaloid was isolated from a marine 
sponge (Hattori et al., 1997). Another possibility that could justify the absorption of MEMA into the algal 
thallus is its bioactivity that was demonstrated to some extent in this investigation. The alga could take the 
compound from the environment and use it in its own biodefense. This investigation is the first report of 
MEMA isolated from a marine plant and its impact on algae should be established in future investigations. 
In a review compiled by Gantrell et al., 2001, they reported on the antimycobacterial activity of plant 
terpenoids with MIG-values below 64 flg/mL most of which were determined using the BAGTEG-460 
system. They reported on the MIG-values of the current first-line anti-tuberculosis drugs to show how the 
terpenoids compare with today's chemotherapeutic agents. It is interesting to note that pyrazinamide had a 
MIG-value in vitro of 100 flg/mL while tile other first-line drugs had MIG-values well below 10 flgl/mL. This 
is relevant to this study as the MIG-value of both MEMA and HEMA were determined to be 100 flg/mL and 
prompts an investigation into its in vivo activity, particularly the in vivo activity of MEMA against a drug-
resistant strain of M. tuberculosis. 
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Chapter 6 
ISOLATION OF 2·METHOXYETHYL-2-METHACRYLATE FROM POLYSIPHONIA 
VIRGATA 
6.1 Introduction 
The isolation of (2-methoxyethyl-2-methacrylate (MEMA) or ethylene glycol methyl ether methacrylate 
from Polysiphonia virgata (0.072% of the crude extract and 0.00 12% of the whole alga) raised a few 
questions, which will be addressed in this chapter. These included whether MEMA was isolated as an 
authentic plant compound, or an artifact or environmental pollutant, was it absorbed into the cells of the 
seaweed or adsorbed onto the algal mucus surface. To clarify the latter the fresh alga was soaked in 
various organic solvents such as dichloromethane, ethanol and methanol to remove compounds that 
might be adsorbed to the algal surface. The resultant solutions were submitted for LC-MS/MS analysis and 
detection set for a [M+ 1] ion at mlz 145. The sample was infused into an Applied Biosystems Sciex API· 
4000 mass spectrometer at atmospheric pressure using chemical ionization for ion production. 
In the previous chapter, the isolation of MEMA was not guided by bioactivity alone. Initially, the fractions 
were tested for antimycobacterial activity, but with increased purity, the sample size reduced significantly. 
Pure compounds in sufficient amounts for characterization were selected for identification and 
subsequently tested for anti-tuberculosis activity. Thus, MEMA could not be said to be the major anti-
tuberculosis compound in the seaweed, but rather a compound present in sufficient amounts for structure 
determination. The fact that MEMA is a known monomer immediately presented the likelihood that it could 
be an environmental pollutant that bioaccumulated in the seaweed. Marine vessels and underwater 
structures coated with antifouling paints in which MEMA was probably a monomer might have been the 
sources from which it leached. However, the seaweed sample from which it was isolated was collected at 
Sweet Water, which is at an exposed area on the Atlantic Ocean of the Cape Peninsula, south from Hout 
Bay. Hout Bay has a small harbour, which is home to fishing boats and a few yachts. Alternatively, MEMA 
could have come from a chemical spill in the ocean in the area. To get answers to these possibilities 5 
litres of seawater were collected at the sites where the seaweeds were collected and screened for the 
presence of MEMA using a LC-MS. 
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Another very important possibility is that the presence of the methacrylate could be ascribed to enzymatic 
biosynthesis within the thallus of the alga or by bacteria associated with the alga. This, however, could not 
be determined in this investigation. Instead, a closer look at published literature was taken and will be 
discussed later in this chapter. 
Environmental events that could influence the quality of algae include upwelling in southern Benguela, 
which is in season from September to March. During this season the water temperatures of newly 
upwelled water is 14° to 16°C (Verheye et a/., 1992) as opposed to the normal lOu to 12uC. Upwelling 
brings about an increase in mesozooplankton (Verheye et al., 1992) and so grazing of the algae in the 
effected area. To determine whether there was an increase in mezozooplankton in the Sweet Water area 
chlorophyll-a concentration images using an ocean colour sensor was obtained from the Department of 
Oceanography, University of Cape Town. 
6.2 Results 
The mass spectra of the solutions obtained from dipping 200 g of freshly collected P. virgata in 500 mL of 
'first ethanol, followed by dichloromethane and finally methanol did not show the presence of the 
characteristic (M+ 1) molecular ion of MEMA at m/z 145. The solvent partitioning procedure in which the 
seawater was partitioned between water and chloroform to extract the organic compounds from the 
seawater samples yielded 3.4 mg and 6.3 mg for the samples taken in Simonstown harbour at the East 
Gate and Boathouse, respectively. The Sweet Water extract amounted to 8.6 mg and the seawater extract 
obtained from Glen Cairn to 2.4 mg. However, MEMA was not detected in the mass spectra of these 
chloroform extracts of the seawater samples. 
The chlorophyll-a concentration images obtained from the Oceanography Department showed cloud cover 
on the day we collected the seaweed (Figure 6.1). As a result, we could not derive any information from 
the ocean colour sensor images, which contain chlorophyll-a concentration data. 
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6.3 Discussion 
1 __ . _1._. 
Figure 6.1 Chlorophyll-a concentration images for 23 April to 24 
April 2002 obtained from the Department of Oceanography, 
University of Cape Town. 
The absence of MEMA from the organic solvents into which the samples were dipped would suggest that 
it was not adsorbed onto the algal surface. Its absence from the collected seawater samples at the sites of 
collection would suggest that it is not present in the marine environment as a pollutant. The LC-MS/MS 
method used for its detection was sufficiently sensitive in that it registers ions present in the solvent in 
nanogram quantities. The 5 liters of water samples seem to be an adequate volume of seawater for the 
evaluation of organic compounds at coastal sites. This was demonstrated in an investigation done by 
Gshwend et al.(1982) when they looked at volatile organic compounds in 4 liters of seawater samples and 
were able to detect alkanes, aldehydes, dimethyl polysulfides, and many more compounds. 
It could be that MEMA is the product of biosynthesis, by either the seaweed or microorganisms associated 
with the alga. A possible precursor of MEMA, acrylic acid, is frequently mentioned in environmental marine 
publications in the context of the by-product of dimethylsulfoniopropionate (DMSP) degradation. DMSP is 
a tertiary sulphonium compound produced by marine algae and plant halophytes (Yoch, 2002). Degrading 
seaweeds release a considerable amount of acrylic acid, as shown in Figure 6.2 (Yoch, 2002). 
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Figure 6.2 Degradation of DMSP to DMS and an acrylate by the 
enzyme DMSP lyase (Yoch, 2002). 
In 1935, Haas (1935) observed that the seaweed Polysiphonia fastigata evolved dimethyl sulfide shortly 
after collection. In 1956, Cantoni and Anderson (1956) found a dimethylpropiothetin bromide (OMPT) 
cleaving enzyme in the extracts of Polysiphonia lanosa and they suggested the catalytic reaction to be: 
o 
~SC/"~OH 
I 
GSH ~s + 
(2~carboxyethyl)(dimethyl)sulfonium dimethyl sulfide acrylic acid hydrogen(1 +) 
In fact, acrylic acid was identified as the major component of the products formed during the enzymatic 
cleavage and the substrate, OMPT, was reported to be present in as high a concentration as 0.04 M. 
Steinke et aJ. (1998) found that more than one dimethylsulfoniopropionate lyase isozyme could be 
associated with a particular organism when they investigated the phytoplankton Emiliania huxleyi. In 
another investigation, Watanabe et al. (1977) obtained an ethylene-synthesizing enzyme from the red alga 
Porphyra tenera. The enzyme was acrylate decarboxylase and formed ethylene from an acrylate detected 
in its presence. More recently, Van Alstyne et al. (2001) completed this picture by describing the activated 
defenses of temperate marine macroalgae. Polysiphonia hendryi was one of the species investigated and 
the only red alga to show detectable amounts of OMSP which was considered to be present as a primary 
chemical defense. In addition, significant OMSP lyase activity was reported for P. hendryi. The release of 
OMS was associated with damage to the algal tissues due to herbivory or crushing and the acrylic acid 
served as a feeding deterrent not because of toxicity, but rather because of its unpleasant taste. 
Glombitza isolated acrylic acid as an antimicrobial compound from Polysiphonia urceolata in its free and 
bound form together with dimethyl-~-propiothetin its precursor (Glornbitza, 1970a; Glombitza, 1970b). 
Glombitza was not the first to report the antibiotic potential of acrylic acid and its derivatives. Walton 
examined the antimicrobial potential of ~-aroyl acrylic acids and their derivatives in 1957 (Walton, 1957a; 
Walton, 1957b). He justified the investigation by comparing their structure to that of the antibiotic penicillic 
acid and synthesized alkyl 4-oxo-2-alkenoates (Figure 6.3). Other investigators followed in searching for 
new antibiotics from acrylic acid derivatives. Iwasaki et al. (1977) synthesized novel acrylarnides and 
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found N-n-propyl-cis-~-n-butylsulfinylacrylamide to be highly herbicidal against Digitaria adiscendens and 
Amaranthus ascendens. 
--:~ 
-c-':;------ - --- ------
(22)-3-rnethoxy-5-rnethyl-4-oxohexa-2,5-dienoic acid 5-hydroxy-5-isopropenyl-4-rnethoxyfuran-2(5H)-one 
Figure 6.3. Structures were taken from Walton (1957a) 
methacrylic acid acrylic acid 
Figure 6.4 Structures of methacrylic and acrylic acid. 
The importance of acrylic acid lies in its close structural association with methacrylic acid (Figure 6.4) with 
the only difference in the structure being the methyl group. The biosynthesis of a methacrylate such as 2-
methoxyethyl methacrylate (Figure 6.5) seems probable when compared to the formation of an acrylate as 
shown in Figure 6.1 with the addition of a methoxyethyl and methyl group. 
o 
H3C00~O'-CH3 
CH2 
Figure 6.5 Structure of 2-methoxyethyl methacrylate. 
Alternatively, microorganisms associated with the alga could have synthesized the methacrylate. From 
published literature, it appears as if Polysiphonia is host to various marine microorganisms. The fungus 
Geniculosporium sp. was isolated from an unidentified species of Polysiphonia and under controlled 
conditions produced botryane metabolites (Krohn et al., 2005). Another fungus, Apiospora montagnei 
isolated from P. violacea presented a diterpene, three acids and a methyl ester of 9-hydroxyhexylitaconic 
acid (Klemke et al., 2004). 
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In a culture broth of a photosynthetic bacterium, Smith et al. (1994) found that the bacterium 
photoassimilated 3-mercapto-2-methylpropionate as a source of sulphur and that a methacrylate 
accumulated in the medium. Ansede et al. (1999) investigated the metabolism of acrylate to ~­
hydroxypropionate in a salt marsh sediment bacterium Alcaligenes faecalis and its association with DMSP 
degradation. DMSP degraded outside the bacterial cell resulting in extracellular accumulation of the 
acrylate. The acrylate was was further metabolized to ~-hydroxypropionate. The overall reaction was 
described as follows: 
(CH3)2S+ CH2CH2CO ---4 (CH3)22S + CH2=CHCO?- + H+ ----, HOCH2CH2C02- ---~ C02 + X (X represents 
an unknown metabolite). 
The role of the acrylate and its analogs (acylamide and methacrylate) appeared to induce DMSP lyase 
activity. Thus, it appears that the biosynthesis of methacrylates by the alga and/or microorganisms is 
higllly possible and more likely the reason for the presence of 2-methoxyetl1yl methacrylate in 
Polysiphonia virgata. 
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Chapter 7 
ISOLATION OF ANTIMYCOBACTERIAL COMPOUNDS FROM POLYSIPHONIA 
VIRGATA: RE-INVESTIGATION 
7.1 Introduction 
The isolation of MEMA from Polysiphonia virgata necessitated a re-investigation into its bioactive 
compounds to determine whether other compounds were responsible for the primary antimycobacterial 
activity. In the re-investigation, bioassay-guided fractionation of the dichloromethane extract of the dried 
alga led to the isolation of a mixture of fatty acids and hydrocarbons according to the 1 HMR spectra of the 
bioactive components. Further identification of the fatty acids and hydrocarbons was achieved by gas 
chromatography mass spectrometry (GC-MS) analysis. The sample was first methylated to form methyl 
esters of the fatty acids since direct analysis in gas chromatography (GC) is made complicated by the 
tendency of lipids samples to be highly polar, less volatile and to form hydrogen bonds (Brondz, 2002). 
Antimycobacterial activity of the purified fractions and mixture of fatty acids and hydrocarbons was 
assessed using Mycobacterium smegmatis since Mycobacterium tuberculosis could not be used in the 
intial stages of this investigation. However, Mycobacterium smegmatis is a non-pathogenic bacterium and 
good indicator of possible anti-tuberculosis activit  as demonstrated by a recent investigation in which the 
initial bioactivity against M. smegmatis assisted the development of a new drug against tuberculosis by 
Andries et al. (2005). The anti mycobacterial activity of the identified fatty acids were determined by testing 
commercially available standards against M. smegma tis using direct bioautography and M. tuberculosis 
H37Rv and a multi-drug resista t isolate of M. tuberculosis in the Bactec-460 radiometric method. 
7.2 Results 
The fractionation of the crude extract using flash chromatography resulted in 45 fractions (Appendix 1: 
Table A2) of which many were active against M. aurum (Table 7.1 and Figure 7.1) and M. smegma tis 
(Table 7.2). 
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Table 7.1. Rf-values obtained for Ihe fraclions in the direct bioautography method against Mycobacterium aurum on 
29 August to 1 Seplember 2005. 
Sample no. Solvent Iront (mm) Zone distance (mm) Zone size (mm) RI-value 
1 89 85 5 096 
2 89 88 3 0.99 
3 89 85 6 0.96 
89 25 2 0.28 
4 89 80 7 0.90 
89 25 6 0.28 
5 89 25 10 0.28 
6 89 25 20 0.28 
7 89 24 14 0.27 
8 89 no zone 
9 89 no zone 
10 83 82 2 0.99 
11 83 22 7 0.27 
12 83 23 10 0.28 
13 83 22 10 0.27 
14 83 23 10 0.28 
15 83 20 10 0.24 
16 83 20 10 0.24 
17 83 20 7 0.24 
18 83 no zone 
19 88 28 30 0.32 
20 88 24 25 0.27 
21 88 18 25 0.20 
22 88 19 28 0.22 
23 88 19 28 0.22 
24 88 20 33 0.23 
25 88 20 32 0.23 
26 88 22 39 0.25 
27 88 23 35 0.26 
28 84 20 36 0.24 
29 84 20 35 0.24 
30 84 18 32 0.21 
31 84 18 30 0.21 
32 84 15 25 0.18 
33 84 15 30 0.18 
34 84 15 28 0.18 
35 84 15 30 0.18 
36 84 17 20 0.20 
37 89 no zone 
38 89 10 22 0.11 
39 89 10 21 0.11 
40 89 10 20 0.11 
41 89 10 30 0.11 
42 89 10 3 0.11 
43 89 no zone 
44 89 no zone 
45 89 no zone 
Ciprofloxacin 11 
Ci~rofloxacin 11 
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Table 7.2. Rf-values obtained for the fractions in the direct bioautography method against Mycobacterium 
smegmatis on 29 to 30 August 2005. 
Sample no. Solvent front (mm) Zone distance (mm) Zone size (mm) Rf-value 
1 88 no zone 
2 88 no zone 
3 88 no zone 
4 88 20 7 0.23 
5 88 22 14 0.25 
6 88 25 19 0.28 
7 88 26 37 0.30 
8 88 no zone 
9 88 no zone 
10 88 no zone 
11 88 no zone 
12 88 no zone 
13 88 no zone 
14 88 no zone 
15 88 no zone 
16 88 no zone 
17 88 no zone 
18 88 no zone 
19 90 30 30 0.33 
20 90 25 30 0.28 
21 90 20 30 0.22 
22 90 20 30 0.22 
23 90 20 30 0.22 
24 90 20 30 0.22 
25 90 22 30 0.24 
26 90 20 30 0.22 
27 90 15 30 0.17 
28 86 18 37 0.21 
29 86 18 33 0.21 
30 86 15 32 0.17 
31 86 15 30 0.17 
32 86 15 30 0.17 
33 86 15 24 0.17 
34 86 17 32 0.20 
35 86 12 22 0.14 
36 86 12 16 0.14 
37 90 no zone 
38 90 18 33 0.20 
39 90 15 30 0.17 
40 90 14 28 0.16 
41 90 16 36 0.18 
42 90 13 27 0.14 
43 90 no zone 
44 90 no zone 
45 90 no zone 
Ciprofloxacin 10 
Ciprofloxacin 10 
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Remvesflgalioll of POlyslplrollla l'lrgala 
Figure 7.1 The inhibition zones obtained against Mycobacterium 
aurum in the direct bioautography method. Numbers 1 to 9 
indicate the fraction numbers as assigned in Table 7.2. 
Figure 7.2 1 HNMR of Fraction 2 (above) and 3 (below) obtained 
using flash chromatography. 
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Fraction 2 and 3 were combined since their tic-profile and 1 H NMR spectra (Figure 7.2) were the same 
and the resultant samples further purified using the Chromatotron. Fractions 17 to 30 were also combined 
for the same reason. Fractions 5 to 10 were kept separately and further purified (Appendix 1: Table A 1.3) 
using preparative HPLC on a Spectra-Physics IsoChrom LC HPLC with a mobile phase of hexane (85%) 
in ethyl acetate at a '!low rate of 4 mUmin. The purified samples were screened for activity against M. 
smegma/is using the direct bioautography method and the bioactive zones reported in Table 7.3. 
Table 7.3. Inhibition zones obtained of the undeveloped purified fractions in direct bioautography against 
Mycobacterium smegma tis. 
Sample no. Mass (mg) Zone size (mm) 
6/1 1.9 5 
6/2 0.6 5 
6/3 0.9 5 
6/6 2.5 5 
6/9 0.7 20 
7/1 2.6 6 
7/2 0.8 5 
1730/1 Wash 6 
R1730/2 16.7 6 
R1730/3 2.6 6 
R1730/4 13.2 5 
R1730/5 4.6 6 
R1730/6 5.3 6 
R1730n 3.8 6 
R1730/8 14.5 5 
6/665 1.4 5 
6/52 0.6 5 
173011 34.9 6 
173012 26.3 8 
1730/3 4.9 15 
173014 4.7 15 
1730/5 1.7 14 
1730/6 2.6 13 
1730n 1.7 6 
173018 1.7 6 
1730/9 10.0 6 
2&3113 10.9 6 
2&3114 4.9 6 
Sample 6/9 with a small sample size of 0.7 mg was the most active against M. smegma/is with an 
inhibition zone size of 20 mm in diameter. The next active samples were those of 1730/3 to 1730/6 with 
inhibition zones of about 14 mm in diameter. All samples were further purified using thin-layer 
chromatography and fractions with about 1 mg in mass were tested against M. smegmatis (Table 7.4). 
Sample 1730/1 produced only one bioactive fraction namely 1730/11 compared to sample 1730/2 that 
produced 2 bioactive fractions and 1730/3 three bioactive fractions. Of sample 2&3, fractions 131 and 142 
appeared to hold the bioactive compounds. 
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Table 7.4 Inhibition zones obtained of purilied samples against M. smegma lis. 
Sample no. Mass (mg) Zone size (mm) 
6ffi1 4.8 9 
1730/11 26 7 
1730/21 17 8 
1730/27 16.2 8 
1730/31 6.8 10 
1730/32 9.4 9 
1730/37 9.4 8 
1730/41 5.8 8 
1730/54 2.8 9 
2&3/131 9.5 10 
2&3/142 6.2 9 
Rl31 6.2 10 
Ciprofloxacin 12 
Ciprofloxacin 12 
The active samples were submitted for 1 HNMR analysis after which samples 1730/31,1730/27, R131, 
2&3/142, 1730/31, 1730/32, 1730/41, 1730/54, 6/9, and 7/11 were combined and numbered C1730(49.4 
mg) because their '1 H NMR spectra were the same (Figure 7.3). Samples R/69, R611, R/55, 1730/55, and 
1730/66 produced the same 1HNMR spectrum and were also combined (Figure 7.4) into sample number 
1730/11 (20.5 mg). 
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Figure 7.3 1 HNMR spectrum of sample 1730/27. 
Figure 7.4. 1 HNMR spectrum of sample R/69 
The combined samples were tested against M. smegmatis and the minimum inhibition concentration (MIC) 
determined to be 15.62 I-Ig (zone size 4 = mm) and 7.4 I-Ig (zone size = 4 mm) for sample C1730 and 
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1730/11, respectively which compared well with Ciprofloxacin that showed a 12 mm diameter zone at an 
amount of 12.5 micrograms on the thin-layer chromatography plate (Table 7.5). 
Table 7S The zones of inhibilion of sample C1730 and 1730/11 obtained against M. smegmatis. 
Sample no. (sample mass on tlc-plate) 
C1730 (500) 
C1730 (250) 
C1I730 (125) 
C1730 (62.5) 
C1730 (31.25) 
C1730 (15.62) 
C1730 (7.8) 
1730/11 (1000) 
1730/1 t (500) 
1730/11 (250) 
1730/11 (125) 
1730111 (62.5) 
1730/1 11 (31.25) 
1730/11 (15.62) 
1730/11 (7.8) 
Ciprofioxacin (12.5119) 
___ C""iprofloxacin (12.5119) 
Zone size (mm) 
9 
7 
8 
7 
4 
4 
o 
10 
10 
10 
7 
6 
6 
5 
4 
12 
12 
It was noted that the 1 HNMR peaks around 7.5 ppm were likely to be due to phthalates that were present 
as contaminants. However, the signals more upfield were suspected to be because 01 fatty acids and/or 
hydrocarbons. Therefore, the two samples were methylated and submitted for GC-MS analysis. After 
methylation, the samples weighed 10.0 mg (CI730E) and 64 mg (1730/11 E). Hydrocarbons, phthalates 
and importantly methyl esters were tentatively identified (Figure 7.5, Figure 7.6 and Table 7.6, Table 7.7, 
Table 7.8) confirming the presence of fatty aCids (Table 7.9). The detailed ion chromatograms of the 
tentitative identification are in Appendix 6. All the methyl esters (Table 7.8) in the mixture were identified by 
comparing the retention times of GC peaks with those of the standard compounds under the same 
chromatographic conditions using commercially available standards purchased from Sigma Aldrich 
Co. (Appendix 6). 
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Figure 7.5 GC-MS total ion chromatogram of sample 1730/11 E 
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Figure 7.6 GC-MS total ion chromatogram of sample C1730E. 
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Table 7.6. The tentative identities of the components of samples 1730/11 E. 
ION NO. 01 173011 E COMPOUND 
1 Aliphatic hydrocarbon 
2 Dimethyl phthalate 
3 Unknown compound 
4 Unsaturated cyclic hydrocarbon 
5 Pentadecane 
6 6utylated hydroxytoluene 
7 Methyl dodecanoate 
8 Aliphatic hydrQCarboo 
9 Hexadecane 
10 Diphenylamine . 
11 Aliphatic hydrocarbon 
12 Heptadecane 
13 Aliphatic hydrocarbon 
14 Methyl tetradecanoate 
15 Aliphatic hydrocarbon 
16 Octadecane 
17 Aliphatic hydrocarbon 
18 Aliphatic hydrocarbon 
19 Nonadecane 
20 Methyl hexadecanoate 
21 Aliphatic hydrocarbon 
22 Icosane 
23 Phthalate 
24 Methyl (l,l)-9,12-octadecadienoate 
25 Methyl l-9-octadecenoate 
26 Henicosane 
27 Methyl octadecanoate 
28 Docosane 
29 Phthalate 
30 Aliphatic hydrocarbon 
31 Tncosane 
32 Tetracosane 
33 Phthalate 
Table 7.7. The tentative identities of the components of samples C1730E 
fON NO. of C1730E 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
COMPOUND 
Aliphalic alcohol 
Unsaturated aliphatic hydrocarboo 
Ahphallc alcohol 
Unsaturated aliphatic hydrocarboo 
Aliphalic hydrocarbon 
Dimethyl Phthalate 
Unknown compcund 
U'nsaturated cyclic hydrocarbon 
Aliphatic hydrocarbon 
BlIIylated hydroxytoluene 
Methyl dodecanoate 
Unknown compcund 
Phthalate 
Heptadecane 
Phthalate 
Methyl tetradecanoate 
Aliphatic hydrocarbon 
Octadecane 
Aliphatic hydrocarbon 
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ION NO. of C1730E COMPOUND 
20 Methyl pentadecanoate 
21 Aliphatic hydrocarbon 
22 Phthalate 
23 Aliphatic hydrocarbon 
24 Nonadecane 
25 Methyl hexadecanoate 
26 Phthalate 
27 Aliphatic hydrocarbon 
28 lcosane 
29 Phthalate 
30 Methyl(Z,Z)-9,12-octadecadienoate 
31 Methyl Z-9-octadecenoate 
32 Aliphatic hydrocarbon 
33 Octadecanoate 
34 Phthalate 
35 Phthalate 
36 Aliphatic hydrocarbon 
37 Aliphatic hydrocarbon 
38 Phthalate ------~------~ 
Table 7.8 Methyl Ester and related fatty acids observed in sample 1730/11 E and C 1730E. 
SAMPLE NO (ION. NO) 
1730/11 E (7) 
1730/11E (14) 
1730/11 E (20) 
1730/11 E (24) 
1730/11 E (25) 
1730/11 E (27) 
C1730E (11) 
C1730E (16) 
C1730E (20) 
C1730E (25) 
C1730E (30) 
C1730E (31) 
C1730E (33) 
METHYL ESTERS OF FATIY ACIDS 
Methyl dodecanoate 
Methyl tetradecanoate 
Methyl hexadecanoate 
Methyl (Z,Z)-9,12-octadecadienoate 
Methyl l-9-octadecenoate 
Methyl octadecanoate 
Methyl dodecanoate 
Methyl tetradecanoate 
Methyl pentadecanoate 
Methyl hexadecanoate 
Methyl(Z,Z)-9,12-octadecadienoate 
Methyl Z -9-octadecenoate 
Octadecanoate 
FATIYACIDS 
Dodecanoic acid 
Tetradecanoic acid 
Hexadecanoic acid 
9,12-0ctadecadienoic acid 
9-0ctadecenoic acid 
Octadecanoic acid 
Dodecanoic acid 
T etradecanoic acid 
Pentadecanoic acid 
Hexadecanoic acid 
9 ,12-0ctadecadienoic acid 
9-0ctadecenoic acid 
Octadecanoic acid 
Table 7.9 Saturated and unsaturated fatty acids isolated from P. virgata and molecular formulas as obtained from 
The Merck Index 12th edition (1997). 
Systematic name Common name Molecular formula 
SATURATED FAnV ACIDS 
Dodecanoic acid Lauric acid Ct2H2402 
Tetradecanoic acid Myristic acid C'4H2802 
Hexadecanoic acid Palmitic acid C16H3202 
Octadecanoic acid Stearic acid, Emersol Ct8H3602 
Pentadecanoic acid C15H3002 
UNSATURATED FATIV ACIDS 
(l,l)-9, 12-0ctadecadienoic acid Linoleic acid, 9,12-linoleic acid C'SH3202 
(Z)-9-Octadecenoic acid Oleic acid CIBH3402 
Of the fatty acids identified in the GC-MS analysis only dodecanoic acid, stearic acid, palmitic acid, oleic 
acid, linoleic acid and myristic acid could be obtained commercially for further analysis. Pentadecanoic 
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acid had to be omitted from further analysis as it could not be obtained within the time of this investigation. 
Antimycobacterial activity of the fatty acids was assessed against Mycobacterium tuberculosis H37Rv and 
a clinical multidrug-resistant (MDR) strain of M. tuberculosis in the Bactec-460 radiometric method and M. 
smegmatis using direct bioautography. In the radiometric method, dodecanoic acid, myristic acid, linoleic 
acid and oleic acid significantly inhibited the growth of M. tuberculosis. Oleic acid was the most bioactive 
compound with an MIC-value equal to 25 ~g/mL showing growth index values (GI-values) similar to 
rifampicin, which was used as the control drug (Table 7.10). 
Table 7.10 Growth-indexes of the fatty acids in the Baclec-460 radiometric method using the H37Rv strain of M. 
tuberculosis obtained over the Qeriod 14 March 2006 to 20 March 2006. 
Sample (Cone. in ~glmL)) 14-Mar-06 15-Mar-06 16-Mar-06 17-Mar-06 18-Mar-06 19-Mar-06 2o-Mar-06 
Negative control 46 131 297 548 710 979 959 
1 : 1 00 control 0 0 0 1 10 23 52 
Solvent control 50 103 148 179 184 192 208 
Rifampicin 19 11 5 2 1 0 0 
Stearic aCid (50) 33 64 113 151 179 220 258 
Stearic acid (25) 29 80 183 353 559 825 999 
Stearic acid (12.5) 36 126 326 664 913 999 999 
Stearic acid (6.25) 39 135 293 560 626 868 949 
Stearic acid (3.125) 62 214 399 660 778 877 810 
Dodecanoic acid (50) 9 3 1 2 1 1 0 
Dodecanoic acid 25) 15 25 42 68 87 128 183 
Dodecanoic acid (12.5) 32 105 221 371 445 680 779 
Dodecanoic acid (6.25) 41 140 251 451 520 617 613 
Dodecanoic acid (3.125) 36 126 263 461 571 739 731 
Myristic acid (50) 10 4 3 4 2 1 1 
Myristic acid (25) 16 30 64 11 8 176 291 388 
Myristic acid (12.5) 25 71 150 249 385 557 806 
Myristic acid (6.25) 34 106 222 385 529 696 871 
Myristic acid (3.125) 42 141 273 466 581 730 666 
Linoleic aCid (50) a 1 0 0 0 0 0 
Linoleic acid (25) 12 22 52 94 158 249 364 
Linoleic acid (12.5) 17 42 92 177 248 349 508 
Linoleic acid (6.25) 27 78 158 274 453 623 835 
Linoleic acid (3.125) 22 74 158 278 402 561 799 
Palm itic acid (50) 29 59 86 109 128 137 154 
Palmitic acid (25) 33 104 217 354 591 937 999 
Palmitic acid (12.5) 29 112 253 433 774 999 999 
Palmitic acid (6.25) 39 147 289 431 635 971 977 
Palmitic acid (3.125) 43 158 290 398 590 728 989 
OleiC acid (50) 6 0 0 0 0 0 0 
Oleic acid (25) 5 1 0 0 0 0 0 
Oleic acid (12.5) 13 31 80 194 289 367 588 
Oleic acid (6.25) 16 50 124 243 320 380 513 
Oleic acid (3.125) 18 66 158 290 417 555 859 
e1730 (125) 34 82 125 172 200 246 296 
C1730 (62.5) 30 117 253 462 571 587 850 
C1730 (31.25) 42 148 292 511 632 687 766 
C1730 (15.625) 41 154 285 487 620 697 822 
C1730 (7.8125) 42 155 298 531 641 713 804 
C1 730 (125) 26 74 133 205 261 295 408 
C1730 (62.5) 39 125 244 343 377 356 560 
C1730 (31.25) 36 130 289 447 537 602 742 
C1730 (15.625) 38 149 306 467 562 654 827 
C1730 (7.8125) 34 130 279 452 450 594 790 
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However, it showed only moderate inhibition at 50 ~g/mL against MDR M. tuberculosis (Table 7.12). 
Dodecanoic acid had an MIG-value of 50 ~g1mL with GI-values similar to rifampicin; while at a 
concentration of 25 ~g/mL it could be considered moderately active against M. tuberculosis H37Rv. It 
inhibited the growth of the MDR-strain to the same extent and at the same concentrations. Myristic acid 
and linoleic acid also had MIG-values equal to 50 ~g/mL with linoleic acid showing moderate inhibition at a 
concentration of 25 ~g/mL against M. tuberculosis H37Rv. The MDR-strain was also moderately inhibited 
by myristic acid at 25 ~g/mL, while linoleic acid showed inhibition at 50 ~g/mL only. Stearic acid and 
palmitic acid was moderately active at 50 ~g/mL against M. tuberculosis H37Rv, while myristic acid 
showed moderate inhibition of M. tuberculosis H37Rv at a MIG-value of 25 ~g/mL. The fatty acid and 
hydrocarbon mixture was also tested against M. tuberculosis H37Rv and showed moderate inhibition at 
125 ~g1mL. Dodecanoic acid, linoleic acid and oleic acid inhibited the growth of M. smegma tis with MIG-
values of 3.125 ~g/mL, 1.56 ~g/mL and 0.8 ~g/mL respectively as opposed to stearic acid, myristic acid 
and palmitic acid that showed no inhibition of M. smegma tis (Table 7.11). 
Table 7.11 Inhibition zones recorded for the fatty acids against Mycobacterium smegma tis using direct 
bioautography. 
Fatty Acid (mass in 1-19) 
Stearic acid (50) 
Stearic acid (25) 
Stearic acid (12.5) 
Stearic (6.25) 
Dodecanoic acid (50) 
Dodecanoic acid (25) 
Dodecanoic acid (12.5) 
Dodecanoic acid (6.25) 
Dodecanoic acid (3.125) 
Dodecanoic acid (1 .5625) 
Dodecanoic acid (0.8) 
Dodecanoic acid (0.4) 
Myristic acid (50) 
Myristic acid (25) 
Myristic acid (12.5) 
Myristic acid (6.25) 
Linoleic acid (50) 
Linoleic aoid (25) 
Linoleic acid (12.5) 
Linoleic acid (6.25) 
Linoleic acid (3.125) 
Linoleic acid (1.56) 
Linoleic acid (0.8) 
Linol'eic acid (0.4) 
Palmitic acid (50) 
Palmitic add (25) 
Palmitic acid (12.5) 
Palmitic acid (6.25) 
Oleic acid (50) 
Oleic acid (25) 
Oleic acid (12.5) 
Oleic acid (6.25) 
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Fatty Aeid (mass in 119) Zone size (mm) 
Oleic acid (3.125) 9 
Oleic acid (1.56) 7 
Oleic acid (0.8) 5 
Oleic acid (0.4) 0 
Ciprofloxacin (12.5) 9 
Ciproiloxacin (12.5) 9 
Table 7.12. Growth-indexes of the fatty acids in the 8actec-460 radiometric method using a clinical multidrug-
resistant strain of M. tuberculosis obtained over the period 23 March 2006 to 27 March 2006. 
Sample (Cone. in llg/mL) 23-Mar..()6 24·Mar..()6 25·Mar..()6 26-Mar..()6 27·Mar..()6 
Negative control 162 346 570 852 999 
1:100 2 1 4 10 49 
Rifampicin 85 136 164 193 234 
Solvent control 114 174 240 325 443 
Oleic acid (50) 50 63 94 172 284 
Oleic acid (25) 35 48 98 229 478 
Oleic acid (12.5) 88 147 319 673 947 
Oleic acid (6.25) 94 167 304 617 836 
Oleic acid (3.125) 114 212 377 707 928 
Dodecanoic acid (50) 34 22 15 15 12 
Dodecanoic acid (25) 63 67 89 141 218 
Dodecanoic acid (12.5) 124 2115 376 657 749 
Dodecanoic acid (6.25) 116 221 388 660 804 
Dodecanoic acid (3.125) 116 208 336 591 782 
Linoleic acid (50) 36 37 45 67 91 
Linoleic acid (25) 56 70 123 244 435 
Linoleic acid (12.5) 89 148 314 633 846 
Linoleic acid (6.25) 108 190 386 666 807 
Linoleic acid (3.125) 177 327 510 735 799 
Myristic acid (50) 19 10 5 4 5 
Myristic acid (25) 45 44 64 104 157 
Myristic acid (12.5) 84 140 288 447 605 
Myristic acid (6.25) 105 199 373 658 861 
Myristic acid (3.125) 93 178 316 565 828 
7.3 Discussion 
Fatty acids are important components of terrestrial plant oils (Evans, 1996b) and the same is true for 
marine plants. Many investigations into marine animal and plant lipids have published (Dembitsky and 
Srebnik, 2002; Carballeira, 2002; San ina et al., 2004; Huang and Wang, 2004). The fatty acids identified in 
this investigation of P. virgata are common to red algae and specifically to the genus Polysiphonia. Johns 
et al. (1979) investigated the fatty acid composition of 10 seaweeds from Australian waters. Polysiphonia 
pungens was one of the species investigated and showed high levels of polyunsaturated fatty acid, such 
as, arachidonic acid. Palmitic acid was the main saturated fatty acid. Cis-vaccenic acid, cis-9-
hexadecenoic or palmitoleic acid and myristic acid were minor components in the fatty acid mixture. Pettitt 
et al. (1989) investigated the lipids of red the red algae Chondrus crispus and Polysiphonia lanosa. The 
major phospholipids were phosphatidylcholine and phosphatidylglycerol with trace amounts of 
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Organism 
phosphatidic acid and diphosphatidylglycerol. The major glycolipids were mono glycosyl- diacylglycerol, 
diglycosyldiacylglycerol and sulphoquinovosyldiacylglycerol. Galactose was the major component of both 
monoglycosyldiacylglycerol and diglycosyldiacylglycerol. The major fatty acids detected were palmitic, 
oleic, arachidonic and eicosapentaenoic acids. Huang and Wang (2004) investigated 16 species of 
seaweeds from China and found species, such as, Porphyra haitanensis and Undaria pinnatifida to have 
lipids totaling 168.3 and 124.1 mg/g dry weight, respectively. The lipids comprised of 9 fatty acids, 14 
alkanes, 1,1' -bicyclopentyl and cholesta-3,5-diene and the fatty acids were divided into saturated and 
unsaturated fatty acids. The seaweeds were tested for antioxidant activity and it was established that the 
type of lipid was a vital consideration for this bioactivity and not the overall lipid content. An red alga with a 
lipophilic portion high in antioxidant activity, Rhodomela confervoides, had only 37.7% mg/g dry weight in 
lipid content, but the most unsaturated fatty acids (46% of lipophylic content). such as, 11-hexadecenoic 
acid and 5,8,11,14,17-eicosapentaenoic acid. Plocamium telfairiae was one of the algae with the lowest 
antioxidant activity and had the least amount of unsaturated fatty acids (7%). In another study, Vaskovsky 
et al. (1996) determined the polar lipid and fatty acid composition of 24 macroalgae from the Yellow Sea. 
They found glycolipids, such as, monogalactosyldiacylglycerol and phospholipids such as phatidylcholine 
present as the major polar lipid components. The red algae were rich in C20 polyunsaturated fatty acids 
mainly arachidonic and eicosapentaenoic acids. Rezanka and Dembitsky (2001) isolated polyhalogenated 
homosesquiterpenic acids from Plocamium cartilagineum from the Mediterranean. Halogenated fatty acids 
are very common in the marine environment and many have been isolated from algae and other marine 
organisms as shown in a review done by Dembitsky and Srebnik (2002). Many other lipids were isolated 
from other marine organisms as shown in Table 7.13. 
Table 7.13. A few examples of fatty acids isolated from marine organisms. 
Type Examples of Fatty acids Bioactivity References 
Amphimedon compressa Sponge 2-methoxyhexadecanoic acid Carballeira el al., 1998a 
Carballeira and Shalabi, 1994 
Carballeira and Pagan, 2001 
Carballeira and Pagan, 2000 
Zaman el al., 1997 
Dembitsky et al., 2003 
Amphimedon viridis Sponge 
Cal/yspongia fal/ax Sponge 
Calyx podatypa Sponge 
Chondria armala Red alga 
Codium dwarkense Green alga 
Eunicea succinea Sponge 
Eunicea succinea Gorgonian 
Gracilaria verrucosa Red alga 
Holothuria mexicana Sea 
cucumber 
Hyalosiphonia caespilosa Red alga 
Kappaphycus alvarezzi Red alga 
Oceanapia sp. Sponge 
Parietochloris incisa Green alga 
Peyssonnelia caulifera Red alga 
Plocamium telfairiae Red alga 
5,13-nonadecadienoic acid 
Methoxylated fatty acids 
9, 13-dimethyltetradecanoic acid 
Domoic acid 
Octadecadienoic acid 
(5Z,9Z)-14-methyl-5,9-pentadecadienoic acid 
(5Z,9Z)-14-methyl-5,9-pentadecadienoic acid 
Chlorinated C12 fatty acid metabolites 
7 -methyl-6-octadecenoic acid 
C20 polyunsaturated fatty acids 
Oleic acid, linoleic acid, heptadecanoic acid 
C14 acetylenic fatty acid 
Arachidonic acid 
03 fatty acids 
Hexadecanoic acid 
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Antimicrobial Carballeira et al., 1997 
Antimicrobial Carballeira et al., 1997 
Shoeb and Jaspars, 2003 
Carballeira et al., 1996 
Vaskovsky el al., 1996 
Antioxidant Fayaz el al., 2005 
Antimicrobial Matsunaga el al., 2000 
Bigogno et al., 2002 
Dna methyl-
transferases McPhail el al., 2004 
inhibitors 
Antioxidant Huang and Wang, 2004 
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Organism Type Examples of Fatty acids Bioactivity References 
Ptilola filicina Red alga Conjugated triene-containing fatty acids Wise el ai, 1994 
Ptilota filicina J. Agardh Red alga Icosapentaenoic acids Lopez and Gerwick, 1987 
Schizymenia dubyi Red alga Methoxy fatty aCids Barnathan el al., 1998 
Sporolhrix flocculosa Fungus 9-heptadecenoic acid Antibiotic 8enyagoub el al., 1996 
Sporolhnx flocculosa Fugus 4-methyl-7,II-heptadecadienoic acid Antifungal. Choudhury and Traquair, 1994 antimicrobial 
Siolonica sp. Ascidian 3,6-epidioxy-7, 1 O-tetrahydrofurano C26 unsaturated fatly Cytotoxic Davies-Coleman el al., 2000 acids 
Synthetic Compound 3-methylnonadecanoic acid Larvicidal Hwang el aI., 1978 
Synthetic Compound (Z)-2-methoxy-5-hexadecenoic acid Antimicrobial Carbalieira el al., 1998b 
Tanacelum balsamila Plant Hexanoic acid, octanoic acid Antimicrobial Kubo and! Kubo, 1995 
T rigonia fasciculala Plant Oleic acid Mafezoli el al., 2003 
This was not the first isolation of bioactive fatty acids from a South African red alga. In an investigation 
done by Cameron et al. (2001) the bioactive compounds isolated from the alga Plocamium corallorhiza 
were partially characterized as long chain fatty acids. Shoeb and Jaspars (2003) investigated a South 
African red alga Graci/aria verrucosa, which was collected from Port Elizabeth and isolated the three fatty 
acid derived compounds shown in Figure 7.6. All three compounds were suggested to originate from 
dodec-2-enoic acid. 
o 
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Figure 7.7. 3-nonyloxirane-2 carboxylic acid methyl ester (1), 2-chlorododec-2-en-l-ol (2) and 2-
chlorododec-2, 11-dien-1-ol (3) were isolated from Graci/aria verrucosa (Shoeb and Jaspars, 2003). 
Hydrocarbons are also common in algae. In the above study, 14 hydrocarbons, such as, heptadecane, 
octadecane and triacontane were isolated (Haung and Wang, 2004). The microalga Botryococcus braunii 
produced a large amount of hydrocarbons such as n-alkadienes and trienes, triterpenoid botryococcenes 
and methylated squalenes as determined by Metzger and Largeau (2005). For this reason, edible algae 
have to be analyzed to determine the healthfulness of the product as was done in the case of the brown 
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alga Hilnanthalia elongata where it was found to have a low aliphatic hydrocarbon content of between 14.8 
and 40.2 ~g/g dry weights (Crespo and Yusty, 2004) which were considered safe. At the isolation of 
volatiles from the seagrass Zostera marina part of the major constituents were characterized pentadecane, 
heptadecane and nonadecane (Kawasaki et al., 1998). Sesquiterpene hydrocarbons were isolated from a 
new sponge species Cymba stela hooperi (Wright and Konig, 1996). Giese et al. (1999) detected iodinated 
and brominated hydrocarbons in an investigation where 29 algal species were collected and the release of 
volaUle iodinated hydrocarbons determined. 
Many publications are available about fatty acids with antibiotic activities. Findlay and Patil (1984) isolated 
the fatty acids (6Z,9Z, 12Z, 15Z)-hexadecatetraenoic acid, (6Z,9Z, 12Z, 15Z)-octadecatetraenoic acid and 
(6Z,9Z, 12Z)-hexadecatrienoic acid as the antibacterial compounds from the diatom Navicula delognei. It 
inhibited the growth of Staphylococcus aureus, Staphylococcus epldermidis and Proteus vulgaris. 
Benyagoub et al. (1996) isolated 9-heptadecenoic acid and 6-methyl-9-heptadecenoic acid as the 
compounds responsible for the antibiotic activity of the fungus Sporothrix flocculosa. Ohta et al. (1993) 
investigated the antibiotic activities of 10 fatty acids and their methyl esters and found y-linolenic acid 
(C18:3) to have the highest antibiotic activity. (X-Linolenic acid along with eicosapentaenoic acid and 
docosahexaenoic acid also had strong antibiotic activity. 
The antimycobacterial activity of long-chain fatty acids have been demonstrated by a few investigations. A 
potent anti mycobacterial compound, 3-nitropropionic acid was isolated from endophytic fungi found on 
Thai medicinal plants with a minimum inhibition concentration of 3.3 ~M (Chomcheon et al., 2005). 
Antimycobacterial (MIC-value of 25 ~g/mL) and antiplasmodial activity (IC50-value of 7.2 ~g/mL) was 
reported for scleropyric acid isolated from the twigs of Scleropyrum wallichianum (Suksamrarn et al., 
2005). Stavri et al. (2004) investigated the hexane extract of hops, namely Humulus lupulus for 
antimycobacterial compounds and found a fatty acid mixture to be the bioactive principle. Amongst the 
fatty acids were palmitic, stearic and oleic acid with small quantities of lignoceric, arachidic, behenic and 
linoleic acids. All saturated fatty acids were inactive against Mycobacterium fot1uitum, while the 
unsaturated fatty acids, namely oleic and linoleic acids showed minimum inhibitory concentrations of 
between 4 and 16 ~ g/mL. Kondo and Kanai (1972) looked at the lethal effect of long-chain fatty acids on 
mycobacteria and found that out of 11 long-chain fatty acids, oleic, linoleic and myristic acid showed the 
greatest activity against Mycobacterium tuberculosis and M. bovis. Seidel and Taylor (2004) investigated 
the dried roots of Pelargonium reniforme and P. sidoides for antibacterial activity against Mycobacterium 
aurum and M. smegma tis and showed the active components to contain palmitic, oleic and linoleic acid as 
88 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
the major bioactive components. AlthoWgh the initial mixture of fatty acids and flydrocarbons were highly 
active against M. smegma tis in direct bioautograph, but weakly active against M. tuberculosis in the 
radiometric method, the anti mycobacterial activity of the individual fatty acids, such as oleic acid and 
linoleic acid are consistent with the above investigations. 
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Chapter 8 
DISCUSSION AND CONCLUSION 
8.1 Discussion 
The primary objective of establishing whether the algal extracts of Plocamium corallorhiza, Gelidium 
pristoides, and Polysiphonia virgata contain antimycobacterial compounds was achieved in this 
investigation. All three algae presented fractions with antimycobacterial activity against Mycobacterium 
tuberculosis in the Bactec-460 method with P. virgata showing the greatest number of bioactive fractions. 
The secondary objective of isolating the bioactive compounds from the algae was achieved for P. virgata, 
but not for P. corallorhiza and Gelidium pristoides. Initially, a moderately anti-tuberculosis compound, 
namely, 2-methoxyethyl methacrylate was isolated from P. virgata. A follow-up investigation revealed that 
instead of the methacrylate, long-chain fatty acids were the major antimycobacterial compounds in 
P. virgata. 
A difference in the conditions at the time the two samples of P. virgata were collected seems to have 
influenced the phytochemical composition of the alga. In the first collection, P. virgata was obtained from 
the tidal pools as opposed to being cut from the stipes of the kelp Ecklonia maxima at the second 
collection. The tidal pools sample was removed from the kelp stipes for much longer allowing more time 
for degradation by-products, such as the methacrylate to be formed as discussed in Chapter 6. This is 
likely to be the reason why the methacrylate was not detected in the extract of the second collection. For 
future algae investigations it is recommended to ensure that the algae are cut from the holdfast or host 
plants to reduce the formation of degradation by-products. In addition, after cleaning the algae it should be 
dipped in boiling water to inactivate enzymes as was done in a study by Sanina et al., 2004. Seasonal 
variations could also have influenced the results as noted by Pratt et al. (1951) and Homsey and Hide 
(1976). The second sample of P. virgata was collected at the middle of winter in July 2004 while the first 
sample was collected in the middle of autumn in April 2002. If a future investigation is aimed at following 
up a particular aspect of this investigation, the time of year the samples are collected should also be taken 
into account. 
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Since MEMA is commercially available, a structure-activity relationship investigation should be done to 
improve the antimycobacterial activity. The diagram below indicates the regions in the structures of MEMA 
and HEMA, where simple chemical modifications could be used to generate a considerable number of 
new compounds. 
o 
1 3 
2 
o 
4 
--~~--~~---I 
____ ~cH~~d 
5 
Figure 8.1 A diagram of the modifiable regions in the structures 
of MEMA and HEMA. 
1. Replacement by H or a variety of alkyl groups. 
2. Functionalisation of the double bond leading to diols, alcohols, epoxides, cyclopropanes, and 
aziridines. 
3. Formation of new esters, amides, thioesters. 
4. Variation of chain length to improve lipophilicity. 
5. Formation of esters, sulphonic acid esters, ethers, amines, ureas and sulphonyl ureas. 
Derivatives of MEMA have been patented and should be easy to obtain, and their syntheses do not have 
to be attempted (see Appendix 4). In addition, in vivo antimycobacterial activity of MEMA and its analogs 
should be investigated. MEMA and its analogs should also be tested against various mycobacteria and 
other pathogenic microorganisms. A difficulty that arises after finding a natural product with pharmaceutical 
potential is the production of significant quantities of the bioactive compound by straightforward extraction 
or by synthesis with the latter being the preferred root. Often the structures of marine compounds are 
complex and their syntheses involve such long procedures that industrial synthesis does not seem 
economically viable (Munro et al., 1999). With MEMA, the simple compound has already been 
synthesized. A thorough investigation into its biological activities is recommended, 
The extraction procedure used in this investigation with dichloromethane: methanol (2:1) proved highly 
effective. However, the initial purification technique of preparative layer chromatography (PLC) was very 
91 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
time consuming. Since seaweeds contain a large number of secondary metabolites with each purified 
band separating into many individual bands, repeated preparative layer chromatography that involved 
scraping the bands from the glass plates and desorbing the compounds using various solvents took too 
long. The Chromatotron, which was introduced in the second year of this investigation, resolved this 
problem immediately. The ease of collecting the bands as they progressed off the centrifugal plates 
reduced the time of fractionation significantly. With purification, the number of bands did not reduce, but it 
was easier to collect and dry the resultant solutions. As with all chromatographic procedures, establishing 
the most effective mobile phase takes time. Another method that could have been used for purification is 
open-column chromatography. In the investigation of Cameron et al. (2001) which led to this investigation, 
PLC was used together with open-column chromatography. The bioactive compounds reported in that 
investigation was indicated by their positions on the TLC plates. As a result, TLC was the initial method of 
choice in this investigation. The Chromatotron used the same principles and it was the logic choice to build 
on previous findings. 
The BACTEC-460 procedure gave a direct indication of anti-tuberculosis activity in the partially purified 
fractions. The direct assessment against a sensitive strain of M. tuberculosis ensured that possible 
negatives with M. aurum or M. smegmatis did not escape M. tuberculosis exposure. However, the re-
investigation of P. virgata showed that M. smegmatis is an ideal candidate for large-scale investigations 
together with the direct bioautography method, which worked very well and eliminated the problems of the 
insolubility of plant compounds with agar-based assays. The bioactivity of the fractions against M. 
smegmatis was right on target as demonstrated by the subsequent inhibition of M. tuberculosis in the 
radiometric method. It would be of value to test the bioactive fractions of the algae against multi-drug 
resistant strains of M. tuberculosis, as there is an increasing demand for more effective drugs. In addition, 
it would be useful to test the bioactive fractions and isolated compounds in combination with existing first-
line tuberculosis drugs and to evaluate their combined cytotoxicity. 
The cytotoxicity analysis could prove useful as toxicity over the long treatment periods is currently 
problematic and could lead to the discontinuation of treatment. In addition, the bioactive fractions and 
isolates could also be introduced into an in vivo anti-tuberculosis model. The water portions of the algal 
extracts should also be tested in an in vivo model, as low cytotoxicity was observed in vitro against 
Chinese hamster ovarian cells. No inhibitory activity was found against M. tuberculosis in vitro, but in vivo 
testing is worth an investigation as the water portion is one of the main reasons for the existence of the 
current seaweed industry and a significant finding might add value to an argument for a local agar plant 
linked to a pharmaceutical industry. 
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The inhibition of the growtl1 of Plasmodium falciparum by the purified fractions of P. coral/orhiza with ICso-
values of 2.4 Ilg/mL to 8.9 Ilg/mL demonstrates the potential of this alga as a source of antimalarial 
compounds. A follow-up investigation into it antimalarial compounds is highly recommended. Such a study 
should include the algae used in this investigation with brown and green seaweeds. 
The crude extracts of the three seaweeds did not inhibit the growth of M. tuberculosis, but the purified 
fractions showed inhibition. This is a valuable strategy in screening plant extracts as many investigations 
rely on the finding for the crude extracts and do not include fractionation unless the crude extract is 
bioactive. From the results of this investigation, it is clear that fractionation is a vital part of the 
experimental procedure and bioactivities can only be reported if the extract was fractionated. 
This investigation was undertaken with tile assurnption that tile antimicrobial activities of the three 
seaweeds, namely, Gelidium pristoides, Plocamium coral/orhiza and Polysiphonia virgata, in the 
investigation by Cameron et al. (2001) would lead to anti-tuberculosis compounds. The assumption was 
confirmed by the significant inhibition of Mycobacterium tuberculosis by the algal purified fractions in the 
Bactec-460 radiometric method and the subsequent isolation of long-chain fatty acids as the major anti-
tuberculosis compounds from P. virgata. 
8.2 Conclusions 
This investigation has demonstrated that seaweeds are potential sources of anti-tuberculosis compounds. 
As an untapped local resource for pharmaceutical agents, the number of investigations that could be 
launched to investigate tl1eir pharmaceutical potential is unlimited. In this study, only three algae were 
investigated. With South Africa's diverse marine plant resource, many red, brown, and green algae remain 
to be investigated and should form part of any drug development program. 
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Table A 1.1 Purified fractions and the sample masses obtained using the Chromatolron. 
Sa no. Sa masa(mg) Sano. Sa mass (mg) Sano. Sa mass (mg) 
1111 55.84 21 120.81 1032 1663.51 
11111 1.09 211 46.59 
11112 31.64 212 57.61 31 183.84 
111121 1.24 311 42.33 
111122 24.33 22 304.32 
111123 8.71 312 25.42 
11113 29.64 23 205.94 3122 0.42 
231 3.49 3123 7.64 
1112 27.07 232 142.03 3124 0.44 
11121 0.94 233 20.9 3124 1.61 
11122 11 .5 234 10.88 3125 -2.62 
111221 41 .23 235 10.91 3126 .e.11 
111222 7.58 3129 0.6 
111223 3.87 24 68.46 
241 1.73 (2531 )31231 0.37 
11123 5.68 242 27.32 (2533)31233 5.2 
111231 -0.08 243 10.11 312331 2.12 
111232 10.3 244 54.8 312332 0.05 
111233 0.73 312333 0.75 
25 84.55 312334 0.84 
112 68.09 251 0.95 312335 0.44 
1121 3.65 252 44.75 312336 0.12 
11221 21.84 253 7.73 312338 0.18 
112211 125.68 254 1.21 312339 0.23 
112212 20.46 255 7.75 3123310 0.37 
112213 4.13 256 5.7 3123311 0.32 
3123311A 0.39 
11223 3.87 26 153.12 3123312 0.61 
112231 4.05 261 8.33 3123312 0.58 
112232 2.04 262 3.63 
112233 0.68 263 4.14 31234 0.93 
264 10.64 
112221 0.41 265 10.24 (2535}31235 -15.46 
112222 1.8 266 12.15 
112223 5.74 267 18.93 3127 4.04 
1122231 0.01 31271 -1.51 
1122232 2.94 221 49.06 31272 0.34 
1122233 2.38 222 36.54 31272A 0.1 
112224 2.18 223 126.59 31273 0.74 
112225 2.63 222RET 21.66 31274 1.36 
3128 1.96 
101 OeM 2546.29 2221 4.91 
11 423.65 22211 2.87 31210A 0.52 
22212 1.2 31210 0.51 
113 133.95 3121 1.61 
1131 6.07 2222 17.6 31211 .(1.83 
11311 0.39 22221 3.78 31212 0.58 
11312 2.72 222211 0.48 31213 0.73 
11313 1.1 222212 
222213 1.12 31 3 12.52 
1132 1.19 2222121 0.19 3131 0.47 
11321 4.86 2222122 24.58 3132 0.50 
11322 1.89 2222123 7.92 3133 1.15 
11323 6.08 3134 0.46 
11324 1.94 22222 12.3 3135 -3.02 
11325 89.83 222221 0.46 3136 0.7 
222222 2.84 3137 1.57 
11325111 2.51 222223 6.5 3138 4.41 
11325112 28.68 222224 1.05 3138A 0.96 
11325113 16.56 3139 0.13 
113251131 0.54 2222231 0.23 31310 0.32 
113251132 7.97 2222232 1.51 31311 0.3 
1132511321 0.26 2222233 2.37 31312 1.53 
1132511322 6 
1132511323 5.8 2222234 1.29 (2611 }31381 0.15 
1132511324 1.33 22222333 0.59 (2612)31382 0.76 
113251133 3.74 2223 31 .92 (2613}31383 -13.53 
113251134 0.00 22231 0.93 (2614)31364 0.69 
113251135 22232 28.16 (2615}31385 0.73 
113251136 -1 .22 222321 29.38 (2616}31386 0.4 
113251 137 0.43 2223211 0.06 (2617)31387 0.67 
113251135 0.68 2223212 0.21 (2618}31388 3.08 
113251138 3.28 2223213 Lost 313882 2.02 
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Sa no. Sa mass (mg) Sa no. Sa mass (mg) Sano. Sa m8ss(mg) 
313883 0.18 
113252 21.92 222322 32.91 313884 0.15 
113253 1.77 2223221 2.14 313885 0.32 
2223222 3.42 (2619)31389 0.64 
11326 7.98 2223223 2.54 (26110)313810 0.65 
11327 2.04 2223224 8.07 (26111)313811 0.75 
1133 2.51 22232242 0.51 (26112)313812 0.33 
1134 0.8 22232243 3.08 313813 0.56 
1135 1.54 
2223225 2.17 314 22.56 
114 92.36 2223226 1.85 3141 1.6 
2223227 0.81 3141 2.34 
115 39.07 2223228 31411 A 0.37 
22232213 0.76 31411 (11) 0.8 
116 19.48 22232214 0.26 31412 0.38 
31413 0.47 
117 26.53 22232223 1.58 31413A 0.06 
1171 0.44 31414 0.17 
1172 0.1 22232231 0.62 31415 1.1 
1173 0.94 22222333 0.59 31418 0.57 
1174 0.05 3145 1.19 
1175 0.06 22232253 1.31 3146 0.83 
3147 3.89 
12 156.98 222323 2.46 3148 0.35 
121 8.08 3148A 0.98 
122 92.6 2224 9.49 3143(2) 0.71 
123 26.46 22241 7.48 3143 -1.23 
124 23.37 222411 0.5 3147 0.6 
125 3.01 222412 5.25 31410 0.34 
222413 1.56 31410 -2.78 
13 105.29 31411 A 0.37 
131 55.14 2225 0.42 315 9.61 
132 35.18 3151A 0.55 
133 23.73 3151 0.80 
134 7.5 3152 0.55 
135 21.03 3153 0.41 
3154 0.46 
14 825.93 31548 0.39 
141 1.76 3154A 0.74 
142 7.18 3155A 1.8 
143 170.67 3155 1.01 
144 129.93 3156 1.04 
145 5.54 3156A 0.74 
141· 3.43 3157 0.31 
142" 38.65 3158 -3.93 
143· 84.67 3169 -14.26 
144" 239.66 
145· 32.98 
316 7.43 
15 640.95 317 325.81 
151 65.82 
152 89.35 32 29.45 
153 3.98 321 2.09 
154 447.22 322 9.18 
323 10.38 
16 28.78 
16 507.92 33 21.41 
161 13.88 331 0.13 
1611 1.00 332 5.81 
1812 0.25 333 8.33 
1613 0.07 334 2.31 
1814 0.28 
1615 0.81 34 20.56 
1818 0.23 341 9.59 
1617 2.00 342 0.15 
1818 0.43 343 1.07 
1619 0.65 344 5.93 
18110 2.18 345 2.04 
1611A 0.64 346 5.88 
1813A 0.34 
1615A 0.46 
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Sa no. Sa mass (mg) Sa no. Sa mass (mg) Sa no. Sa mass (mg) 
35 52.22 
162 66.25 351 5.1 
163 87.62 352 11.26 
164 83.42 353 224.71 
165 9.77 354 11.71 
166 77.94 355 6.84 
167 43.87 356 5.63 
36 4.5 
37 11.78 
38 212.46 
381 1.41 
382 70.21 
383 48.78 
384 7.69 
385 14.74 
386 30.87 
39 48.81 
391 14.24 
392 10.39 
393 15.66 
394 3.58 
120 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Appendix 1 
Table A 1.2 Sample masses obtained using flash chromatography. 
Sa no. Solvent System Fractions Mass (mg) 
1 1 - 6 = 100:0 Hex: EtOAc 1 - 12 110.1 
2 7 - 10 = 95:5 13 -14 55.7 
3 11-18=90:10 15 - 16 125.2 
4 19-2485:15 17 22.7 
5 25 - 48 = 80:20 18 - 20 22.7 
6 49 - 68 = 75:25 21 - 23 37.8 
7 24 - 27 45.5 
8 28 28.5 
9 29 25.7 
10 30 - 36 347.3 
11 37 - 39 44.7 
12 40 - 41 14.8 
13 42 - 45 39.9 
14 46 - 51 54.9 
15 52 - 53 24.6 
16 54 - 63 75.5 
17 69 -131 = 70:30 64 -72 52.7 
18 73 7.1 
19 74 - 79 36.8 
20 80 - 81 17.8 
21 82 - 89 35.9 
22 90 - 91 9.2 
23 92 - 95 15.9 
24 96 - 98 11.6 
25 99 - 107 34.5 
26 108 - 109 7.6 
27 110-111 13.1 
28 112-116 29 
29 117 - 125 32.1 
30 126 - 134 30.1 
31 132 - 153 = 65:35 135 - 148 60 
32 149 -153 17.6 
33 154 - 171 = 60:40 154 - 162 44.4 
34 163 -171 38 
35 172 - 195 = 55:45 172 - 175 20.6 
36 176 - 184 38.6 
37 185 4.4 
38 196 - 203 = 50:50 186 - 203 72.1 
39 204 = 50:50 204 25.7 
40 205 = 40:60 205 67.2 
41 206 = 30:70 206 17.8 
42 207 = 20:80 207 71.5 
43 208 = 10:90 208 335.4 
44 209 = 0:100 209 258.6 
45 210 = EtOH 210 1046 
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Table A 1.3 Masses of preparative HPLC purified fractions. 
Sample no. Sample mass (mg) 
5/1 3.5 
5/2 3 
5/3 3.5 
5/4 10.9 
5/5 5 
516 3.8 
517 22.8 
5/8 9.1 
5/9 6.7 
6 Hex 24.8 
6 EtOAc 1.5 
7 Hex 52.1 
7 EtOAc 1.8 
6/1 1.9 
6/2 0.6 
6/3 0.9 
6/4 1.6 
6/5 1.6 
6/6 2.5 
6/7 1.1 
6/8 1.4 
6/9 0.7 
6110 1 
6/11 
7/1 2.6 
7/2 0.8 
7/3 0.8 
7/4 1.1 
7/5 1.3 
7/6 0.7 
7/7 1.4 
7/8 0.5 
7/9 2.2 
7/10 0.6 
7/11 0.7 
7/12 1.8 
1730Hex 187.1 
1730EtOAc 57.1 
1730Crude 
1730/1 1.9 
1730/2 16.7 
1730/3 2.6 
1730/4 13.2 
173015 4.6 
1730/6 5.3 
1730/7 3.8 
1730/8 14.5 
6/664 0.7 
6/61 0.1 
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Sample no. Sample mass (mg) 
6162 0.2 
6/63 0.0 
6/64 0.2 
6/65 0.4 
6/66 
6/67 0.8 
6/68 0.2 
6/69 0.1 
6/610 0.4 
6/661 -0.3 
6/662 0.2 
6/663 0.1 
6/664 
6/665 1.4 
6/51 0.1 
6/52 0.6 
6/53 0.8 
6/54 0.4 
6/55 0.3 
6/56 0.4 
6/57 0.3 
6/58 0.8 
2&3Hex 152.8 
2&3EtOAc 2.5 
1730/1 34.9 
1730/2 26.3 
1730/3 4.9 
1730/4 4.7 
1730/5 1.7 
1730/6 2.6 
1730/7 1.7 
1730/8 1.7 
1730/9 10.0 
1730/10 17.7 
1730/11 8.7 
1730/12 5.2 
1730/13 2.9 
2&3/1 3.6 
2&3/2 1.3 
2&3/3 0.9 
2&3/4 1.1 
2&3/5 0.4 
2&316 13.2 
2&3/7 16.6 
2&318 14.3 
2&3/9 59.5 
2&3110 24.7 
2&3/11 6.3 
2&3/12 10 
2&3/13 10.9 
2&3114 4.9 
1730/11 26 
1730/21 17 
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Sample no. Sample mass (mg) 
1730/27 16.2 
1730/31 6.8 
1730/32 9.4 
1730/37 9.4 
1730/41 5.8 
1730/54 2.8 
2&3/131 9.5 
2&3/142 6.2 
6/91 4.8 
R/31 6.2 
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PARASITE LACTATE DEHYDROGENASE ASSAY 
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The data are were processed on 20020610 (15:25: 14) 
Row of wells A: 100 50 25 12.5 6.~5 3.1~ 1.56 .78 .39 .195 
8.51 29.7 70.2 80.8 112. 101. 94.6 89.3 94.6 84.0 
Row of wells B: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
5.20 31.2 76.0 72.9 96 8 100 92.7 81.2 95.8 88.5 
DC··1 
mealls: 6.85 30.5 73.1 76.8 104 . .lOO. 93.6 85.3 95.2 86.2 
1.39 5.73 .814 3.18 stdev: 2.33 1.03 4.12 5.61 11.2 .752 
Row of wells C: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
o 8.91 24.7 52.4 81.1 100 87.1 87.1 98.0 88.1 
Row of wells D: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
2.66 13.3 28 73.3 102. 118. 120 117. 137. 125. 
DC~2 
meanf3: 1.33 11.1 26.3 62.9 91.9 109. 
3.12 2.29 14.7 15.1 13.1 
103. 102. 
23.2 21.3 
117.106. 
27.7 26.3 stdev: 1.88 
Row of wells E: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
4.85 9.70 17.4 47.5 74.7 81.5 75.7 71.8 86.4 88.3 
Row of wells F: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
2.80 7.47 22.4 49.5 73.8 81.3 80.3 78.5 67.2 92.5 
DC-3 
means: 3.82 8.59 19.9 48.5 74.2 81.4 78.0 75.1 76.8 90.4 
stdev: 1.45 1.57 3.50 1.38 .654 .173 3.28 4.70 13.5 2.95 
Row of wells G: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
4.08 13.2 30.6 67.3 80.6 81.6 90.8 84.6 85.7 93.8 
Row of wells H: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
DC 4 
meallS: 
~;tdev : 
5.15 12.3 39.1 76.2 77.3 86.5 98.9 87.6 79.3 81.4 
4.61 12.8 34.8 71.8 78.9 84.1 94.8 86.1 82.5 87.6 
.758 .632 6.05 6.32 2.32 3.51 5.76 2.07 4.47 8.79 
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Row of wells A: 100 50 25 12.5 6.2 :J -3 . 12 1.56 .78 . ] 9 .195 
14.1 22.3 42.3 81.1 97.6 92.9 97.6 107. 102. 97.6 
Eow of wells B: 100 50 25 12.5 6 . ~;5 3.12 1. 56 .78 .39 .195 
4.49 15.7 46.0 74.1 92.1 96.6 103. 88.7 98.8 100 
DC' -[-) 
rneallS: 9.30 19.0 44.2 77.6 94.8 94.7 100. 97.9 100. 98.8 
stdev: 6.80 4.68 2.62 4.96 3.89 2.60 4.04 12.9 2. L15 1.()6 
Row of wells c: 100 50 ~~ 5 12.5 6.25 ].12 1. 56 .78 .39 . 19 r) 
59.7 89.1 80.4 100 100 107. 104. 102. 97.8 103. 
Row uf wells D: 100 50 25 12.5 6. 2~) 3.12 1 .56 .78 .39 .195 
46.8 90.4 76.5 102. 103. 108. 97.8 107. 94.6 107. 
DC-6 
mean[; : [~3 .2 89.7 '18.5 101. 101. 108. 101. 104. 96.2 10':; . 
~3tdev : 9.17 .9E' 2.71 1. 50 2.25 .637 4.57 3.72 2.22 2.95 
Row of wells E: 100 50 25 12.5 6.25 3.12 1. 56 .'78 .39 .195 
5.82 11.6 29.1 69.9 86.4 83.4 85.4 96.1 97.0 99.0 
Row of wells F: 100 50 25 12.5 6.25 3.12 1. 56 .78 .39 .195 
8.57 13.3 32.3 63.8 92.3 88.5 92.3 89.5 95.2 90.4 
DC-'7 
means: 7.19 12.4 30.7 66.8 89.3 86.0 88.9 92.8 96.1 94.7 
f3tdev: 1. 94 1.18 2.30 4.30 4.22 3.58 4.91 4.66 1.30 6.04 
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The data are being processed on 20020624 (14:42:44) 
Row ot wells A: 100 
o 
Row of wells B: 100 
2B-1 
means: 
stdev: 
Row of wells C: 
o 
o 
o 
100 
50 25 12.5 6.25 3.12 1.56 .78 . J 9 . 195 
o 22.2 34.5 69.1 93.8 112. 108. 133. 103. 
50 25 12.5 6.25 3.12 1.56 .78 .39.195 
o 15.5 31.0 58.6 90.5 82.7 100 101. 81.8 
o 18.8 32.8 6l.8 92.1 97.5 104. 117. 
o 4.74 2.49 7.43 2.34 20.9 6.11 22.3 
50 25 12.5 6.25 3.12 1.56 .78 .39 
92.8 
15.4 
.195 
o 0 14.7 36.4 58.1 80.6 89.1 98.4 94.5 71.3 
l(.ClW of wells D: 100 
2B-3 
mearn; : 
stdev: 
Pow of "'Jellf" E: 
o 
o 
o 
100 
o 
Row of wells F: 100 
o 
2B-4 
means: 0 
stdev: 0 
Row of wells G: 100 
50 25 12.5 6.25 3.12 1.56 .78 .39 . 19"; 
o 19.2 33.8 57.6 79.2 86.1 98.4 93.0 70 
o 16.9 35.1 57.9 79.9 87.6 98.4 
8.43 
93.8 
1. 05 
70.6 
.9"31 o 3.18 1.82 .316 .982 2.11 
50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
o 
50 
o 
o 
o 
50 
o 11.1 37.3 69.0 88.8 102. 90.4 77.7 
25 12.5 6.25 3.12 1.56 .78 .39 .195 
o 12.4 33.3 73.6 89.1 99.2 89.1 74.4 
o 11.7 35.1 71.3 89.0 100. 89.8 76.0 
o .913 2.80 3.24 .182 2.23 .939 2.37 
25 12.5 6.25 3.12 1.56 .78 .39 .195 
o 0 5.55 23.0 51.5 75.3 84.9 95.2 84.9 63.4 
Row of wells H: 100 
2B-6 
ITH-:;ans: 
stdev: 
o 
o 
o 
50 25 12.5 6.25 3.12 1.56 .78 
o 10.8 28.8 48.6 75.6 88.2 99.0 
o 8.18 25.9 50.1 75.5 86.6 97.1 
o 3.71 4.11 2.07 .197 2.38 2.73 
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Row of wells A: 100 so 25 12.5 6.25 3.12 1.S6 .78 .39 .195 
84.8 81.0 98.7 113. 10~. 108. 110. 121. 103. 91.1 
Row of wells B: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
6 G . G 84 . 6 91 . 4 94 . 8 92 . 3 9 C:) • 'I 90 . 5 88 . 0 89 . '7 80 . 3 
Sample 1 
meallS: 
stdev: 
7S.7 82.8 95.0 104. 98.0 102. 100. 104. 96.7 8').7 
12,8 2.54 5.14 13.4 8.12 9.28 13.8 23.6 9.93 7.63 
Row of wells C: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .19') 
4.54 9.09 16.3 53.6 80 88.1 96.3 97.2 98.1 83.6 
Row of wells D: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
2.41 B.B7 14.5 42.'1 64.5 69.3 83.8 87.0 91.9 78.2 
SampLe 2 
Tneans: 3.48 
stdev: 1. 50 
Row of wells E: 100 
8.98 15.4 48.1 72.2 78.7 
.155 1.30 7.70 10.9 13.3 
50 25 12.5 6.25 3.12 
90.1 92.1 95.0 80.9 
8.83 7.19 4.41 3.82 
1.56 .78 .39 .19'0 
29.2 72.3 78.0 88.6 87.8 83.7 66.6 90.2 90.2 78.0 
Row of wells F: 100 .50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
32.5 63.4 75.6 83.7 84.5 91.0 91.0 92.6 97.5 86.1 
Sample 3 
means: 30.8 67.8 76.8 86.1 86.1 87.3 78.8 91.4 93.9 82.1 
stdev: 2.29 6.32 1.72 3.44 2.29 5.17 17.2 1.72 5.17 5.74 
Row of wells G: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
o 
Row of wells H: 100 
Sample 2.4 
means: 
stdcv: 
o 
o 
o 
o 
50 
o 
o 
o 
o o 1.83 33.9 76.1 80.7 77.9 69.7 
25 12.5 6.25 3.12 1.56 .78 .39 .195 
o 
o 
o 
o 8.04 32.1 78.1 88.5 95.4 79.3 
o 4.94 33.0 
o 4.39 1.24 
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DENISE'S FRACTIONS 
Row of wells A: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
52.1 88.0 100. 112. 105. 113. 112. L17. 111. 102 . 
Row of wells B: 100 50 25 12.5 6.25 3.12 1.56 .78 . 39 .195 
44.1 74.1 91.6 113. 111. 113. 115 117. 119. 125 
DEN 1 
means: 48.1 81.1 96.2 113. 108. 113. 113. 11'7. IE'). 113. 
stdev: 5.63 9.80 6.49 .362 4.62 .241 1.54 .317 5.09 15.8 
Row of wells C: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
51.2 85.7 83.1 103. 107. 113. 110. 113. 118. 115. 
Row of wells D: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
50.988.6103.104.120.126. 123. 128. 133. 132. 
DEN 2 
means: 51.1 87.1 93.4 104. 114. 119. 117. 120. 125. 124. 
stdev: .224 2.09 14.5 .958 9.32 9.17 8.95 10.5 10.2 11.3 
Row of wells E: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
55.3 60.6 75.5 Ill. 130. 140. 134. 142. 13r~. 147. 
Row of wells F: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .19°) 
53.9 46.0 80.2 128. 1'.i9. 171. 168. 176. 177. 182. 
DEN -j 
means: 54.6 53.3 77.8 120. 14';. 15[c). 151. 159. 156. 165. 
stdev: .969 10.3 3.34 12.1 20.0 21.6 24.3 23.8 30.0 24.7 
Row of wells G: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
50.6 51.9 71.4 125. 148. 163. 166. 161. 171. 181. 
Row of wells H: 100 50 25 12.5 6.25 3.12 1.56 .78 
40.8 53.7 63.4 1]2. 133. 138. 137. 140. 
DEN 4 
means: 
stdev: 
45.7 52.8 67.4 
6.92 1.28 [C).64 
119. 
9.24 
140. 
10.4 
151. 
17.6 
The dat.a are being processed on 20021021 (14:44:12) 
151. 
20.2 
Row of wells A: 100 50 25 12.5 6.25 3.12 1.56 
] Co 0 . 
14.2 
.78 
.39 .195 
141. 143 . 
E)6. 162. 
20.8 27.4 
.39 .19'; 
23.1 30.5 74.3 114. 130. 121. 131. 134. 121. 118. 
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Eow of welle" B: 100 ')0 12.5 3.12 1.56 .78 .39 .195 
18.0 23.8 57.1 119. 147. 160. 159. 160 160. 148. 
DS 
means: 20.6 27.1 65.7 116. 139. 141. 145. 147. 141. 133. 
stdev: 3 56 4.78 12.1 3.53 12.0 27.9 19.5 17.8 27.9 21.4 
Row of wells C: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
30.1 27.7 36.J 125. 183. 203. 203. 207. 200 189. 
Eow of wells D: 100 50 12.5 6.2Cj 'l .12 1. 56 .78 .39 .19S 
31.7 42.8 46.0 125. 230. 2r)8. 255. 255. 247. 2 Cj5. 
DC; 
means: 30.9 35.2 41.0 125. 206. 231. 
10.7 6.99 6.76 33.2 38.9 
229.231.223.222. 
36.7 34.1 33.6 46.9 stdev: 1.14 
Eow of weLls E: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
36.'5 39.6 47.6 144. 212. 230. 247. 25:;. 263. 249. 
Row of wells F: 100 so 25 12.S 6.25 3.12 1.56 .78 .39 .195 
34.3 38.8 44.7 123. 200243.250. 252. ~;50. 237. 
D7 
means: 35.4 39.2 46.1 134. 206. 
14.S 8.97 
236. 249. 253. 257. 
9.28 2.21 2.34 9.01 
243. 
8 . ~1 0 E.1tdev: 1.54 .619 2.01 
Row of wells G: 100 SO 25 3.12 1.56 .78 .39 .195 
7.04 29.5 35.2 102. 180. 215. 228. 221. 242. 22~,). 
Row of wells H: 100 50 25 12,5 6.2S 3.12 1.56 .78 .39 .195 
6.15 33.8 44.6 112. 204. 223. 243. 226. 247. 247. 
D8 
means: 6.59 31.7 39.9 107. 192. 219. 235. 223. 244. 236. 
stdev: .628 3.01 6.64 6.71 17.2 5.36 10.5 3.55 3.84 15.7 
Row of wells A: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
17.1 40.7 36.8 lOS. 207. 238. 261. 269. 26S. 268. 
Row of wells 8: 100 50 25 12.5 6.25 3.12 1.56 .7F3 .39 .195 
14.4 28.9 31.3 114. 186. 220. 242. 248. 239. 238. 
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D9 
means: 15.7 34.8 34.0 109. 197. 229. 252. 25El. 2'- " JoC,. 253. 
~~t(h:v : 1. en 8.39 3.90 6. 'iO 14.9 12.4 13.9 15.2 18.4 21 .1 
Row of wells c: 100 'J 0 25 12.5 6. ;:5 .3 .12 1.56 .713 .39 .195 
13.3 22.6 32 72 18'; . 241. 276 26'5. 282. 26'5. 
Row uf wells D: 100 50 25 12.':-> 6.25 3 .12 1. 56 .713 .39 .195 
14.7 :~ 9.5 39.3 80.3 236. 303 331. 321. 326. 327. 
DID 
means: 14.0 ~; 6.0 35.6 'lG.l 210. 272. 303. 293. 304. 296. 
"te-lev: 1. 00 4.83 5.19 5.88 3 ~~ .8 43.8 38.9 39.5 30.8 44.2 
Row of wells E: 100 50 ., c ..:.... ,) 12.5 6.25 3.12 1 .56 .78 .39 .195 
21 . 0 45.6 47.3 .ll 9 . 301. 314. 354 361. 357. 347. 
How of wells F: 100 50 25 12.5 6 .2:-) 3.12 1 . ~'i6 .78 . .39 .195 
9.67 40.J 37.0 109. 248. 287. 309. 316. .327. 32 'J . 
Dll 
means: 15.3 42.9 42.2 114. 27'i. 300. 332. 33f:l. 342. 337. 
stdev: 8.04 3.74 7.26 6.80 37.7 19.0 31.6 32.0 21.5 14.1 
Row of wells G: 100 50 25 12.5 6.25 3.12 1. 56 .78 . J 9 . 19 ~'i 
15.6 43.7 39.0 1 :13 . 23:, . 278. 293. 298. 318. 312. 
Row of wells H: 100 50 25 12.5 6 ') c· .0:-. ) 3.12 1. 56 .78 .39 .195 
14.2 38.9 35.0 132. 203. 227. 259. ~;4 2 246. 25,). 
D12 
mean,,; : 14.9 41.3 37.0 142. 219. 252. 276. 270. 2 El;2 . 2El4. 
stc1ev: .947 .3.3El 2.82 14.6 2;2 .6 35.9 24.0 39.3 50.9 40.0 
Row of wells 11. : 100 SO 2 '0 12.5 6 . :; 5 3.12 1.56 .78 .39 .19.5 
12.5 21.8 25 87.5 1. 8 'J . 242. 239. 260. 243 264. 
Row of wells B: 100 50 2 ,-_'J 12. ':i 6 2' • "J 3.U 1.56 .78 .39 .19.'0 
1") ,-
.::.... .. .J 17.8 35.7 96.4 212. 285. 269. 280. 289. 296 . 
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D13 
mealW: 12.5 
stdev: 0 
Row of wells C: 100 
19.8 
2.84 
:;0 
30.3 91.9 200 263. 254. 270. 266. 
7.57 6.31 17.6 30.7 21.6 13.7 32.] 
25 12.5 6.25 3.12 1.56 .78 .39 
280. 
22.8 
.19:; 
8.06 4.83 9.67 30.6 75.8 201. 225. 250 235. 267. 
Row of wells D: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
8.19 9.83 13.1 24.:1 7:1.4 181. 229. 250. 259. 263. 
DJ4 
means: 8.13 
stdev: 9.34 
Row of wells E: 100 
7.33 
3.53 
50 
11.3 
2.43 
2" [" "~ 
27.6 
4.28 
12.5 
75.6 
.280 
6.25 
191. 
13.8 
3.12 
227. 
2.61 
1. 56 
2':,0. 
.579 
.78 
247. 
16.6 
.39 
265. 
2 69 
.195 
9.37 32.8 31.2 62 .. 5 168. 231. 7.40. 242. 248. 254. 
Row of wells F: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
10.4 26.8 26.8 65.6 161. 222. 214. 253. 246. 253. 
DE; 
means: 9.91 29.8 29.0 64.0 164. 226. 227. 247. 247. 254. 
stdev: .758 4.20 3.10 2.24 5.34 6.26 18.1 8.16 1.53 .676 
Row of wells G: 100 50 25 12.'} 6.25 3.12 1.56 .78 .39 .195 
6.94 11.1 23.6 48.6 134. 202. 208. 225 229. 237. 
Row of wells H: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
8.98 13.4 13.4 40.4 108. 165. 191. 187. 186. 184. 
D16 
means: C/.96 
stdev: 1.44 
Row of wells A: 100 
12.2 
1.67 
50 
18.5 
7.16 
25 
44.5 
~:; . 77 
12.5 
121. 
18.1 
6.25 
183. 
26.5 
3.12 
199. 
12.2 
1.56 
206. 
26.4 
.78 
207. 
30.1 
.39 
210. 
37.6 
.195 
10.4 20.8 27.0 84.7 161. 192. 195. 202. 195. 215. 
Row of wells B: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
9.52 15.0 34.9 90.4 183. 224. 229. 230. 233. 242. 
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Dll 
rneanE'; : 
Pow of well3 c: 
Pow of well3 D: 
D14 
9.97 17.9 31.0 87.5 172. 
.631 4.06 5.54 4.06 15.2 
208. 
22.7 
212. 
24.2 
100 50 25 12.5 6.25 3.12 1.56 
216. 214. 229. 
19.9 27.0 19.5 
.78 .39 .195 
4.44 1.48 7.40 28.1 76.2 170. 195. 208. 200 223. 
100 50 25 12.5 6.25 3.12 1.56 .78 .39 .19~) 
4.58 5.34 8.39 20.6 76.3 159. 196. 212. 217. 223. 
means: 4.51 3.41 
2.73 
7.90 
.699 
76.3 
2.79 
164. 
7.65 
196. 
.983 
;no. 
2.89 
208. 223. 
2.79 ",tdev: 9.59 
Row oE wells E: 100 50 2 Ie -) 
5.32 
12. I) 6.2 ro 
12.4 
3.12 1.56 .78 .39 .19 r) 
6.10 28.2 31.2 64.8 159. 205. 212. 213. 216. 223. 
Row of wells P: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
6.71 25.3 30.5 68.6 155. 200 193. 222. 221. 226. 
D15 
means: 6.41 26.8 30.9 66.7 157. 202. 203. 218. 218. 224. 
stdev: .431 2.03 .495 2.66 2_52 3.77 13.9 6.11 3.96 1.73 
Row of wells G: 100 50 25 12.5 6.25 3.12 1.56 .78 .39 .195 
4.10 10.2 23.9 49.3 130. 182. 186. 197. 200. 210. 
Row of wells H: 100 50 12.5 6.25 3.12 
6.74 10.6 ]6.8 43.8 108. 151. 
D16 
mealll3: 5.42 
stdev: 1.86 
Row of wells A: 100 
10.4 20.4 46.5 119. 167. 
.282 5.03 3.88 15.4 22.0 
50 25 12.5 6_25 3.12 
1.56 .78 .3<) .195 
168. 165. 168. 170. 
177.181. 18 i!. 190. 
12.5 22.2 22.7 28.4 
1.56 .78 .39 .195 
8.23 10.5 15.2 32.9 105. 180 241. 243. 264. 270. 
Row of wells B: 100 50 25 12. C:; 6"" 'J r:: • ..::...:=1 3.12 1.56 .78 .39 .195 
12.3 13.8 23.0 43.0 153. 263. 327. 347. 356. 352. 
D17 
me ans : 1 0 . 2 12 . 2 1 9 . 1 3 8 . 0 12 9 . 22 1 . 284 . 2 9 5 . 3 1 () . 3 11 . 
stdev: 2.87 2.30 5.50 7.16 33.9 58.7 61.1 73.6 65.2 S7.7 
Row () f we 11 s C: 100 50 25 12 . 5 6 . ~~ ') 3 . J 2 1 . 56 . c18 . 39 . 195 
14 24 18 44 196 364 428 430 456 
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Row uf wells D: 100 50 ~~ S 12 . 'e, 6.25 3.12 1.56 .'78 .39 . .L9S 
1'7.0 31 .7 21. 9 ~-) ~ .6 56.0 28 r) . 441. S19. 560. ') 68. 
U 1 fJ 
meallc~ : lS.5 27.8 19.9 48.8 56.0 240. 402. 473 495. 512. 
stdev: 2.17 5.44 2.79 6.82 G.B9 63 .1 54.7 6,1.7 92.6 79.4 
Row of wellE3 E: 100 50 2S 12.5 6.25 3 l'} 1 .56 .78 .39 195 
23 . 8 42.8 38.0 66.6 52.3 ~;47 . 407. 509. :>35 . 521. 
Row of wells F: 100 50 2 " oJ 12.5 6 ')" . .:..,:,) 3.12 1 .56 .78 .39 .195 
9 . 5::~ 23 .8 19.0 61. 9 ,~ 0 216. 419. 495. S42. 538. 
D19 
rneanE':; : 16.6 33 . " 28. Co 64.2 S1.1 232. 413. 502. S39. S29 . 
stdev: 10.1 13.4 13 .4 3.36 1.68 21.8 8.41 10.1 S.OS 11.7 
Row of wells G: 100 50 2 ') 12. S 6 .)c' • ~.::J 3.12 1. ')6 .78 .39 19S 
17.0 6:; . 8 73.1 78.0 226. 397. 536. 536. 539. S63. 
Row ot wells H: 100 50 ~; S 12.5 6.2.5 3.12 1. 56 .78 .39 .195 
14.5 39.5 66.6 79. L 222. 393 460. 466. 472. 470. 
D20 
means: 15.8 52.7 69.9 78.6 224. 395. 498. 501. ') 0 'i . 517. 
stdev: 1.76 18.5 4.59 .790 2.76 2.69 53 .8 49.4 46.7 65.4 
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Appendix 3 
HPLC, NMR AND MASS SPECTRA 
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Figure A3.1. 'H NMR spectrum of 3155A in CD2CI2, 600 MHz. 
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Figure A3.2 I3C NMR spectrum of MEMA in CD2Cb, 150 MHz. 
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Figure A3.3. COSY spectrum of 3155A in CD2CI2. 
Figure A3.4 HSQC spectrum of 3155A in CD2CI2. 
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Figure A3.5. HMBC spectrum of 3155A in CD2CI2. 
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Figure A3.6 Mass spectrum of 3155A 
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Figure A3.7. Expansion of 1 H NMR spectrum of MEMA at 0 6.1 
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Figure A3.8. Expansion of IH NMR spectrum of MEMA at 0 5.6. 
140 
I 
-J 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
:\PP'J di( .. 
~ ~ ;;; 
~ 
I 
'J ( 
/ 
~J 
;;; 
~ 
I 
M 
;;; ;;; ;;; g 
~ ~ ~. 
I I 
I 
\]I / 
\) 
",-'----'--1 -,. '--r-'=',-----.-, -,,-----.--, -=;:'='-"1 =-,,-----.--=;=-,-, -'1-'-' --j=-"r-r, -'I-----r. "'T''-'--,--,=----'I ' , , , , .. , .--;::.-,-,.-
4 Jl~O <1 :3300 4 J250 'U200 4.3150 4 J I 00 4 3050 4.3000 
ppm(!l) 
Figure A3.9. Expansion of 1H NMR spectrum of MEMA at .5 4.3. 
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Figure A3.10. Expansion of'H NMR spectrum ofMEMA at 0 3.6. 
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Figure A3.11 . Expansion of lH NMR spectrum of MEMA at 63.4. 
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Figure A3 .12. Expansion of 1 H NMR spectrum of MEMA at 81.9. 
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Figure A3.13 1HNMR spectrum of HEMA, 600 MHz 
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Appendix 4 
PATENTED DERIVATIVES OF MEMA 
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The following derivatives were obtained from a SciFinder 2004 search. 
Component Registry Number: 26915-72-0 
Formula: (C2 H4 O)n C5 HS 02 
Component Registry Number: 212S2-97-3 
Formula: C10 H14 05 
H 2 C 0 o 
II II II 
o 
II 
Me - C - C - 0 - CH 2 - CH 2 - 0 - C - CH 2 - C - Me 
Component Registry Number: 156-S7-6 
Formula: C3 H9 N 0 
H 2 N- CH 2 - CH 2 - CH 2- OH 
Component Registry Number: 106-91-2 
Formula: C7 HlO 03 
o 
~ o II CH 2 II 
CH 2 - 0 - C - C - Me 
Component Registry Number: 100-42-5 
Formula: CS HS 
H2 C==CH-Ph 
Component Registry Number: SO-62-6 
Formula: C5 HS 02 
H 2 C 0 
II II 
Me -C-C-OMe 
Component Registry Number: 79-41-4 
Formula: C4 H6 02 
CH 2 
II 
Me - C - CO 2 H 
Component Registry Number: 27637-03-2 
Formula: (C4 HS 0 . C2 H4 O)x 
Component Registry Number: 109-99-9 
Formula: C4 HS 0 
o 
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Component Re~Jistry Number: 75-21-8 
Formula: C2 H4 0 
o 
~ 
Component Registry Number: 124424-70-0 
Formula: C15 H22 02 
o CH2 
II II 
O-C-C-Me 
Component Registry Number 103-11-7 
Formula: C11 H20 02 
o 
II 
CH 2 - 0- C- CH == CH 2 
I 
Et-CH-Bu-n 
Component Registry Number: 80-62-6 
Formula: C5 H8 02 
H2 C 0 
II II 
Me-C-C-OMe 
Component Registry Number: 178824-27-6 
Formula: C14 H20 02 
o 
II 
O-C- CH==CH2 
Component Registry Number: 98900-82-4 
Formula: C11 H18 04 
Me 
Me 
Me 
Component Registry Number: 6976-93-8 
Formula C7 H12 03 
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H2C 0 
II II 
Me- C- C- 0- CH2 - CH 2- 0- Me 
Component Registry Number: 110-63-4 
Formula: C4 H10 02 
HO - (CH 2) 4 - OH 
Component Registry Number: 26915-72-0 
Formula: (C2 H4 O)n C5 H8 02 
Component Registry Number: 24448-20-2 
Formula: C27 H32 06 
Component Registry Number: 13676-54-5 
Formula: C21 H14 N2 04 
o 
Component Registry Number: 3290-92-4 
Formula: C18 H26 06 
o 
o CH2 
II II 
CH 2 - 0- C- C- Me 
I 
Me-C- C- O-CH 2-C- Et 
I 
o CH2 
II II 
CH 2 - 0- C- C- Me 
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Component Registry Number: 2867-47-2 
Formula: C8 H15 N 02 
o CH 2 
/I II 
Me 2N- CH 2- CH 2- 0- C- C-Me 
Component Registry Number: 2530-85-0 
Formula: C 10 H20 05 Si 
OMe 
\ 
Me-C-C-O- (CH 2) 3-Si-OMe 
\ 
OMe 
Component Registry Number: 106-91-2 
Formula: C7 H10 03 
o 
~ o II CH2-0-C-C-Me 
Component Registry Number: 26915-72-0 
Formula: (C2 H4 O)n C5 H8 02 
Component Registry Number: 24448-20-2 
Formula: C27 H32 06 
Component Registry Number: 13676-54-5 
Formula: C21 H14 N2 04 
Qo ~CH2~pO ~ N~ ~N / ~ 
o 0 
148 
o CH2 
II 11 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Appendix 5 
DIRECT BIOAUTOGRAPHY 
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Figure A5.1. Inhibition zones obtained against Mycobacterium 
aurum in the direct bioautography method. l'Jumbers 1 to 18 
indicate the sample numbers as assigned in Table 7.2. 
Figure A5.2. Inhibition zones obtained against Mycobacterium 
aurum in the direct bioautography method. Numbers 19 to 36 
indicate the sample numbers as assigned in Table 7.2. 
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Figure A5,3, Inhibition zones obtained against Mycobacterium 
aurum in the direct bioautography method, Numbers 37 to 45 
indicate the sample numbers as assigned in Table 7,2, 
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GC-MS ANALYSIS RESULTS 
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Submitted by: Denise Saravanakumar (UCT, Dept. of Pharmacology; Prof. Peter Smith) 
Analysis date: 31 January 2006 
Instrument: ArviD 604 High Resolution Mass Spectrometer 
Sample: 1730/11 E 
Data folder: 200601 January 
Calibration: 2006\0060119 __ CAL500 _res 1000 
Scan: m/z 25-500 
Sample preparation: The sample solution was injected (1 ~11) directly into the gas chromatograph (GC) 
inlet. 
Inlet method: Gas Chromatography 
• Instrument 
r Carlo Erba GC 6000 Vega Series 
r Transfer line temperature: 250°C 
• Column 
r LECUS, PS089-0H (08-5 equivalent) silanol-terminated (95%)-methyl-(5%)-
phenylpolisiloxane copolymer stationary phase 
r 40 m x 0.3 mm I.D. 
r Column number: P201 
• GC Inlet 
r He pressure: ca. 40 kPa (linear velocity: 28.2 cm/sec at 40°C) 
r Split flow: 20 ml/min (septum purge: 5 rnl/min) 
r Temperature: 250°C 
• Oven 
r 130 - 270°C at 3°C/min, hold 10 min 
Ionization technique: EI+ (Electron Energy: 70eV Source: 200°C) 
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Total Ion Current Chromatogram: 
ION TRACE. Max.Scan=1967#1 :14:15.28. 
70 Total Ion Current. Max.lnt.=696JJ293. 100% Int.=696.0293. 
60 
m 50 
OJ 
co 
~ 40 
.c-
Ui 30 9 
c \ OJ 
E 20 
10 
0 
0:00 5:00 10:00 
Retention Tirne 
ION TRACE. Max.Scan=1967#1 :14:15.28. 
Total Ion Current. Max.lnt.=696 0293 100% Int.=696.0293. 
70 
60 
W')O 
OJ' 
co 
~~ 40 
.c-
Ui 30 
c 
OJ E 20 
10 
22 26 
/ 
1 16 19 \ 20 
/ 
17 
! 
I 1 I 
1 
1 
20:00 25:00 
33 
O~r-r-rl-rl-'I-'-'-'I-'I-'I-'-'-'I-'I-'I-'I-ol-o1-01-'-'-'-'1-'1-'1-''''-'1 -'I-r~ 
30:00 3500 40:00 45:00 50:00 55:00 
Retention Time 
Low resolution EI+ mass spectra of the sample components, providing their tentative identities: 
SCAN GRAPH. Flagging=Norninal M/z. Highlightlllg=Base Peak 
a:; 
OJ 
co 
,.0 
~~ 
.c-
Ui 
c: 
}!l 
.E: 
Scan 255#9:37.24. Sub=247#9:19.12. Entries=55. Base rv1Iz=57.1. 100% Int.=1.7712. 
100 
57 
"" 80 85 
60 \ 
40 
198 
20 / 
0 
50 100 150 200 250 300 350 400 
Low Resolution M/z 
1. EI mass spectrum of an aliphatic hydrocarbon. 
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SCAN Gf~APH. Flagging=Nominal M/z. Highlighting=Base Peak. 
<lJ 
OJ 
tU 
~ 
2:' 
r/) 
c 
El 
c 
Scan 285#10:45.19. Su b=272#1 0: 15.74. Entries=71 . Base Mlz=163. 100% Inl=6.9952. 100 
16 
\ 
80 
60 
40 
17 
20 50 
I 
0 * 50 100 150 200 250 300 350 400 Low Resolution Mlz 
2. EI mass spectrum of dimethyl phthalate. 
SCAN GRAPH. Flagging'"Nominal Mlz. Highlighting=Base Peak. 
<lJ 
OJ 
tU 
2/2 
C 
if) 
c 
El 
c 
100 Scan 304#11 :28.23. Sub=314#11 :50 .. 88. Entries=82. Base Mlz=28. 100% Inl"071 04. 
28 
/ 
80 
91 
60 '" 205 
165 \ 40 111 \ 
/ 
20 261 
0 
50 100 150 200 250 300 350 400 
Low Resolution Mlz 
3. EI mass spectrum of an unknown compound. 
SCAN C;RAPH. Flagging=Nominal Mlz. Highlighting=Base Peak. 
QJ 
OJ 
m 
;f'-
C 
if) 
c 
El 
c 
Scan 312#11 :46.35. Sub=314#11 :50.88. Entries=86. Base Mlz= 161. 100% Int=O .922. 
100 
80 
60 
91 
40 28 
'" 
133 
1 '" 20 0 
50 100 
1 1 
\ 
150 
218 
~ 
200 250 300 
Low Resolution Mlz 
350 400 
450 
461 
/ 
450 
450 
4. EI mass spectrum of an unsaturated cyclic hydrocarbon (could contain hydroxyl and/or carbonyl 
groups). 
155 
500 
500 
500 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
SCAN GRAPH, Flagging=Nominal Mil. Highlighting=Base Peak, 
(j) 
OJ 
<1l 
,.0 
0' 
.c 
<fJ 
c 
!!] 
c: 
100 Scan 325#12:15,79, Sub=318# 1159,94, Entries=83, Base Mlz=57 , 1, 100% Int=3,7339, 
80 43 
/ 
60 
40 29 
\ 
20 
57 
/' 
85 
\ 
99 
\ 113 127 155 212 
0 
/ /' \ 168 183 ~ 'H-r'rrY+'r-.-..Y+'I'/-r,ly'l'+'l'l-rYrrl'f'+t'-r'I+r't'r-r'rr~I' ,III, I' '" liP" , I' ,I, 'I ",I!(" , , I ,( ,II ,I, , I" ,III, ,II' " 'I 
20 40 60 80 100 120 140 160 180 200 220 
Low Resolution Mlz 
5. EI mass spectrum of pentadecane. 
SCAN GRAPH, Flagging=Nommal Mlz. Highlighting=Base Peak, 
100 Scan 334#12 :36.18. Sub=318#11 :59,94. Entries=173, Base Mlz=205,1, 100% Int=14,9696, 
20 
\ 
80 
(j) 
0) 
C\J 60 ,0 
0' 
.c 28 
<fJ 40 / c 220 !!] 
c /" 
20 
0 
50 100 150 200 250 300 350 400 
Low Resolution Mlz 
6. EI mass spectrum of butylated hydroxy toluene. 
SCAN GRAPH, Flagging=Nominal M/z, Highlightlllg=Base Peak, 
Scan 338#12:45.23. Sub=317#11 :57.67 Entries=92, Base Mlz=74 , 100% Int=1 4032, 100 
4 
/ 
80 
(j) 
OJ 
C\J 60 ,0 ~~ 
C 
. iii 
40 41 c \ !!] 
E 
20 
0 
50 100 150 200 250 300 350 400 
Low Resolution Mlz 
7. EI mass spectrum of methyl dodecanoate. 
156 
450 
450 
~ 
500 
500 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
SCAN GRAPH. Flagging=Nominal flNz. Highlighting=Base Peak. 
(]) 
0) 
(1) 
?3 
.c 
iJj 
c 
El 
c 
Scan 382#14:24.89. Sub=357#13:28.26. Entries=88. Base flNz=57.1.100% Int.=2.7491 
100 
57 
""-80 
60 71 
/ 
40 
141 197 
20 /' / 
0 
50 100 150 200 250 300 350 400 
Low Resolution flNz 
8. Elmass spectrum of an aliphatic hydrocarbon. 
SCAN GRAPH. Flagging=Nominal flNz. Hlghlighting=Base Peak. 
(]) 
0) 
IT) 
~ 
.c 
(fJ 
c 
El 
.s 
Scan 406#15:19.25. Sub=392#14:4 7 .54. Entries=98. Base flNz=57.1 . 100% Inl=22.4172. 100 
57 
43 /' 
80 29 / 
/ 
()O 
40 
20 
0 
20 40 60 
85 
\ 
80 100 120 140 
Low Resolution flNz 
160 180 200 
9. Elmass spectrum of a hexadecane. 
SCAN GRAPH. Flagging=Nomll1al flNz. Highlighting=Base Peak. 
(]) 
0) 
(1) 
o~ 
.c 
'iJj 
c 
(]) 
C 
100 Scan 419#15:48.70. Sub=392#14:4 7 .54. Entries=127. Base flNz= 168.1. 100% Inl=1 .2476 
168 
80 57 
/' 85 
43 60 \ 
28 / 
40 / 
105 119 139 
20 \ / ! 
0 
20 40 60 80 100 120 140 160 180 200 
Low Resolution flNz 
10. EI mass spectrum of diphenylamine. 
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SCAN GRAPH. Flagging=Nominal Mlz. Highlighting=Base Peak. 
OJ 
OJ 
ro 
,,0 
;:::::. 
.0 
rf) 
c 
2 
E 
100 Scan 450#16:58.92. Sub=433#16:20.41. Entries= 116. Base Mlz=57.1. 100% Inl.=04,8176 
57 
80 
60 
40 
20 
~ 
71 
/ 
0 ¥ I I I Ii II I 1'1'1'1'1'1'1'1'1'1'1'1'11'1'1'1'1'1'1'1'1'1'1'1'1'1'1 
50 100 '150 200 250 300 350 400 450 500 
Low Resolution Mlz 
11. EI mass spectrum of an aliphatic hydrocarbon (the surrounding peaks from 16 min to 18 min have 
similar mass spectra). 
SCAN GRAPH. Flagging=Nominal Mlz. Highlighting=Base Peak. 
OC Scan 493#18:36.32. Sub=484#18:15,94 Entries=109. Base Mlz=57.1. 100% Inl.=35,8304. 1 .1-
57 
""-80 -
OJ 
-OJ 
ro 60-• .0 
0' 
.0 - 71 
'iii 40 -c 
ill 
-c 
20 -
-
0 ,I I il, ~ 'f~ ~\ o'fo'l ! 1''' 0 I' , I~ 0'/0 , 0 ,71 0 , 0 , 0 , 0 , 0 1 0 , 0 , 0 , 0 I I 1 \ , 0 , 0 , 0 , 0 1 0 , 0 , 0 I 'I 0 1 0 I 0 I 0 , 0 I 0 I 
50 100 150 200 250 300 350 400 450 500 
Low Resolution M/z 
12. EI mass spectrum of heptadecane. 
SCAN GRAPH. Flagging=Nominal Mlz, Highlighting=Base Peak, 
Scan 500#18:52,18 Sub=484#18:15,94. Entries=144, Base Mlz=57.1. 100% Inl.=8.0992, 
100 
57 
~ 71 
/ 80 OJ 
Ol 
co 60 ~ 
.0 
iii 40 c 
2 
c 
20 
0 
50 100 
113 
/ 
150 
183 
,/ 
200 250 300 
Low Resolution Mlz 
13. EI mass spectrum of an aliphatic hydrocarbon. 
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SCAN GRAPH Flagging=Norninal Mlz. Highlighting=Base Peak. 
<IJ 
01 
m 
~ 
C 
CJ) 
c 
(j) 
C 
Scan 509#19:12.56. Sub=514#19:23.89. Entries=149. Base Mlz=28. 100% Int.=4.7808. 100 
80 
60 
40 
20 
0 
20 
8 74 87 
/ \ / 
41 
/ 
40 60 80 100 120 
143 
/ 
140 160 
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14. EI mass spectrum of methyl tetradecanoate. 
SCAN GRAPH. Flagging=Norninal Mlz. Highlighting=Base Peak. 
Scan 557#21 :01 .28. Sub=566#21 :21 .67. Entries=125. Base Mlz=57. 1. 100% Int.=6.3376. 100 
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15. EI mass spectrum of an aliphatic hydrocarbon (the surrounding peaks from 20 min to 22 min have 
similar mass spectra). 
SCAN GRAPH. Flagging=Norninal Mlz. Highlighting=Base Peak. 
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Scan 585#22:04.70. Entries=262. Base Mlz=57.1. 100% Inl.=99.1744. 
100 
57 71 
"'" / 80 
60 
40 
20 
0 
50 100 150 200 250 300 350 
Low Resolution Mlz 
16. EI mass spectrum of octadecane. 
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SCAN GRAPH. Flagging=Nominal M/z. Highlighting=Base Peak. 
100 Scan 594#22:25.09. Entries=226. Base M/z=57.1. 100'% Inl.=20.4544. 
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17. EI mass spectrum of an aliphatic hydrocarbon. 
SCAN GRAPH. Flagging=Nominal M/z. Highlighting=Base Peak. 
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Scan 648#24:27.40. Sub=615#23:12.66. Entries=172. Base M/z=57.1 . 100% Inl.=6.1872. 
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18. EI mass spectrum of an aliphatic hydrocarbon (possibly branched) (the surrounding peaks from 23 
min to 25 min have similar mass spectra). 
SCAN GRAPH. Flagging=Nominal M/z. Highlighting=Base Peak. 
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Scan 675#25:28.56. Entries=292. Base M/z=57.1. 100% Inl.=76.16. 
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19. EI mass spectrum of nonadecane. 
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SCAN GRAPH. Flagging=Nominal M/z. Highlighting=Base Peak. 
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20. EI mass spectrum of methyl hexadecanoate. 
SCAN GRAPH. Flagging=Nominal Mlz. Highlighting=Base Peak. 
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100 Scan 738#27:51.27. Sub=702#26:29.72. Entries=155. Base M'z=57.1. 100% InL=7.072. 
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21. EI mass spectrum of an aliphatic hydrocarbon (possibly branched) (the surrounding peaks from 26 
min to 28 min have similar mass spectra). 
SCAN GRAPH. Flagging=Norninal M'z. Highlighting=Base Peak. 
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22. EI mass spectrum of icosane. 
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SCJ\N GRAPH. Flagging=Nominal Miz. Highlighting=Base Peak. 
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Scan 783#29:33.21. Sub=778#29:21 .88. Entries=174. Base Miz=163. 100% In!.=8 5294. 
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23. EI mass spectrum a phthalate. 
SCJ\N GRAPH. Flagging=Nominal Miz. Higtllighting=Base Peak. 
QJ 
OJ 
ro 
"" ~: 
£ 
Ul 
c 
2 
c 
Scan 843#31 :49.12. Sub=833#31 :26.4 7. Entries=199. Base Miz=41 .1. 100% In!.= 1.2048. 
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24. EI mass spectrum of methyl (Z,Z)-9,12-octadecadienoate. 
SCJ\N GRAPH. Flagging=Nominal Miz. Highlighting=Base Peak. 
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Scan 850#32:04.97. Sub=833#31 :26.4 7. Entries=1 84. Base Miz=55. 1. 100% In!.=2.4256. 
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25. EI mass spectrum of methyl Z-9-octadecenoate. 
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SCAN GRAPH. Flagging=Nominal tvVz. Hi(Jhlighting=Base Peak. 
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26. EI mass spectrum of henicosane. 
SCAN GRAPH. Flagging=Nominal tvVz. Highlighting=Base Peak. 
OJ 
Ol 
ctl 
,0 
~ 
.2:' 
(f) 
c 
22 
E 
100 Scan 876#33:03.87. Sub=869#32:48.D1 Entries='173. Base tvVz=74.1. 100% Int=13.2308. 
4 
80 
60 
43 
\ 
40 
20 
0 
50 
/ 
100 
143 
/ 
150 200 250 
298 
~ 
300 
Low Resolution M/z 
350 400 450 
27. EI mass spectrum of methyl octadecanoate. 
SCAN GRAPH. Flagging=Nominal tvVz. Highlighting=Base Peak. 
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Scan 876#33:03.87. Sub=869#32:48.D1 Entries=173, Base tvVz=7 4.1. 100% Inl,=13.2308. 
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28. EI mass spectrum of docosane. 
163 
500 
500 
500 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
SCAN GRAPH. Flagging=Nominal M/z. Hlghlighting=Base Peak. 
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29. EI mass spectrum of a phthalate. 
SCAN GRAPH. Flagging=Nominal Mlz. Highlightl/lg=Base Peak. 
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100 Scan 984#37:08.53. Sub=937#35:22.05. Entries=193. Base Mlz=57.1. 100% Int.=3.1184. 
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30. EI mass spectrum of aliphatic hydrocarbon. 
SCAN GRAPH. Flagging=Nominal Mlz. Highlighting=Base Peak. 
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Scan 1048#39:33.50. Sub=1 032#38:57.26. Entries =203. Base Mlz=57.1 . 100% Int.=6.3008. 100 
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31. EI mass spectrum of tricosane. 
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SCAN GRAPH. Flag£llng=Nominal M/z. Highlightlng=Base Peak. 
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32. EI mass spectrum of tetracosane. 
SCAN GRAPH. Flagging=Nominal rvvz. Highlighting=Base Peak. 
100 Scan 1328#50:07.79. Sub=1261#47:36.02. Entries=193. Base rvvz=:149. 100% Int.=5.0512. 
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Submitted by: Denise Saravanakumar (UCT, Dept. of Pharmacology; Prof. Peter Smith) 
Analysis date: 31 January 2006 
Instrument: AMD 604 High Resolution Mass Spectrol11eter 
Sample: C1730E 
Data folder: 200601 January 
Calibration: 2006\0060119 __ CAL500 _res 1000 
Scan: m/z 25-500 
450 500 
Sample preparation: The sample solution was injected (1 pJ) directly into the gas chromatograph (GC) 
inlet. 
Inlet method: Gas Chromatography 
• Instrument 
, Carlo Erba GC 6000 Vega Series 
, Transfer line temperature: 250°C 
• Column 
, LECUS, PS089-0H (DB-5 equivalent) silanol-terminated (95%)-methyl-(5%)-
phenylpolisiloxane copolymer stationary phase 
, 40 m x 0.3 mm 1.0. 
, Column number: P201 
• GC Inlet 
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,.. He pressure: ca. 40 kPa (linear velocity: 28.2 cm/sec at 40°C) 
, Split now: 20 rnl/min (septum purge: 5 ml/min) 
, Temperature: 250°C 
• Oven 
, 130 - 270°C at 3°C/min, hold 10 min 
Ionization technique: Elt (Electron Energy: 70eV Source: 200°C) 
Total Ion Current Chromatogram: 
ION TRACE. Max.Scan=1696#1:04:00.70. 
Total Ion Current Max.lnt=630.7151. 100% Int=630.7151 
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Low resolution EI+ mass spectra of the sample components, providing their tentative identities: 
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SCAN GRAPH. Flagging=Nominal Mlz. Highlighting=Base Peak. 
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1. EI mass spectrum of an aliphatic alcohol. 
SCAN GRAPH. Flagging=Nominal Mlz. Highlighting=Base Peak. 
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100 Scan 147#5:32.52. Sub=122#4:35.90 Entries=82. Base Mlz=55.1. 100% Int= 1.4648. 
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2. EI mass spectrum of an unsaturated aliphatic hydrocarbon. 
SCAN GRAPH. Flagging=Nominal Mlz Highlighting=Base Peak. 
100 Scan 152#5:43.84. Sub=122#4:35.90. Enlries=76. Base Mlz=69.1. 100% InL=2.5697. 
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3. EI mass spectrum of an aliphatic alcohol. 
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SCAN GRAPH, Flagging=Nominal Mlz, Highlighting=8ase Peak, 
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Scan 156#5:52,90, Sub=127#4:4 7 .23, Entries =68, Base Mlz-..::55 , 1, 100% In[.=3.4895, 
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4. EI mass spectrum of an unsaturated aliphatic hydrocarbon, 
SCAN GRAPH, Flagging=Nominal Mlz, Highlighling=Base Peak, 
100 Scan 251#9:28,05, Sub=231#8:42,75, Entries=47, Base Mlz=57 ,1 ,100% Int=0,6485, 
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5. EI mass spectrum of an aliphatic hydrocarbon. 
SCAN GRAPH, Flagging=Nominal Mlz, Highlighting=Base Peak, 
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Scan 283#10:40.51, Entries=120, Base Mlz-..::163. 100% Inl.=31.5136, 
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6. EI mass spectrum of dimethyl phthalate. 
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SCAN GRAPH. Flagging=Norninal M/z. Highllghting=Base Peak. 
Scan 302#1123.54. Sub=294#11 :0542. Entries=78. Base M/z=205.1. 100% InL=04188. 
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7. EI mass spectrum of an unknown compound. 
SCAN GRAPH. Flagging=Norninal M/z. Highlighting=Base Peak. 
100 Scan 309#11 :3940. Sub=294#11 :0542. Entries=147. Base M/z=151.1. 100% In1=2.8944. 
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8. EI mass spectrum of an unsaturated cyclic hydrocarbon (could contain hydroxyl and/or carbonyl 
groups). 
SCAN GRAPH. Flagging=Norninal M/z. Higl1lighting=Base Peak. 
100 Scan 323#12:11.10. Sub=319#12:02.04. Entries=64. Base M/z=57.1. 100% Inl.=1.5562. 
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9. EI mass spectrum of an aliphatic hydrocarbon. 
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SCAN GRAPH. Flagging=Nominal fWz. Hlghlighting=Base Peak. 
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Scan 332#12:31.4 7. Sub=318#11 :59.78. Entries=-166. Base fWz=205.2 100% Int.= 12.544. 
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'10. EI mass spectrum of butylated 11ydroxytoluene. 
SCAN GRAPH. Flagging=Nominal fWz. Highlighting=Base Peak. 
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11. EI mass spectrum of methyl dodecanoate. 
SCAN GRAPH. Flagging=Nominal fWz. Highlighting=Base Peak. 
Scan 351#13:14.50. Sub=345#13:00.91. Entries=94. Base fWz=28. 100% Int.=O.9856. 
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12. EI mass spectrum of an unknown compound. 
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SCAN GRAPH. Flagging=Nominal Mlz. Hlghlighting=Base Peak. 
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Scan 1190#44:55.49. Sub=1182#44:37 .37. Entries =60. Base Mlz=: 149. 100% Int.=3.3008. 100 
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13. EI mass spectrum of a phthalate 
SCAN GRAPH. Flagging=Norninal Mlz. Highlighting=Base Peak. 
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14. Elmass spectrum of heptadecane. 
SCAN GRAPH. Flagging=Nominal Mlz. Hlghlighting=Base Peak. 
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15. Elmass spectrum of a phthalate. 
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SCAN GRAPH. Flagging=Nominal Mlz. Highlighting=Base Peak. 
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Scan 510#19:14.58. Sub=486#18·20.23. Entries=154. Base Mlz=74.100% Inl=9.9712. 
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16. EI mass spectrum of l11ethyl tatredacalloate. 
SCAN GRAPH. Flagging=Norninal Mlz. Highlighting=Base Peak. 
100 Scan 545#20:33.84. Sub=524#19:46.29. Entries=149. Base Mlz=28. 100% Inl=3.4432. 
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Low Resolution Mlz 
17. Ell11ass spectrul11 of an aliphatic hydrocarbon. 
SCAN GRAPH. Flagging=Nominal Mlz. Highllghting=Base Peak. 
100 Scan 584#22:02.17. Sub=571#21:32.72. Entries=112. Base Mlz=57.1.100% In[=30.9552. 
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18. EI mass spectrul11 of octadecane. 
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SCAN GRAPH, Flagging-=Norninal Mlz. Highlighting=Base Peak. 
{J) 
01 
(\1 
~:.w 
.2:' 
.U) 
c 
2 
E 
Scan 594#22:24.81. Sub=571#21 :32.72. Entriesc.;;137. Base Mlz=57.1 100% Int=6.4752. 
100 
57 
~ 
80 
71 
60 
I 
40 
20 
0 ~I I tit t I I' 11 I' I' Ii I' I 'I' 1'1 iii Ii I' I' I i I' I i I' I iii I ' I 'I' I 
50 100 150 200 250 300 350 400 450 500 
Low Resolution Mlz 
19. EI mass spectrum of an aliphatic hydrocarbon. 
SCAN GRAPH. Flagging=Norninal Mlz. Highlighting=Base Peak. 
100 Scan 602#22:42.93. Sub=571#2132.72. Entries=140 Base Mlz=74. 100°/r, Int=2.5677. 
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Low Resolution Mlz 
20. EI mass spectrum of methyl pentadecanoate. 
SCMI GRAPH Flagging=Nominal Mlz. Highlighting=Base p(.,ak. 
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21. EI mass spectrum of an aliphatic hydrocarbon. 
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SCAN GRAPH. Flagging"'Norninal Mlz. Highlighting=Base Peak. 
Scan 636#23:59.94. Sub=615#2312.37,653#2438.44. Entries=156. Base Mlz=149. 100% Int=60342 
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Low Resolution M/z 
22. EI mass spectrum of a phthalate. 
SCAN GRAPH. Flagging=Norninal Mlz. Highlighting=Base Peak 
Scan 649#24:29.38. SUb=612#23:0558,659#24:52.03. Entnes=132 Base Mlz=28. 100% Int=2.1952. 
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Low Resolution Mlz 
23. EI mass spectrum of an aliphatic hydrocarbon (possibly branched). 
SCAN GRAPH. Flagging=Norninal Mlz. Highlighting=Base Peak. 
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Low Resolution Mlz 
24. Elmass spectrum of nonadecane. 
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SCAN GRAPH. Flagging=Nornlrlal M/z. Higtllighting=Base Peak. 
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Low Resolution Mlz 
25. EI mass spectrum of methyl hexadecanoate. 
SCAN GRAPH. Flagging=Nominal M/z. Highllghtlng=Base Peak. 
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Low Resolution Mlz 
26. EI mass spectrum of a phthalate. 
SCAN GRAPH. Flagging=Norninal Mlz. Higtllighting=Base Peak. 
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Low Resolution Mlz 
27. EI mass spectrum of an aliphatic hydrocarbon. 
175 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
SCAN Gf~APH, Flagging=Nominal Mlz, Highlighting=Base Peak, 
100 Scan 766#28:54,37, Sub=l55#28:29.45, Entries=151, Base Mlz=57 ,1,100% Int,=25,808, 
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28. EI mass spectruill of icosane, 
SCAN GRAPH Flaggmg=Nominal Mlz, Highlighting=Base Peak. 
100 Scan 787#29:41.93, Entries=306, Base Mlz=163, 100% 1111.=95,9232, 
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29. EI mass spectrum of a phthalate, 
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Low Resolution M/z 
30. EI mass spectruill of methyl (Z,Z)-9,12-octadecadienoate, 
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SCAN GRAPH, Flagging=Nominal M/z, Highligtlting=Base Peak, 
100 Scan 852#32:09,15, Sub=835#31:30.65, Entries=208, Base Miz=55,1.100%, Inl.=8,624. 
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31. EI mass spectrum of methyl Z-9-octadecenoate. 
SCAN GRAPH. Flagging=Nominal Miz. Highlighting=Base Peak, 
Scan 859#32:25. Sub=842#31 :46.50. Entries=179, Base Miz=57.1, 100% Inl.=5.5232. 100 
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Low Resolution Miz 
32. EI mass spectrum of an aliphatic hydrocarbon. 
SCAN GRAPH. Flagging=Nominal Miz, Highlighting=Base Peak, 
Scan 878#33:0803. Sub=865#32:38.59. Entries=180, Base Miz=74 , 100% InL=14.6084. 100 
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Low Resolution Miz 
33. EI mass spectrum of methyl octadecanoate. 
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SCAN GRAPH. Flagging=Norninal Mlz. Highlighting=Base Peak. 
Scan 909#34:18.25. Sub=903#34:04.65. Entries=187. Base Mlz=163 100% Inl.=8.4 176. 100 
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34. EI mass spectrum of a phthalate. 
SCAN GRAPH. Flagging=Norninal Mlz. Highllghting=Base Peak. 
Q) 
Ol 
co 
cf!. 
~ 
'w 
c 
.ill 
c 
100 Scan 970#36:36.41. Sub=903#34:04.65. Entries=183. Base Mlz=163. 100% Inl.=27.7136. 
163 
130 
60 
41 
40 "'- 57 \ 
LO 
0 
50 100 
~ 
150 
181 
\ 
Low Resolution Mlz 
200 250 300 
35. EI mass spectrum of a phthalate (the surrounding peaks from 35 min to 39 min have similar mass 
spectra). 
SCAN GRAPH. Flagging=Norninal Mlz. Highlighting=Base Peak. 
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36. EI mass spectrum of an aliphatic hydrocarbon. 
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SCAN GRAPH. Flagging=Nominal Mil. Highlighting=Base Peak. 
100 Scan 1163#4353.54. Sub=1126#42 :29.74. Entnes=216. Base Mlz=43. 100% Int=3.8584. 
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37. EI mass spectrum of an aliphatic hydrocarbon (possibly branched). 
SCAN GRAPH Flaggmg=Nominal MIL Highlighting=Base Peak. 
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38. EI mass spectrum of a phthalate. 
Reported by: 
Dr. Stefan Louw 
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DS_UCT·PHARM_060329_C1730E __ GC·summary-page 
Gas Chromatography Analysis Report - Summary Page 
Submitted by: Denise Saravanakumar (UCT, Dept. of Pharmacology; Prof. Peter Smith) 
Analysis date: 29 March 2006 
Instrument: HP 5890 Series II Gas Chromatograph 
Sample: C1730E 
Data folder: HPCHEM\2006\DATA\060329 
SUMMARY OF RESULTS: 
The identities of the following sample components were confirmed by retention time comparison by the co-
injection of the sample with reference standard solutions into a gas chromatograph. 
Co~pone~t number ~ ___ .______ Compound 
1----' 
__ 1_1_ .~_. ______ methYLc!oj~canoat~ _______ _ 
_____ 1L._.____ . ____ methyl tetra~_cano~ __ _ 
_____ 1!._______ __._. ____ methyll!~r:!!ad~canoate 
__ ._ .. ____ ~___ _ __ . __ f!1~~hyl hex§decanoale ___ _ 
30 __ . __ meth1L(Z,Z)-~,g-octadecadienoat~ ___ _ 
f--____ 3_1 _____________ . methyl Z-9-octadecenoate 
33 methyl octadecanoate 
Reported by: 
Dr. Stefan Louw 
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